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Abstract 
Introduction 
For many decades gastrooesophageal reflux has been implicated in patients suffering 
from lung disease and in lung allograft injury. From the early 1970s studies have taken 
place investigating reflux in idiopathic pulmonary fibrosis (IPF) and cystic fibrosis (CF). 
However, these early studies were small and used primitive techniques to assess reflux. 
In addition, the role of microaspiration secondary to reflux has often been postulated as 
a cause of deteriorating lung function in these patients but has been under studied. It is 
also known that many of these patients require a lung transplant due to end-stage lung 
disease. Asymptomatic reflux and aspiration may be associated with allograft 
dysfunction post lung transplant. Early anti-reflux surgery has been suggested to 
improve long-term survival by treating reflux. This thesis reports a prospective 
assessment of reflux/aspiration in patients with IPF and CF. In addition, the study 
reports the largest European series of fundoplication in lung transplant patients. 
Methods 
Over a 2 year period patients with IPF and CF were recruited from specialist clinics. All 
patients completed objective assessment of oesophageal physiology using manometry 
and impedance-pH. Symptom and quality of life assessment using RSI, Demeester and 
GIQLI questionnaires were performed on all patients at the time of recruitment. For 
those patients taking proton pump inhibitor, questionnaires were done ‘on’ and ‘off’ 
their medication. IPF patients then had a bronchoscopy and lavage (BAL) whilst CF 
patients produced sputum. Cytospins of the BAL and sputum were produced and 
differential cell counts were performed and the cells were stained with Oil Red O and 
Prussian Blue (Perls). ELISA and mass spectrometry assays were also performed on the 
samples for pepsin and bile salts respectively. Lung transplant patients attended for 
impedance-pH studies over 3 years and those with symptomatic reflux or reflux and 
deteriorating lung function were referred for a laparoscopic fundoplication. Lung 
function assessment, symptom and quality of life questionnaires were performed before 
surgery and at 6 weeks and 6 months after surgery 
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Results 
IPF Patients: 
Thirty eight patients with IPF were initially approached and 29 consented to be studied. 
Nine patients dropped out from the study after consent. Twenty patients with IPF 
completed both the oesophageal physiology and BAL aspects of the investigation. In 12 
patients there was objective evidence of reflux including 6 patients with proximal reflux. 
60% of patients had an abnormal RSI score whilst taking a PPI and scores for the other 
questionnaires were not significantly different ‘on’ and ‘off’ PPI. Lung function was not 
related to the degree of reflux. The principal cell type identified was macrophages and 
both Oil Red O and haemosiderin scores were well above the normal range. Bile salts 
were detectable in 17/20 IPF patients but the levels were not higher than the normal 
range. 11/20 patients had higher than normal levels of pepsin in the BAL.  
CF Patients: 
Twenty-six patient with CF consented to the study but 15 dropped out. Eleven CF 
patients attended for oesophageal investigation and each provided 2 samples of sputum. 
9/11 had reflux, including five with proximal reflux. All patients were taking acid-
suppression medication and questionnaire assessments were abnormal whilst on their 
medication with 82% still having a GIQLI score below 121 despite medication for 
reflux. Twenty one samples of sputum were processed altogether. The principal cell 
type was neutrophils. Bile salts were detectible in all samples but these were at very low 
concentrations. Elevated pepsin was seen in 7/11 sputum samples with the median 
concentration ten times above the normal level.  
Lung Transplant Patients 
16 lung transplant patients with symptomatic reflux or deteriorating lung function and 
reflux on impedance-pH had a laparoscopic fundoplication. Symptom questionnaire and 
quality of life assessment was significantly improved in all patients. Half the patients 
had presented with declining lung function and all showed an improvement in 
respiratory function after surgery. 
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Summary 
We have demonstrated that reflux is present in patients with IPF, CF and in patients 
after lung transplant. Using impedance-pH we have identified patients with proximal 
reflux. The presence of reflux appears to affect the patients’ quality of life and despite 
PPI therapy the majority still had symptoms. High levels of haemosiderin stained 
macrophages in IPF indicate oxidative stress which may or may not be secondary to 
reflux. Pepsin levels are elevated in both IPF and CF patients, possibly indicating 
microaspiration.  
Conclusion 
Despite PPI therapy there is significant reflux in IPF and CF identifying a clinical gap in 
patient treatment that should be considered in management. Our results in the post lung-
transplant group indicate there is a role for surgery in treating reflux and potentially 
reducing microaspiration. This has been shown to stabilise lung function in this cohort 
and may have implications for the treatment of reflux in patients with lung disease 
before transplantation. 
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1  Introduction 
1.1 Idiopathic Pulmonary Fibrosis 
1.1.1 Definition 
The term interstitial lung disease (ILD) encompasses a heterogeneous group of acute 
and chronic disorders characterised by diffuse pulmonary infiltrates with histologic 
features of pulmonary inflammation, exertional dyspnoea and restrictive lung patterns 
[1]. Under normal conditions the interstitium of the alveolar cells contain small 
quantities of macrophages and fibroblasts as well as collagen-related macromolecules. 
During injury an inflammatory process begins with an increase in permeability of the 
alveolar cell lining, enabling serum contents to enter the alveolar space. This results in 
an inflammatory cell response during which pro-inflammatory and pro-fibrotic 
cytokines are released. After this, fibroblastic proliferation and collagen deposition 
dominate leading to the histological hallmarks of interstitial lung disease. In ILD a 
number of different sources may be responsible for the injury of the lung parenchyma 
producing a disease with similar clinical, radiological and physiological features. The 
alveolar structures as well as the lumen and walls of the small airways can be affected in 
ILD[2]. 
Since the publication of the first ILD guidelines by the British Thoracic Society [3] 
almost 15 years ago the consensus on the definition of certain lung conditions within the 
spectrum of ILD has undergone considerable change; mainly brought about by a better 
understanding of the disease process. The term ‘interstitial lung disease’ is synonymous 
with ‘diffuse parenchymal lung disease’ and in the initial guidelines published in 1999 
[3] it was this latter term that was commonly used.  This was replaced only a few years 
later with ILD.  However, a more difficult issue is the definition of the subgroups of 
diseases under the umbrella term of ILD. In the UK, the term ‘crytogenic fibrosing 
alveolitis’ (CFA) corresponded to a the characteristic clinical picture we now see as 
defined by idiopathic pulmonary fibrosis (IPF) but also encompassed other idiopathic 
interstitial pneumonias (IIP) as well as cases of hypersensitivity pneumonitis. This 
demonstrates that the use of the term CFA was unable to distinguish between IIP 
subsets as much as to say some patients had fibrotic lung disease and others had an 
inflammatory picture [4]. 
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Two years after the first BTS guidelines the American Thoracic Society (ATS) in 
association with the European Respiratory Society (ERS) proposed a new classification 
system paying particular attention to developing a distinction between the diseases 
defined generally as CFA [5]. They compared the outcomes of subsets of patients with 
IIP and found that patients with ‘fibrotic’ non-specific interstitial pneumonia (NSIP) 
had a better prognosis than those with a histological pattern consistent with usual 
interstitial pneumonia (UIP). On this basis the core entity of idiopathic pulmonary 
fibrosis was redefined: characteristic clinical features were required in association with 
a histological pattern of UIP at surgical biopsy or a high resolution CT (HRCT) pattern 
typical of UIP. In addition, the absence of lymphocytosis on bronchoalveolar lavage 
(BAL) or the absence of features of an alternative diagnosis on trans-bronchial biopsy at 
bronchoscopy was required in patients not undergoing a surgical biopsy.  Table 1-1 
indicates the current internationally accepted standards by which a diagnosis of IPF can 
be made in the absence of a surgical lung biopsy [4]. In the immunocompetent adult the 
presence of all of the major criteria and three out of four of the minor criteria increase 
the likelihood of the diagnosis being IPF. 
Major Criteria Minor Criteria 
Exclusion of other causes of ILD such as certain 
drug toxicities, environmental exposures and 
connective tissue diseases 
Age > 50 years 
Abnormal pulmonary function studies that 
include evidence of restriction (reduced VC, 
often with an increase FEV1/FVC ratio) and 
impaired gas exchange (increased P(A-a)o2 with 
rest of exercise or decreased TLCO) 
Bibasilar inspiratory crackles (dry or ‘Velcro’ type 
in quality) 
Bibasilar reticular abnormalities with minimal 
ground glass opacities on HRCT scans 
Insidious onset of otherwise unexplained dyspnoea 
on exertion 
Transbronchial lung biopsy or BAL showing no 
features to support an alternative diagnosis 
Duration of illness > 3months 
Table 1-1: ATS/ERS criteria for the diagnosis of idiopathic pulmonary fibrosis (IPF) in the absence 
of surgical lung biopsy [5] 
Since the development of these definitions of IPF, a further set of guidelines have been 
published in 2011. This document is a joint consensus between the ATS, ERS, the Latin 
American Thoracic Association and the Japanese Respiratory Society (JRS) [6] .  Their 
definition of IPF, in agreement with the BTS definition, states that IPF is a specific form 
of chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring 
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primarily in adults during the sixth and seventh decades of life, limited to the lungs and 
associated with the histopathological and/or radiological pattern of UIP. 
In this document there is particular attention paid of the radiological diagnosis of UIP 
and the diagnostic criteria of IPF. UIP is characterised on HRCT by the presence of 
reticular opacities (Figure 1-１), often associated with traction bronchiectasis. 
Commonly honeycombing is seen in UIP. The distribution of UIP on HRCT is 
characteristically basal and peripheral, but often can be patchy.  The positive predictive 
value of a HRCT diagnosis of UIP is 90-100% [6]. 
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Figure 1-１: High-resolution computed tomography (HRCT) images demonstrating usual 
interstitial pneumonia (UIP) pattern and possible UIP pattern. 
 
Legend: (A and B) UIP pattern, with extensive honeycombing: axial and coronal HRCT 
images show basal predominant, peripheral predominant reticular abnormality with 
multiple layers of honeycombing (arrows). (C and D) UIP pattern, with less severe 
honeycombing: axial and coronal CT images show basal predominant, peripheral 
predominant reticular abnormality with subpleural honeycombing (arrows). (E and F) 
Possible UIP pattern: axial and coronal images show peripheral predominant, basal 
predominant reticular abnormality with a moderate amount of ground glass abnormality, 
but without honeycombing [6]. 
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The histological diagnosis of UIP is made at low magnification and is characterised by a 
heterogenous appearance in which areas of fibrosis and honeycombing alternate with 
areas of normal lung parenchyma. The areas of fibrosis are composed mainly of dense 
collagen and the honeycomb areas are cystic fibrotic airspaces lined with bronchial 
epithelium and often filled with mucus and inflammatory cells (Figure 1-2). When such 
strict criteria are used to make the histological diagnosis of UIP there are only several 
remaining possibilities for a differential diagnosis and these include some connective 
tissue diseases, chronic hypersensitivity pneumonitis and some pneumoconioses. 
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Figure 1-２:  Surgical lung biopsy specimens demonstrating UIP pattern.  
 
Legend: (A) Scanning power microscopy showing a patchy process with honey comb 
spaces (thick arrow), some preserved lung tissue regions (thin arrow), and fibrosis 
extending into the lung from the sub-pleural regions. (B) Adjacent to the regions of 
more chronic fibrosis (thick arrow) is a fibroblast focus (asterisk), recognized by its 
convex shape and composition of oedematous fibroblastic tissue, suggestive of recent 
lung injury [6]. 
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1.1.2 Diagnosis of IPF 
The diagnosis of IPF should be made in a multidisciplinary team discussion involving 
respiratory physicians specialising in ILD, radiologists and pathologists. Where this is 
not possible and a diagnosis of IPF maybe suspected, specialist referral should be made 
to an ILD centre. Although HRCT and a better understanding of the histological pattern 
of IPF have been useful adjuncts in the diagnosis of IPF, the ability to take a focused 
history and detailed examination remains paramount. A thorough medical, occupational, 
environmental and family history along with examination, lung function assessment and 
blood tests allow other diagnosis to be eliminated so that a diagnosis of IPF can be 
made. 
The diagnosis of IPF requires the following [6]: 
1. Exclusion of other known cause of ILD 
2. The presence of UIP pattern on HRCT  
3. The presence of UIP pattern on HRCT and confirmation of the diagnosis on lung 
biopsy when required.   
The exclusion of other causes of ILD can be very subjective and therefore it is 
recommended that physicians use a standardised approach. It is most important to 
differentiate between chronic hypersensitivity pneumonitis and IPF as these two 
conditions have very similar patterns of presentation. The diagnosis of chronic 
hypersensitivity pneumonitis is more likely in the presence of a lymphocytosis (>40%). 
This demonstrates the importance of a multidisciplinary setting when making the 
diagnosis of IPF. The diagnostic criteria are presented in the flow chart below (Figure 
1-３). 
The most recent recommendations for the diagnosis and management of IPF do not 
include the use of routine bronchoalveolar lavage (BAL) cellular analysis or trans-
bronchial lung biopsy in making the diagnosis [6]. However, both maybe appropriate in 
a minority of cases. BAL can be useful in differentiating between IPF and chronic 
hypersensitivity pneumonitis. The sensitivity and specificity of trans-bronchial biopsy 
varies considerably between studies. 
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 Figure 1-３: Diagnostic algorithm for Idiopathic Pulmonary Fibrosis (IPF) [6].  
 
Legend: The patients with suspected IPF are those with evidence of interstitial lung 
disease (ILD), unexplained exertional dyspnoea and/or cough. If an identifiable cause is 
isolated then clearly this is not IPF. In the absence of an identifiable cause of ILD, 
HRCT is used. If this clearly demonstrates a pattern of usual interstitial fibrosis (UIP) 
then IPF can be diagnosed. When UIP is not clearly identified on HRCT, an MDT 
discussion using histology in combination with the radiology is important to identify 
those patients with IPF. 
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1.1.3 Incidence of IPF 
There is considerable variability between studies of the incidence and prevalence of IPF. 
Studies from America estimate the incidence to be between 6.8 and 16.3 per 100,000 
people [7]. In Mexico a population based study estimated the incidence of IPF in males 
to be 10.7 per 100000 and in females 7.4 per 100000 [8]. Studies from the UK have 
estimated a slightly lower overall incidence of IPF at 4.6 per 100000 people but claim 
that between 1991 and 2003 the incidence of IPF has increased by 11% annually with 
the current incidence of IPF in the UK 7.44 per 100000 [9] [10]. 
The large discrepancy in the estimates of the incidence of IPF are due to the fact that 
until recently there has been a lack of a uniform definition of IPF as well as the 
variation of study design and populations. It is also unclear the influence of geographic, 
racial and cultural differences on the incidence of the disease [6]. 
The incidence of deaths from IPF increases with advancing age. Studies from America 
suggest the mortality rate in men was 61.2 per 1 million and in women 54.5 per 1 
million with the death rate being greatest over winter [11].  
1.1.4 Aetiology of IPF 
IPF is a disease normally found in older patients beyond their 5
th
 decade of life and 
typically at the ages of 70-80. It classically presents with unexplained chronic exertional 
dyspnoea, cough and on examination patients have bi-basal inspiratory crackles and 
often have finger clubbing. There are a number of risk factors that may be associated 
with the development of IPF including: 
 Smoking – Patients smoking more than 20 pack-years maybe at a higher risk of 
developing IPF [6]. 
 Environment – Various environmental agents have been associated with the 
development of IPF, including metal dust particles and both animal and 
vegetable dust through farming. Supporting this has been the identification of 
these dust particulates in the lymph nodes of patients at autopsy who have been 
diagnosed with IPF [6]. 
 Microorganisms – There have been several studies that have shown a 
relationship between certain viruses and the development of IPF. In particular 
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the Epstein-Barr virus (EBV) has been shown to have the most common 
association with IPF with several studies demonstrating the presence of EBV in 
lung tissue of patients with IPF [12],[13]) However, the association must be 
taken judiciously as EBV is generally a common virus and can be found in lung 
tissue of patients with other disease. In addition, patients with IPF maybe on 
steroids predisposing them to the development of EBV and other viruses rather 
than the relationship to IPF being a causal one. 
 Genetics – Genetic factors play a role in IPF where two or  more members of the 
same family may be affected by the disease (familial pulmonary fibrosis) and in 
sporadic cases of IPF. Familial IPF tends to affect patients at a younger age and 
has been suggested in studies [14] to be associated with a gene controlling anti-
viral responses called ELMOD2, located on chromosome 4q31[15]. The genetic 
transmission of the disease is in an autosomal dominant fashion with variable 
penetrance. The genetic association with sporadic cases of IPF has been through 
polymorphisms of genes encoding  various factors associated with development 
of lung fibrosis including genes coding for various cytokines and profibrotic 
molecules [6]. 
There has been more recent evidence suggesting the importance of genetic 
factors in the pathophysiology of IPF. MUC5B is the gene coding for Mucin 5 
subtype B. A single nucleotide polymorphism (rs35705950) in this gene has 
been shown to be associated with interstitial lung disease in the general 
population [16]. More recently Stock at al [17] demonstrated in a prospective 
case controlled study consisting of 110 IPF patients and 416 healthy controls an 
association between the MUC5B polymorphism and IPF. The authors also 
investigated whether the MUC5B polymorphism increased the risk of lung 
fibrosis in systemic sclerosis and sarcoidosis; 440 patients with this subtype of 
fibrosis were studied but no association was discovered. Although MUC5B may 
indicate a predisposition to developing IPF, Pelijto et al [18] demonstrated that 
the IPF phenotype consists of at least two clinical subsets separable by the 
MUC5B genotype. In patients with the proven polymorphism of the MUC5B 
gene there appeared to be a survival advantage compared to those with IPF 
associated with other environmental or genetic factors.  
Many of the studies involved with the genetics behind the development of IPF 
are small and further work in necessary. However, recent advances in the 
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understanding of the genetic basis of IPF may help identify those individuals 
who are at risk of developing the disease and develop new targeted therapy   
The majority of patients with IPF demonstrate a slow progressive decline in respiratory 
function over 2-3 years and may then succumb to the disease once they develop 
respiratory failure. However, in a minority of patients (5-10%) it can be rapidly 
progressive. These patients present with sudden  unexplained worsening dysponea, 
hypoxia, and severe impairment of gas exchange with new alveolar infiltrates on chest 
imaging and the absence of other causative factors such as pulmonary embolism or 
infection. 
1.1.5 Management of IPF 
Patients who have been diagnosed with IPF have to have their disease staged 
appropriately into mild, moderate, severe and early or advanced disease to determine the 
prognosis and most appropriate therapy. Several important factors help the specialist 
appreciate the severity of the disease in an individual, these include: 
 Baseline dyspnoea and the change of dyspnoea over time can correlate with the 
severity of IPF 
 Pulmonary function tests can be very helpful and are part of the routine clinical 
assessment. The lung volumes (TLC, functional residual capacity and residual 
volume) are reduced. Early in the course of the disease  the lung volumes maybe 
normal and can be higher in smokers with IPF compared to those who have 
never smoked. Expiratory flow rates (FEV1 and FVC) maybe reduced but the 
overall ratio is maintained or increased. The diffusing capacity of the lung for 
carbon monoxide (TLco) is reduced due to the contraction of the pulmonary 
capillary volume and the presence of ventilation-perfusion mismatch. 
These tests are very valuable at rest but the magnitude of the abnormalities is 
accentuated by exercise. In particular the alveolar-arterial partial pressure 
oxygen gradient (A-a) PO2 widens by up to 20-30% causing severe desaturation. 
In an effort to compensate and maintain adequate oxygenation, patients with IPF 
increase their minute ventilation by increasing their respiratory frequency 
whereas individuals with healthy lungs tend to increase their tidal volume. 
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 Six-minute walk testing – this is often used in clinical practice where the shorter 
the distance walked and the longer the heart rate takes to recover may correlate 
to the severity and subsequent risk of mortality from IPF [6]. 
 Pulmonary Hypertension – Pulmonary hypertension rarely occurs at rest but can 
occur during exercise even in early IPF. The cause of the hypertension is due to 
the damage on the pulmonary vasculature as the fibrosis develops. The mean 
pulmonary artery pressure has to be greater than 25mmHg at rest. A mean artery 
pressure above 30mmHg is associated with a poor prognosis [6]. 
Once the diagnosis and clinical severity are established most patients require some form 
of medical management as without any intervention mortality from IPF is very high. 
The median survival after diagnosis is two to three years. Early diagnosis and 
management may have some control on the progression of the fibrosis and help 
maintain a degree of lung function compatible with a good quality of life. It is 
recommended that any therapeutic agent used in controlling a patient’s IPF be trialled 
for at 3 months to ascertain the effect. The following agents may be useful in the 
management of certain patients with IPF: 
 Corticosteroids – These have only achieved an improvement in symptoms in a 
minority of patients and the effects tend to be short-term. The recent consensus 
[6] does not recommended corticosteroids in the management of IPF. 
 Azathioprine – This is an immunomodulatory agent that can be used in 
combination with a corticosteroid. Azathioprine is a purine analogue and acts as 
a prodrug for mercaptopurine inhibiting an enzyme that is required for the 
synthesis of DNA and affects the activity of lymphocytes. In addition, 
azathioprine supresses the activity of natural killer cells and some antibodies. 
However the drug needs to be used with caution particularly in the elderly due to 
its effects on the bone marrow, gastrointestinal tract and liver. The combination 
of azathioprine with a corticosteroid is not recommended in the management of 
IPF. 
 Cyclophosphamide – This is also an immunomodulatory agent that is sometimes 
used in combination with a corticosteroid to manage some patients with IPF. It 
is an alkalyting agent of the nitrogen mustard group that is absorbed orally and 
metabolised in the liver into several cytotoxic products that target the activity of 
lymphocytes. The clinical response to treatment can take up to 9 months in some 
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patients and so a longer trial of these agents is required. Again the drug can have 
profound effects on the bone marrow, gastrointestinal tract and liver. 
 Proton Pump inhibitors – Lee et al [19] reported that patients taking medication 
for gastro-oesophageal reflux had a lower fibrosis score on HRCT and the use of 
these medications was an independent predictor of longer survival time. 
 Other treatments – Colchicine, Interferon Gamma, and Pirfenidone are some 
other agents that have been trialled but the data on their efficacy is limited. 
Consensus on the treatment of asymptomatic gastrooesophageal reflux is still 
very variable. Recent evidence has demonstrated clinical improvements of lung 
function with regular proton pump inhibitor use [19]. However, their benefit for 
patients with non-acid reflux is still questionable and anti-reflux surgery may 
have a more valuable role in the stabilisation of lung function but more research 
is required in this field [6]. 
 Long term oxygen therapy – there is very little evidence to support the value of 
long-term oxygen therapy in IPF, but recent guidelines [6] recommend its use in 
patients with significant resting hypoxaemia. 
 For some patients, once they become unresponsive to medical management, 
lung transplantation may be offered. This is normally reserved for young 
patients with minimal comorbidities. The following objective parameters are 
used as part of the selection criteria for lung transplantation in end-stage IPF[6]: 
1. New York Heart association functional class III or IV; class III is physical 
activity limited severely enough that minimal exertion can result in dyspnoea, 
angina pain, fatigue and palpitations. Class IV is characterised by the 
inability to carry out physical activity often associated with discomfort at 
rest. 
2. Honeycombing or pulmonary hypertension on chest x-ray or HRCT 
respectively 
3. Physiological deterioration of TLC < 60%, (A-a)PO2 at rest > 30, severe 
exercise desaturation 
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1.2 Cystic Fibrosis 
1.2.1 Definition 
Cystic fibrosis was formally known as mucoviscoidosis or fibrocystic disease of the 
pancreas. It is the commonest serious inherited metabolic disorder with the autosomal 
recessive gene being carried by 1 in 20 of the Caucasian population [20]. It affects about 
1 in 2500 live births. The genetic defect is on the long-arm of chromosome 7 that codes 
for the 1480-amino acid protein, cystic fibrosis transmembrance conductance regulator 
(CFTR). The most common form of this mutation is the ∆508 in which three base pair 
deletions causes the loss of phenylalanine at position 508 of the protein. This mutation 
results in a dysfunctional CFTR protein which would normally function as a cyclic 
AMP-dependent chloride channel in the apical membrane of epithelial cells. The 
physiological result of this is reduced chloride conductance in all epithelial membranes 
and the most profound effects are seen in the gastrointestinal, respiratory, hepatobillary 
and reproductive systems.  
The CFTR protein also regulates the activity of epithelial sodium channels (ENaC) and 
calcium activated chloride channels (CaCC), resulting in the inhibition of sodium 
transport through ENaC and an inhibition of CaCC (Figure 1-4). In addition, the CFTR 
affects the bicarbonate-chloride exchange. In sweat ducts, the failure of the reabsorption 
of chloride ions results in high levels of both chloride and sodium within the sweat 
which is the characteristic hall mark of cystic fibrosis [21]. 
There are numerous mutations of the CFTR gene and these are divided into five classes 
based on their effect on CFTR function: 
 Class 1 – These defects affect protein synthesis of the CFTR 
 Class II -  These defects affect protein processing (this includes the ∆508 
mutation) 
 Class III – These defects affect activation of the CFTR protein 
 Class IV – These defects lead to  impaired chloride conductance 
 Class V –  These defects reduce the synthesis of normally functioning CFTR 
Class I-III causes the more life threatening diseases whereas the other classes have less 
severe clinical manifestations. 
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Figure 1-４: The CFTR protein and sites of the mutaations 
 
Legend: The cystic fibrosis gene codes for a 1480 amino acid protein names Cystic 
Fibrosis Transmembrane Conductance Regulator (CFTR) that is trafficked through the 
cell via the endoplasmic reticulum and Golgi apparatus and inserted into the apical 
membrane where it functions as a cAMP-dependent chloride channel. Class I mutations 
disrupt synthesis of CFTR and include mutations that lead to premature termination 
codons and no protein production. Class II mutations result in misfolded CFTR proteins 
that get degraded in the endoplasmic reticulum. Class III mutation CFTR protein 
reaches the apical membrane but fails to be activated and Class IV mutations produce 
CFTR protein with reduced conductance. In Class V mutations there is reduced 
synthesis of normal CFTR and thus reduced CFTR function at the cell membrane. 
CFTR also affects the regulation of sodium channels (ENaC) and calcium activated 
chloride channels (CaCC) [20]. 
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1.2.2 Diagnosis of Cystic Fibrosis 
The diagnosis of cystic fibrosis is made through a combination of sophisticated tests and 
clinical presentation. In children the presentation of meconium ileus at the time of birth 
is characteristic of cystic fibrosis. Other signs in the young are failure to thrive and 
recurrent chest infections.  
The diagnosis of cystic fibrosis is confirmed by both DNA analysis and the sweat test. 
The sweat test identifies elevated levels of chloride ions caused by the effect of the 
defective CFTR gene on the chloride channels. Sweat chloride levels greater than 
60mmol/L (normal<29mmol/L )after several tests are highly suggestive of CF [22]. In 
addition, the demonstration of two known CF mutations on DNA analysis is used to 
confirm the diagnosis. The DNA analysis can be made on chorionic villous samples 
allowing diagnosis to be made in the antenatal period. In some individuals DNA 
analysis may reveal only a single gene mutation and this may indicate that they are a 
carrier of the disease and these individuals may exhibit few or no symptoms.  
As the ability to perform more sophisticated genetic tests becomes increasingly 
available a group of patients have been identified and diagnosed with ‘atypical’ cystic 
fibrosis. In the clinical setting they tend to be older patients with isolated manifestations 
of cystic fibrosis rather than the spectrum of clinical diseases seen in classical CF. In 
addition their sweat tests may reveal a chloride concentration of 30-59 mmol/L [22]. 
The early diagnosis of cystic fibrosis has also been also improved by newborn screening. 
A single dried blood spot is obtained using a Guthrie card; elevated levels of trypsin are 
seen in cystic fibrosis. The ability to identify individuals with CF early allows prompt 
management of the disease which may help slow the progression of the disease. 
1.2.3 Clinical Manifestations of Cystic Fibrosis 
Respiratory Manifestations: 
The CFTR defect and subsequent effect on the chloride channel causes a reduction in 
chloride ion secretion and increase in sodium reabsorption from the bronchial mucosa 
epithelial cells resulting in viscous secretions. These secretions not only disrupt the 
mucocilliary clearance mechanisms but the elevated salt concentration of the secretion 
inactivates defensins on the epithelial membranes predisposing to bacterial infections. 
The sequeleae of infection and inflammation repeats itself eventually leading to 
bronchiectasis and respiratory failure (Figure 1-５). 
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Figure 1-５: The cycle of infection, airway damage, increased mucous production and ineffective 
bacterial clearance [21]. 
18 
 
The persistent chest infections and development of bronchiectasis leads to progressive 
airway obstruction. In younger patients with cystic fibrosis the common 
microorganisms causing infection are Staphylococcus aureus, Haemophilus influenza 
and Streptococcus pneumoniae. In adult patients the most common infection tends to be 
a mucoid strain of Pseudomonas aeruginosa.  In addition to these infections a Gram-
negative plant pathogen called Burkholderia cepacia complex is responsible for causing 
serious chest infections  including a fulminant necrotising pneumonia known as 
‘cepacia syndrome’.  This organism was thought not to be pathogenic to humans but has 
since been discovered to be an extremely aggressive infection amongst CF patients 
particularly those in close social circle. Over time with recurrent infection, irreversible 
lung injury with the destruction of lung parenchyma leads to severe life threatening 
complications including cor pulmonale, major haemoptysis, recurrent pneumothorax 
and progressive respiratory failure. 
Gastrointestinal Manifestations 
The main organ in the gastrointestinal tract affected by the defective ion transport is the 
pancreas. The blockage of the ducts by the thick mucus prevents the exocrine secretions 
being released into the duodenum resulting in irreversible damage to the pancreas often 
with inflammation (pancreatitis). The complete blockage of the pancreatic ducts by 
mucus often seen in young CF patients can lead to complete atrophy and fibrosis of the 
pancreas resulting in the complete loss of pancreatic function. This causes 
malabsorption and diabetes. In addition to the effects on the pancreas, abnormalities 
with the secretion of bile from the liver can cause biliary cirrhosis and gallstone 
formation. 
In addition to pancreatic and hepatobiliary complications, from even early life the 
effects of the CFTR mutation on the functioning of the intestines can be very serious. 
Sludging of the intestinal contents in about 10% of neonates with cystic fibrosis can 
cause meconium ileus [20]. A similar condition can occur in the terminal ileum of adult 
cystic fibrosis patients and is described as distal intestinal obstruction syndrome. It is 
caused by semi solid faecal material obstructing the terminal ileum as a result of fluid 
malabsorption and disordered gut motility. 
Other Manifestations 
Both male and female patients with cystic fibrosis can be affected by infertility 
problems. The defective ion transport causes viscous secretions that can block the vas 
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deferens and affect cervical mucus. Another major complication of cystic fibrosis is the 
arthropathy caused by the deposition of antigen-antibody complexes in the joints. The 
joints can be also affected by the development of osteoporosis which is more common 
in cystic fibrosis. 
1.2.4 Management of Cystic Fibrosis 
The management of CF is through a multidisciplinary approach due to the multiple 
systems affected by the disease. The way this is best achieved is through specialist 
clinics with individual members of the multidisciplinary team managing the patients 
through these clinics. The following are the principal components of the management of 
CF patients: 
1. Physiotherapy – The airways of CF patients become obstructed with thick viscous 
sputum which requires clearance with specialist physiotherapy employing a number 
of techniques including, postural drainage, chest percussion and devices using 
positive expiratory pressure to clear the peripheral airways. 
2. Nutrition – The main supplementation is required due to destruction of the pancreas. 
Pancreatic enzymes are given to the patient in the form of Creon, taken after each 
meal. In addition, patients require fat-soluble vitamin supplementation, that is, 
vitamins A, D E and K. Due to the general malabsorption of nutrients and the need 
to combat recurrent chest infection, patients are encouraged to consume between 
120 and 150% of their recommended daily calorie intake. In severe cases of nutrient 
deficiency patients may require admission and feeding via a nasogastric tube. 
3. Medication – Antibiotics form a major part of the medical management of cystic 
fibrosis and begins in childhood. One of the major pathogens at this age is 
Staphylococcus aureus and patients are sometimes given long-term flucloxacillin to 
suppress the infection. Other antibiotics maybe required depending on the pathogens 
isolated from sputum. As patients advance in age the common pathogen is 
Pseudomonas aeruginosa and patients can become chronically colonised. Initial 
antibiotic therapy is usually in the form oral ciprofloxacin. However, nebulised 
colistin or tobramycin can also be used to combat the organism. Sometimes 
intravenous antibiotics are required and these can be given in hospital or at home. 
Infection caused by Burkholderia cepacia are often resistant to the more 
conventional antibiotics but can be sensitive to ceftazidime or meropenam. 
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Several strategies are employed to manage the thick mucus secretions in CF. 
Mucolytic agents include deoxyribonuclease, a genetically engineered enzyme used 
to cleave DNA from degrading neutrophils which contribute to the viscosity of the 
mucus. Rubin et al [23] suggested that in CF, the necrotic death of inflammatory 
and epithelial cells releases a large amount of F-actin which produces the thick 
viscous secretions.  They used depolymerising agents such as thymosin Beta 4 
(TBeta4) and gelsolin and demonstrated a dose-dependent decrease in Cf mucus 
cohesitivity.  The use of nebulised hypertonic saline and mannitol as osmotic agents 
to increase the water content of the secretions remains controversial. 
4. Lung Transplant – In patients with advance disease and deteriorating lung function a 
lung transplant maybe an option if a donor lung is available and the patient is 
suitable for surgery. 
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1.3 Gastro-Oesophageal Reflux Disease 
1.3.1 The normal anatomy and physiology  
The oesophagus is a muscular tube measuring approximately 25cm from the pharynx to 
the stomach and is situated in the posterior mediastinum. The distal 1-3cm is normally 
intra-abdominal having passed through the diaphragmatic hiatus. The oesophagus and 
stomach are united at the gastro-oesophageal junction (GOJ) or cardia (Figure 1-６). 
The lining of the oesophagus is squamous epithelium up to the GOJ where it terminates 
at the Z-line and integrates with the columnar-lined epithelium of the stomach. The 
oesophagus is also divided into three histological layers, the mucosa, submucosa and 
muscularis layer. The muscularis layer of the proximal oesophagus is composed of 
striated muscle and the distal oesophagus is composed of smooth muscle. Between these 
sections the composition is a mixture of smooth and striated muscle fibres [24]. 
 
Figure 1-６:  Important anatomical and functional structures in the human oesophagus [24] 
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The upper oesophageal sphincter (UOS) separates the pharynx and the oesophagus and 
functions to prevent aspiration of the gastrointestinal contents. It is formed by the 
cricopharyngeus muscle and is 3-4 cm long with a functional pressure of 50-100mmHg. 
The lower oesophageal sphincter (LOS) is found at the GOJ across the diaphragmatic 
hiatus. It is a high pressure zone measuring 2-5 cm and situated in the lower oesophagus. 
The pressure of the LOS demonstrates postural, diurnal and prandial variations in 
pressure.   
The LOS is closed at rest and maintains a pressure of approximately 20mmHg. It is 
composed of two muscle components, a circular component which forms a semi-
circular clasp and the gastric sling muscles form the most lateral aspect of the sphincter. 
Two main peripheral neurons mediate active contraction and relaxation of the LOS, 
acetylcholine is an excitatory neurotransmitter and nitric oxide acts mainly in an 
inhibitory way. In addition, relaxation of the LOS can part occur when tonic vagal 
cholinergic excitation to the LOS is switched off on the initiation of a swallow [25]. The 
sling muscles respond to cholinergic excitation and relaxation is predominately through 
turning off this excitation. The clasp component has a high intrinsic resting tone and 
relaxation is stimulated through the release of nitric oxide.  
The diaphragm acts as an external sphincter as the distal oesophagus passes through the 
hiatus which is formed mainly by the right crus. The compression of the lower 
oesophagus from the hiatus varies with inspiration and the resulting LOS pressure can 
vary between 10-100mmHg. Increases in intra-abdominal pressure cause contraction of 
the diaphragm and thus an increase the LOS pressure. During swallowing, belching and 
vomiting the crural portion of the diaphragm relaxes. The phreno-oesophageal ligament 
is a distinct structure that runs between the diaphragm and the gastro-oesophageal 
junction. It is a two-layered structure, the upper layer attached to the oesophagus above 
the diaphragm and the lower layer runs caudally and is attached to the oesophagus just 
above the angle of His. It is composed of collagen and elastin fibres and so whilst the 
ligament is firmly attached to the oesophagus there is some flexibility as it functions to 
prevent migration of the oesophagus into the chest.  
The oesophagus itself effectively delivers food to the stomach and this is only possible 
due to its histological composition. The oesophagus is normally collapsed but the lumen 
expands without mucosal injury when a bolus of food is swallowed. The mucosal lining 
is non-keratinised stratified squamous epithelium in humans. The underlying lamina 
propria consists of diffuse lymphatic tissue. The deep mucosa layer is the muscularis 
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mucosa consisting of longitudinal smooth muscle fibres, thicker at the proximal 
oesophagus to aid swallowing. The submucosal layer is dense connective tissue 
consisting of larger lymphatic and blood vessels as well as some nerve fibres 
(Meissner’s Plexus). The muscularis externa is the final layer and is composed of an 
inner circular layer and an outer longitudinal layer. The fibres are different in these 
layers for each level of the oesophagus; the upper third is composed of striated muscle 
fibres, the middle third is smooth and striated fibres and the lower third is smooth 
muscle like the rest of the gastrointestinal tract. Between the inner and outer layers is 
the Auerbach’s nerve plexus which helps coordinate peristalsis. Along the length of the 
oesophagus there are mucus secreting glands. They secrete slightly acidic mucus into 
the wall of the oesophagus except near the stomach where the secreted mucus is neutral.  
1.3.2 Incidence of GORD  
Gastro-oesophageal reflux (GOR) which is often short lived and may affect an 
individual on occasion can be regarded in these circumstances as a normal physiological 
phenomenon. It is often associated with completion of a meal or belching. It may 
sometimes affect an individual at night in particular after alcohol or spicy food. 
Pathological GOR is associated with symptoms and is usually caused by more frequent 
reflux episodes including some at night. This type of reflux may even lead to 
inflammation of the oesophagus called oesophagitis [24]. Gastro-oesophageal reflux 
disease (GORD), gastric reflux disease, or acid reflux disease are chronic diseases 
caused by mucosal damage due to gastrointestinal content coming up from the stomach 
into the oesophagus [26] .  
GOR is very common and it is believed up to 60% of the normal population may have 
symptoms of reflux at some point in their lives; 11% of Americans experience 
symptoms of daily reflux, and 33% experience these over a 72 hour period [27].  
1.3.3 Aetiology of GORD 
GOR occurs due to failure of one or more of the physiological protective mechanisms. 
The reflux of gastric contents in health is prevented through the combined action of the 
oesophageal musculature including the lower oesophageal sphincter (LOS) and the 
diaphragmatic crura providing an extrinsic pressure [28]. The majority of episodes of 
GOR occur during transient periods of LOS relaxation which is an abnormal 
phenomenon when it is not preceded by a corresponding primary peristaltic wave in the 
oesophageal body initiated by a voluntary swallow [24]. 
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Disorders affecting the LOS maybe functional (transient LOS relaxation) or mechanical 
(reduced LOS tone) and may be caused by a number of factors including smoking, 
hiatus hernia, diet and drugs. Although the LOS in an important barrier to GOR it is 
only one of a number of factors that prevents reflux. The table below summarises the 
patho-physiological factors which contribute to reflux (Table 1-2). 
Gastro-oesophageal reflux can occur in any period of life which suggests its aetiology is 
multifactorial. A multitude of anatomical and physiological defects caused by external 
factors such as smoking as well as other diseases may account for the development of 
reflux.  
PRIMARY SECONDARY 
LOS hypotension 
LOS overall Length < 2cm 
LOS intra-abdominal length  < 1.5cm 
Hiatus Hernia 
Loss of angle of His (hiatus hernia) 
Crural diaphragm failure 
Loss of mucosal rosette (inflammation) 
Salivation production impairment 
Impaired oesophageal peristalsis 
Gastric acid hypersecretion 
Gastric outlet impairment – gastroparesis 
Small intestine outlet dysfunction (mechanical 
obstruction/visceral enteropathy) 
Table 1-2: Possible Mechanisms of failure of the anti-reflux mechanisms[24] 
 The Anti-reflux Mechanism 
Although the resting pressure of the LOS plays a major part in the barrier against reflux 
there are a number of factors that contribute to the anti-reflux mechanism. These are 
divided as follows: 
Oesophageal Factors: 
 LOS – The LOS acts as a two-way valve by using the flutter valve principle and is a 
weak sphincter with an intrinsic pressure of 10-25mmHg. It plays a major role in 
preventing the retrograde movement of gastric content back towards the oesophagus 
against the high variations of intra-abdominal (100mmHg) and intra-thoracic 
pressure (60mmHg). This discrepancy in pressure between these components and 
the basal tone of the LOS account for the high incidence of LOS dysfunction. The 
LOS overall length is important as it relates to valve competence. LOS length less 
than 2cm is associated with failure of the anti-reflux mechanism. Intra-abdominal 
LOS length is also a significant factor in the anti-reflux mechanism. There are 
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pressure differences across the diaphragm; positive pressure in the abdomen means 
negative pressure in the thorax. The greater the LOS length in the abdomen, the 
greater the augmentation of LOS pressure with any progressive rise in intra-
abdominal pressure [24]. 
 Oesophageal Motility – Coordinated oesophageal contractions in the form of 
ordered peristalsis are required to propel the food bolus through the oesophagus and 
into the stomach. Any dysfunction in oesophageal motility can worsen gastro-
oesophageal reflux due to inadequate clearance of refluxate [24]. Certain soft tissue 
disorders such as scleroderma can result in oesophageal dysmotility and a 
hypotensive LOS. However, inflammation of the oesophagus (oesophagitis), in 
itself is associated with reduced LOS pressure and oesophageal motility. In the body 
of the oesophagus, both reduced amplitude of the primary and secondary peristaltic 
waves and failed peristalsis are common. There is a vicious cycle between 
inflammation and dysmotility, with the disorder being most pronounced in patients 
with severe oesophagitis. It is unclear on the exact mechanism through which 
inflammation results in dysmotility but a decrease in cholinergic excitation and an 
increase in nitric oxide inhibitory mechanisms may have a role [25]. 
Anatomical Factors:  
 Angle of His – This angle is formed at the cardia and creates a flap-valve 
mechanism which forms an effective anti-reflux mechanism. This angle is absent in 
a hiatus hernia and thus reflux is facilitated; as the hiatus hernia increases in size it 
can perpetuate the reflux symptoms. In patients with severe oesophagitis it is 
common to have a low pressure sphincter and hiatus hernia [25]. Oesophageal 
clearance of acid is reduced with a hiatus hernia [24]. The hernia acts as a reservoir, 
the diaphragm trapping acid resulting in repeated reflux predisposing to 
inflammation around the cardia. 
 Mucosal Rosette – A mucosal rosette is formed by the convoluted folds of 
oesophageal mucosa and this forms a fluid and gas tight seal which acts as an anti-
reflux barrier, but in oesophagitis the integrity of the rosette is disrupted and 
increases the frequency of reflux [24]. 
 LOS vagal reflex – A vasovagal reflex exists that responds to a rise in the intra-
abdominal pressure and protects against reflux by causing a rise in the LOS pressure. 
Damage to the vagus nerve during some surgical procedures can abolish this reflex 
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 Salivary secretion – During mastication of food salivary secretions which contain 
bicarbonate ions increase and when swallowed neutralise stomach acid and protect 
against refluxed acid. 
Gastric Factors: 
 Gastric Motility – A loss of gastric motor function can cause gastric stasis. This can 
cause an increase in the intra-gastric pressure predisposing to reflux. Delayed gastric 
emptying is common in patients with GORD and present in 26% of patients on the 
basis of retention at 4 hours [29]. 
 Gastric acid secretion – The majority of studies do not demonstrate an increase in 
gastric acid secretion in patients with gastrooesophageal reflux disease (GORD)[24]. 
 Duodenogastric Reflux – the reflux of gastric content may include pepsin and 
substances such as bile and pancreatic and intestinal enzymes from the duodenum. 
Pepsin exhibits its maximum activity at pH2  and the combination of pepsin and 
gastric acid in reflux is responsible for inflammation of the oesophagus [26]. 
Exposure to the combination of bile acids and gastric acid appears to be more 
harmful than gastric acid alone and can damage the oesophageal epithelial layers, 
leading to oesophagitis, Barrett's oesophagus, and even oesophageal cancer [30]. 
There are marked differences in behavior of bile acids depending on the pH of the 
solution in which they reside. In strongly acidic conditions, conjugated bile acids 
enter mucosal cells in a non-ionized form, which occurs at a pH close to or below 
their acid dissociation constant (pKa)[30]. These refluxed bile acids can cause 
intracellular damage by the dissolution of cell membranes and tight junction 
proteins. Patients with both acid and duodenal reflux have a high incidence of 
oesophagitis and duodenogastric reflux is more common in GORD patients with 
strictures and Barrett’s oesophagus [31]. 
1.3.4 Management of Gastro-Oesophageal Reflux Disease 
The goal of treatment for gastrooesophageal reflux disease (GORD) has evolved over 
30 years from short term symptom relief to long-term symptom control. Treatment is 
based on a step wise approach commencing with a single drug regime, progressing to 
multiple drug regimes and finally in some cases endoscopic and surgical treatment.  
Before any type of medical treatment, lifestyle modifications are initially recommended. 
These measures include alterations in eating habit, dietary restrictions, postural changes 
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during sleep and eliminating exacerbating factors to reflux such as smoking and alcohol. 
However, whilst lifestyle changes are frequently requested the evidence suggests that 
these changes or attempts to carry out these modifications  have limited effects [32]. 
Below is a summary of the treatment strategies employed for reflux disease (Figure 
1-７): 
 Medical Treatments 
 Over the Counter - These include simple antacids and alginates such as 
Gaviscon. These are both effective at providing some symptom relief but in 
severe reflux or patients with oesophagitis they are less effective [32]. 
 Acid Suppression – The first effective treatment for GORD were H2-receptor 
antagonists like cimetidine which worked by suppressing the production of 
stomach acid. These were replaced by proton pump inhibitors (PPIs) which were 
not only better at symptom control but were also effective at healing 
oesophagitis. In patients that respond well to a treatment dose of PPI, a 
maintenance dose is often prescribed long-term to prevent the relapse of 
oesophagitis [32] .  
 Motility agents - As well as improving peristalsis prokinetics often enhance 
gastric emptying and may reduce reflux of gastric contents. 
 Helicobacter Pylori Eradication – The treatment of H.Pylori infection has not 
been shown to effect GORD. However, many patients with reflux-like and 
dyspeptic symptoms often have ulceration from infection by the microorganism. 
These symptoms can be effectively managed by eradication therapy [32].  
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KEY: 
NERD = non-erosive reflux disease 
EO = erosive oesophagitis 
Figure 1-７:  Algorithm for diagnosis and treatment of GORD[32]
TYPICAL GORD 
SYMPTOMS 
RED FLAGS PRESENT 
OGD 
NERD 
CONSIDER 
ON 
DEMAND 
THERAPY 
EO 
TREAT 
CHRONIC 
MAINTENANCE 
THERAPY 
RED FLAGS ABSENT 
PHASE I THERAPY – LIFESTYLE, OVER THE 
COUNTER MEDS, PRN PPI OR H2-
ANTAGONIST 
PHASE 2 TX – PPI BD OR H2-ANTAGONIST 
BD 
AFTER OGD 
PHASE 3 TX – PPI BD WITH PROKINETIC OR 
PPI BD WITH H2 ANTAGONIST AT NIGHT 
PERFORM OESOPHAGEAL PHYSIOLOGY 
AND/OR SWALLOW 
PHASE 4 TX – ANTI-REFLUX OR 
ENDOLUMINAL PROCEDURE 
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 Surgical Management 
 The primary indication for surgery is the failure of medical treatment which may 
be defined as persistent symptoms whilst on medical treatment or soon after 
stopping maximal medical treatment; the decision here being a balance between 
the reliance on medication and the suitability of an operation. 
Anti-reflux surgery is effective in patients where reflux is secondary to a 
defective lower oesophageal sphincter (LOS) or where there is reflux in the 
presence of a normal LOS. There are a number of reasons that explain the 
success of anti-reflux surgery and these include the following [24]: 
a. The floppy valve principle of the abdominal oesophagus is created by using 
the fundus to compress the lower oesophagus. As the intra-gastric pressure 
this acts as an antireflux mechanism. 
b. A possible reduction in TLOSRs. 
c. Exaggeration of the flap valve at the angle of His where the oesophagus 
joins the stomach. 
d. An increase in mean LOS resting pressure as measured in post surgery 
manometry studies. 
e. A reduction in the volume of the gastric fundus which may help gastric 
emptying and reduce acid secretions. 
f. Prevention of shortening of the intra-abdominal oesophagus during gastric 
distention. 
The principal behind any anti-reflux procedure is the creation of the barrier 
between the oesophagus and stomach. There are several ways of accomplishing 
this and surgery may be performed either as an open or laparoscopic technique. 
The most popular antireflux procedure is a Nissen 360º fundoplication. In this 
procedure, any hiatus hernia is reduced in to the abdominal cavity and the 
fundus of the stomach is brought behind the oesophagus and sutured anteriorly 
to the remainder of the fundus in a loose fashion hence the term ‘floppy’ Nissen.  
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Some surgeons choose to do a partial (180º) wrap such as the Toupet or Dor 
hemi-fundoplication (Figure 1-８). The rationale behind this is that by partially 
wrapping the fundus around the oesophagus there is less likely to be 
complications of dysphagia sometimes associated with a complete 
fundoplication [24]. 
 
 
 
 
 
Figure 1-８: Diagrams of a floppy ‘Nissen’ fundoplication and a ‘toupet’ partial fundoplication.  
 
Legend: The Nissen fundoplication is a full 360º loose wrap around the oesophagus and 
sutured anteriorly to the remainder of the fundus using non-absorbable sutures. The 
Toupet wrap is a posterior hemi-fundoplication with the fundoplicature sutures placed 
in the crural margins on both sides.[33] 
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1.4 Assessment of GORD 
1.4.1 Endoscopy 
Upper gastrointestinal endoscopy is the ‘gold standard’ for documenting the type and 
extent of mucosal injury to the oesophagus  (Figure 1-９)[32]. Only 40-60% of patients 
with positive pH tests for reflux have oesophagitis so the sensitivity of endoscopy for 
the detection of GORD is only around 60% at best but the specificity is between 90-
95%. A third of patients with a normal oesophagus on endoscopy will have pathological 
reflux [34].  
Beyond simply assessing the extent of mucosal damage secondary to reflux, endoscopy 
can be used to diagnose the other complication associated with GORD including 
Barrett’s oesophagus and strictures secondary to inflammation. In addition, endoscopy 
can be used to exclude malignancies and some dysmotilty disorders such as achalasia.  
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Figure 1-９: Endoscopic views of the oesophagus with the Los Angeles oesophagitis scoring system 
[34]. 
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1.4.2 Manometry 
Oesophageal manometry is the gold standard for the assessment of oesophageal motor 
function by providing information on contractile activities of the oesophageal body and 
lower oesophageal sphincter (LOS) [24]. In the assessment of GORD, oesophageal 
manometry is used to determine whether there is normal oesophageal motility and to 
identify the LOS to ensure accurate placement of the pH/impedance catheter 5cm above 
the sphincter. 
The equipment necessary to perform manometric testing includes the catheter, pressure 
transducers and a recorder. Over recent years oesophageal manometry has become 
much more sophisticated to incorporate a variety of recording devices and approaches to 
manometric measurement and analysis [35].   The manometric systems can use either a 
water-perfused catheter system or one based on solid –state circuitry. The solid-state 
systems are more expensive and fragile but provide a better assessment of the proximal 
oesophagus and pharynx.  
Oesophageal manometry is used to record the resting pressures of the lower and upper 
oesophageal sphincters as well as the timing and completeness of the relaxation. In the 
oesophageal body it provides an assessment of the peristalsis by measuring the velocity, 
amplitude and duration of the contraction in response to a swallow [32]. The number of 
readings obtained is dependent on the number of sensors, typically spaced 3 to 5 cm 
apart along the catheter. Traditional systems use an 8-channel catheter where each of the 
8 sensors is connected to a pressure transducer which converts the physical changes in 
pressure into electrical signals. These signals are transmitted to a recorder which 
transforms the signal into a visual display by way of a polygraph (Figure 1-１０). 
Testing is performed by passing the catheter trans-nasally into the stomach and pulling 
it back across the LOS into the oesophagus 
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Figure 1-１０: 8 Channel Manometry trace for a single swallow [36]. 
 
Legend: The figure illustrates tracings obtained from the proximal four channels 
positioned in the oesophagus and distal four channels arranged radially in the LOS. A 
pull-through technique is used for sphincter assessment. At intubation the recording 
ports are passed beyond the LOS and withdrawn in small increment (usually 0.5-1cm). 
The LOS, oesophageal body and UOS can be identified by their responses to a 5ml 
bolus of water. The trace above illustrates the progression of a peristaltic wave through 
the body of the oesophagus. Detailed measurements of the LOS including assessing the 
degree of LOS relaxation and the resting pressure can also be assessed. 
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Technical advances in manometry have led to the development of a wide variety of 
recording equipment and approaches to manometric measurements and their analysis. 
The development of powerful computerised acquisition systems, along with high-
fidelity multichannel perfusion pumps and manometric catheters has enabled 
measurement of oesophageal motility with high resolution manometry (HRM).  
High Resolution Manometry (HRM) is simply an adaptation to the traditional 8-channel 
manometry basically incorporating an increased number of pressure sensors spaced 
closely together. However, a polygraph image using information from over 20 sensors 
can become very difficult to interpret. Clouse and Staiano [37] used a process of 
interpolation or averaging between sensors to display the information in the form of 
isobaric colour regions on oesophageal topography plots, or Clouse plots 
 (Figure 1-１１). 
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Figure 1-１１: High Resolution manometry trace for a normal swallow 
 
Legend: These topographic plots have the capacity to convert manometric information 
into distinct patterns that illustrate the physiology of contractile coordination and 
provide a better understanding of oesophageal body peristaltic function due to more 
detailed and accurate measurements [38]. 
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1.4.3 Ambulatory pH Testing 
Ambulatory pH monitoring has been used for many years to evaluate GORD. It has 
previously been called the “gold-standard” for detecting  pathological reflux [39]. pH 
monitoring is very useful for assessing acid reflux and its function is through the 
measurement of H
+
 ions [40]. The test is performed with a pH probe passed trans 
nasally and positioned 5cm above the lower oesophageal sphincter [39]. Measurements 
can be collected and logged into a data recorder as frequently as every 4 to 6 seconds 
and reflux episodes are considered significant when the pH of the oesophagus is less 
than 4. There was strong consensus agreement among specialists that acid reflux should 
be defined as reflux episodes that decrease oesophageal pH below  4, or reflux that 
occurs when oesophageal pH is already below 4 [41].  However there are several 
disadvantages of this definition. One important problem with pH monitoring is in the 
ability to correlate accurately with pathological evidence of GORD with studies 
producing a wide variation in sensitivity and specificity of 24-hour pH monitoring [32].  
The sensitivity of pH monitoring to detect individual acid reflux episodes is determined 
by sampling frequency, duration threshold, pH threshold, and the recurrence of reflux 
prior to pH recovery [41]. Sampling frequency affects the number of reflux episodes 
detected. To be optimal this should be at a frequency of 1Hz but normal pH monitoring 
sampling frequency is considerably less at 0.25Hz which affects the sensitivity of the 
probe [41]. The specificity of pH monitoring is affected by the ingestion of acidic food 
substances as well as respiratory changes, movement and electrode drift. All these 
factors cause significant and frequent variations in the pH.  Its other shortcoming is its 
inability to detect or acknowledge weakly acid and non-acid reflux. It is also unable to 
measure the proximal extent of reflux, although dual channel pH monitors have been 
designed to measure proximal and distal reflux [41].  
1.4.4  Multichannel Intraluminal Impedance 
Standard pH monitoring may underestimate the degree of reflux. In 1991 Sliny [42] was 
the first to describe multichannel intraluminal impedance (MII), a novel method of 
assessing intraoesophageal bolus movement . This was further developed to combine 
impedance with pH assessment in  order  to determine the nature of the reflux [40]. 
Through the improvements in catheter technology and the development of computer 
software in the last decade there has been a steady increase in the availability of 
Multichannel Intraluminal Impedance (MII) [36]. The direction and the proximal extent 
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of liquid and gas reflux events can be accurately measured by MII [40]. It is becoming 
the gold standard for assessment of reflux [43].  
Theory, validation, intra-observer variability & reproducibility 
Impedance is inversely proportional to electrical conductivity and cross sectional area of 
the oesophageal lumen. It is studied using a catheter with multiple spaced, pairs of 
cylindrical metal rings connected in circuits to the lumen of the tubular organ [36]. Each 
paired ring circuit has a voltmeter outside the body. As boluses pass, there are changes 
in impedance recordings. Gases cause a sharp rise in impedance, with rapidly 
decreasing conductivity. Fluids (food, water and gastric contents) decrease impedance 
by connecting circuits between electrodes [40].  
The empty oesophagus has an impedance value which is intermediate and reflects the 
conductivity of the oesophageal mucosa (approximately 2000Ohm). When a fluid bolus 
passes, impedance is low (e.g physiological saline solution = 100Ohm). After it has 
passed, impedance returns to the intermediate level of the oesophageal mucosa. (Figure 
1-１２). These changes in impedance occur when the bolus is between a pair of 
electrodes. Liquid reflux will drop impedance by 50% in 2 consecutive sensors. Gas 
reflux is defined as a retrograde, simultaneous rise in impedance to >3,000 ohms [40]. 
Initially impedance was measured in the lumen of the gastrointestinal tract and has been 
validated by studies using barium radiographs in anaesthetised cats [44].  
Multichannel Intraluminal Impedance collects data samples at high frequency rates, 50 
Hz. This technique enables to determine the direction of the bolus[36].  This allows 
normal swallowing of  liquids to be distinguished from reflux events and means 
swallowed air can be distinguished from “belched” air [40]. There is some intra- and 
inter-individual variability with impedance measurements. Bredenoord et al evaluated 
20 healthy volunteers, 2 weeks apart and found that there was more variability between 
different subjects by >50%, than within the same subjects measured at different times 
[40, 45]. 
Refluxate can be acid (pH 4), weakly acid (pH 4-7) or weakly alkaline (pH>7) and can 
be composed of liquid, gas or a mixture of the two. Patients with pathological GORD, 
have more acid events and fewer non-acid and weakly acid reflux events when 
compared to normal subjects [36]. Pure gas reflux is a non-acidic event [40]. Gas reflux 
often occurs whilst in the left lateral decubitus position, and liquid reflux tends to occur 
in the right lateral decubitus position [40]. 
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Figure 1-１２: A Weakly-acid Liquid Reflux Event [36] 
 
                 
 
 
Legend: This picture shows a combined pH/impedance trace. The bottom reading is of 
pH, from the pH sensor located 5cm above the lower oesophageal sphincter, and as this 
does not drop below pH 4, this shows this to be a weakly-acidic event. The traces above 
this (1
st
 ring to 6
th
 ring) represent the impedance values from 3,5,7,9,15 and  17cm 
above the lower oesophageal sphincter. The traces measure electrical impedance within 
the oesophagus and the sequential drop in impedance from the 1
st
 to the 6
th
 ring, 
demonstrates a reflux event reaching the proximal oesophagus. 
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It has been known for a long time that “some” reflux is physiological, with an 
oesophageal acid exposure of <4.5%/24 hours considered within normal limits [46]. In a 
“normal” population (72 healthy French and Belgian volunteers with a mean age of 35 
years, with no known gastrointestinal disease or history of thoracic or abdominal 
surgery), a study showed that on average there will be 40 reflux events per 24 hours 
[47]. Using pH impedance monitoring, after a standardised liquid meal, most events 
were mixed gas and liquid, post-prandial reflux events [40]. In addition, Two thirds of 
reflux events are non-acidic or weakly-acidic events [40]. 
Impedance allows detailed evaluation of refluxate and also allows evaluation in patients 
on proton pump inhibitor (PPI) therapy [36, 40]. PPIs have been shown not to decrease 
the number or volume of reflux events, but render them non-acid or weakly acid events. 
Thus they do not prevent reflux [40]. Furthermore there is evidence to suggest that the 
volume of gastric secretions is not reduced with PPI [48]. A study of pH monitoring of 
250 patients on PPI therapy, showed 3.8% to have an abnormal study. Impedance 
showed that weakly acid events were just as common after proton pump inhibitor 
therapy as acid events prior to acid suppression, i.e. acid levels detected were greatly 
reduced, but impedance showed that reflux events were just as common [40]. At least a 
third of reflux events are weakly alkaline or weakly acidic. These may elicit extra-
oesophageal reflux symptoms such as cough, sore throat, hoarse voice and even 
pulmonary symptoms such as wheeze and dyspnoea [49, 50].  
The association between atypical extra-oesophageal symptoms with reflux has been 
difficult to prove [36]. A study involving 10 subjects with extra-oesophageal symptoms 
used pH-impedance to study their episodes of reflux. Half of patients had a temporal 
association with reflux and their cough, though a causative link has yet to be proven 
[40]. 
Standard definitions have been created for acid reflux, superimposed acid reflux, 
weakly acid reflux and weakly alkaline reflux on the basis of combined pH/impedance 
measurements (Table 1-3). Oesophageal and extra-oesophageal symptoms can be 
related to less acid reflux [41, 47, 51, 52]. 
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Table 1-3: Standard Definitions for Reflux Events [41, 47, 51, 52] 
 
Weakly acid reflux events often occur near meal times. In patients with prolonged 
gastric emptying, there may be an increase in weakly acid reflux and a decreased acid 
reflux [41]. Weakly acid refluxate causes less heartburn when compared to acid reflux, 
but patients may still suffer regurgitation or chronic cough. [41]. 
 Comparison of pH monitoring to Impedance 
Acid reflux events, detected by impedance appear to be shorter, as neutralisation of acid 
takes longer than the clearance of oesophageal volume. There is a higher detection rate 
of reflux events with impedance compared to pH monitoring [36]. In one study, 
Impedance detected 96% of reflux events compared to 28% detected by pH study using 
acid reflux event definition. Non-acid and weakly acid reflux events are common in 
both normal subjects and those with GORD [40, 53].  
The Porto consensus devised in 2006 [35] and the British Society of Gastroenterology 
guidelines [54] on the detection of reflux both state that reflux is best evaluated by a 
combination of impedance and pH monitoring.   
1.4.5 Other Techniques for Assessing Reflux 
Barium Swallow 
A barium swallow is an inexpensive, non invasive and widely available radiographic 
investigation using double-density barium as well as a gas forming agent. The test can 
delineate the oesophagus and oesophagogastric junction, revealing subtle strictures, 
rings and hiatus hernias. In addition, often with some specialised manoeuvres involving 
the patient, including coughing and rolling side-to-side, reflux can also be demonstrated 
[24]. The ability of the swallow to detect oesophagitis varies considerably. Sensitivities 
Acid reflux Refluxate of gastric juice which reduces the pH<4 
Superimposed acid 
reflux 
Further refluxate of gastric juice before the pH has recovered to >4. 
Weakly acid reflux Refluxate of gastric juice when the pH remains between 4-7. 
Weakly alkaline 
reflux 
Refluxate of gastric juice when the nadir pH is greater than 7 
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of between 79% and 100% have been shown in the presence of severe oesophagitis, but 
the barium swallow is less accurate in the detection of mild inflammation [32]. The 
barium swallow is very useful for demonstrating peristalsis and disorders of 
oesophageal motility.  
Bravo Capsule 
To remove the technical difficulties of nasal catheterisation, the Bravo Capsule 
(Medtronic, Minneapolis, MN, USA) has been developed. This is a wireless pH probe 
which is attached to the lower oesophageal mucosa during endoscopy about 6cm above 
the normal z-line [36]. Its advantages are its tolerability; it is painless and does not 
interfere with normal daily activities or sleep and the fact that  it allows recording for 
over 24 hours [39].  
 Bilitec 
The Bilitec 2000 (Medtronic, Minneapolis, MN, USA) device only measures bile reflux 
[39]. It requires that patients adhere to a specific diet which can be difficult and affect 
compliance. In addition, refluxate can get stuck in the sensor opening, thereby causing 
an overestimation of bile exposure. The detection of bile refluxate is important, but a 
better understanding of bile reflux and aspiration may be achieved by the biomarker 
approach of assessing levels of bile salts in the bronchoalveolar lavage fluid [36]. 
1.4.6 Reflux Questionnaires 
Questionnaires have been designed to detect symptoms suggestive of both oesophageal 
and extra-oesophageal reflux. Laryngopharyngeal reflux does not always cause classical 
heartburn or oesophagitis. Signs & symptoms of laryngopharyngeal reflux include 
hoarseness, vocal fatigue, excessive throat clearing, globus pharyngeus, chronic cough, 
post-nasal drip and dysphagia.  
Several laryngopharyngeal reflux questionnaires have been designed. One such 
questionnaire, which has been validated is the Reflux Symptom Index (RSI) (Figure 
1-１３), which is 9 item questionnaire [55].  
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Figure 1-１３: Reflux Symptom Index (RSI) questionnaire.  
 
Legend: The patient is asked to assess the severity of their symptoms on a scale of 0 to 
5 for each of the nine parameters tested by the questionnaire. The score is then added up 
to give a total RSI score. A score above 13 indicates an abnormal RSI score. 
Within the last Month how did the following problems affect 
you 
0 = No Problem        5 = Severe Problem 
Hoarseness or a problem with your voice 0 1 2 3 4 5 
Clearing your throat 0 1 2 3 4 5 
Excess throat or postnasal drip 0 1 2 3 4 5 
Difficulty swallowing food, liquids or pills 0 1 2 3 4 5 
Coughing after you eat or after lying down 0 1 2 3 4 5 
Breathing difficulties or choking episodes 0 1 2 3 4 5 
Troublesome or annoying cough 0 1 2 3 4 5 
Sensation of something sticking in your throat or a lump in 
your throat 
0 1 2 3 4 5 
Heartburn, chest pain, indigestion or stomach acid coming up 0 1 2 3 4 5 
 RSI  
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 The RSI is easily administered and highly reproducible. It was validated on 25 
laryngopharyngeal reflux patients and 25 controls [56]. The RSI correlates well with the 
Voice Handicap Index, another validated assessment of laryngopharyngeal reflux. A 
RSI score of greater than 13, is abnormal [55]. A limitation of this questionnaire is that 
5/45 possible points can be attributed to heartburn. Thus, the RSI is not limited to extra-
oesophageal reflux symptoms but can be elevated in patients with isolated oesophageal 
reflux.  
The DeMeester Reflux Questionnaire is a validated assessment tool looking at basic 
reflux symptoms[57]. It is based on a score of 0-3 for symptoms of reflux, regurgitation 
and dysphagia. Sequential questionnaires are also useful in assessing the response to 
treatment. 
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1.5 Reflux and lung disease 
1.5.1 Reflux Disease and advanced lung disease 
The association between reflux, aspiration and lung disease is not well characterised. As 
early as 1927 it had been postulated that a dysfunctional gastrointestinal tract may lead 
to aspiration and lung disease. Following this several studies in the 1960s and 70s 
reported a high prevalence of pulmonary fibrosis in patients with clinical diagnosed 
GOR [58]. A landmark paper was written in 1979 addressing some of the key principles 
linking GORD and chronic lung disease [59]. In this study Pellegrini et al showed that 
patients were more likely to have respiratory disease if they had reflux associated with 
weak oesophageal peristalsis and slow oesophageal clearance. Some of the first studies 
describing the association between reflux and lung disease describe high incidence of 
impaired oesophageal motility in patients with parenchymal lung disease[60]. Since 
these small studies, many large epidemiological studies have been carried out which 
describe an association between GOR and respiratory disease. In 1999 El-Serag et al 
retrospectively studied 101,366 patients and showed that erosive oesophagitis and 
oesophageal disease was associated with a wide variety of upper and lower respiratory 
conditions including sinusitis, pharyngitis, COPD but were most strongly associated 
with bronchial asthma and pulmonary fibrosis [61]. More recently in 2006 Ford et al 
performed a questionnaire study of 4000 volunteers, the results of which show a strong 
correlation between chronic cough and GOR [62]. There is a high prevalence of foregut 
motility problems and GORD in patients with advanced lung disease [63]. In their study 
D’Ovidio et al [63] demonstrated that 72% of patients had decreased lower oesophageal 
sphincter pressure and 33-47% of patients had oesophageal body dysmotility and 
impaired peristalsis; in total almost 80% of these patients have oesophageal dysmotility 
and/or a hypotensive lower oesophageal sphincter [63]. Sweet et al, in their study of 
end-stage lung disease patients, suggest that 55% of patients with reflux had a 
hypotensive lower oesophageal sphincter compared with only 26% of patients without 
reflux. In addition, patients with GOR had impaired oesophageal peristalsis [64]. 
The prevalence of GORD in patients with advanced lung disease awaiting lung 
transplant has been reported to be in the range of 63-68% [65], though some studies [63] 
do report a lower prevalence of 38%; the latter figure may be as a result of cessation of 
acid suppression therapy for only 5 days as opposed to the recommended 10 days to 
ensure the effects of medication did not interfere with objective pH assessment. 
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The movement of stomach content into the upper airway is described as 
laryngopharngeal reflux (LPR) and can lead to extra-oesophageal reflux symptoms. 
There are three potential mechanisms causing the presence of extra-oesophageal 
symptoms associated with reflux [66]: 
1. Direct irritation of the airway epithelium by reflux material 
2. Afferent cough reflex hypersensitivity of the airway due to reflux 
3. A neural reflex between the oesophagus and airway tract. Up to 50 episodes of 
reflux from the stomach to the oesophagus are within the physiological limits of 
normal but just one event of reflux that reaches the laryngopharynx could be 
enough to produce symptoms in the upper airway. 
Characterisation of the reflux seen in patients with advanced lung disease was 
performed by Patti et al in 1993 [67]. They used a dual sensor pH monitor to correlate 
cough with proximal oesophageal reflux and extra-oesophageal reflux symptoms. They 
later suggested that micro-aspiration caused by proximal reflux was the likely aetiology 
of the cough [68]. There is some controversy as to whether proximal reflux occurs more 
commonly in the supine or upright position [63] [64], and people may suffer from 
proximal reflux despite having normal distal reflux [64]. A loss of laryngeal 
mechanosensitivity may contribute to microaspiration when associated with cough and 
significant respiratory disease [66].   
Another theory that may account for the high prevalence of GORD in advanced lung 
disease is related to the exaggerated pressure fluctuations between the thorax and 
abdomen seen in pulmonary disease; these may challenge the normal gastro-
oesophageal barrier and predispose to the movement of stomach contents up the 
oesophagus [69].  In their study Ayazi et al suggested that an inspiratory thoraco-
abdomianl pressure gradient higher than the resting LOS pressure accounted for 
increased oesophageal acid exposure in 85.2% of patients. However, their study only 
used patients with manometrically normal lower oesophageal sphincters and no history 
of pulmonary disease, and though their conclusions imply that exaggerated ventilatory 
effort can result in GOR its application in patients with advanced lung disease may be 
limited [69]. 
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1.5.2 GORD and Idiopathic Pulmonary Fibrosis (IPF) 
Interstitial Lung Disease (ILD) comprises of a group of both acute and chronic disorders 
characterised by diffuse pulmonary infiltrates producing histological features of 
pulmonary inflammation as well as evidence of restrictive lung function [1] . Interstitial 
lung disease also encompasses the diagnosis of idiopathic pulmonary fibrosis when the 
aetiology of ILD is unknown. Despite IPF carrying a prognosis worse than most cancers 
it remains poorly understood with no effective disease modifying treatment [28]. It has 
been noted that IPF appears to be substantially more prevalent than previously reported. 
This could be as a result of changes in clinician diagnosis, but it is also likely that there 
has been a real increase in disease prevalence[70]. The pathophysiology of IPF is 
believed to be a result  of fibroblast proliferation from chronic lung epithelial injury 
[58]. Understanding the source of the initial lung injury would provide a better 
understanding of IPF and may lead to more effective treatment strategies. 
Since the early 1960s several studies have demonstrated an association between ILD 
and gastro-oesophageal reflux (GOR) [58]. Recently it has been demonstrated through 
24-h pH monitoring that GOR is highly prevalent but often clinically occult in patients 
with ILD when compared to normal subjects; the use of standard dose proton pump 
inhibitors, appears to only affect the pH of the refluxate but the number and magnitude 
of reflux events remains unchanged [58, 71].  
It has been postulated that the variations between the abdominal and thoracic pressure 
seen in ILD may account for increased GOR [1] but the exact mechanism behind GOR 
leading to the progression of ILD has never been elucidated.  Until recently the 
assessment and treatment of GOR focused on using conventional pH monitoring. When 
performed in patients with interstitial lung disease, there has been limited benefit of acid 
suppressive therapy after pH assessment [72]. Conventional pH measurement is limited 
to detecting only acid refluxing from the stomach. The addition of oesophageal 
impedance measurements allows the detection of non-acid and weakly acid reflux 
events (refluxate pH >4) [27]. A recent study [72] demonstrated using oesophageal 
impedance in subjects with systemic sclerosis associated ILD, that increased non-acid 
reflux episodes could be associated with the progression of pulmonary disease. 
Savarino et al concluded that further studies should include reflux reducing measures to 
test whether the development and progression of ILD could be prevented by treating 
GOR.  
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A relationship between IPF and GOR was first postulated by Mays et al [73] when they 
noted that hiatus hernia is more common in IPF patients. Tobin et al [74] demonstrated 
in 17 patients with biopsy-confirmed IPF, that 94% had reflux confirmed with 24-hour 
manometry, 75% of these patients reported no reflux associated symptoms. Recently 
this has been confirmed in a larger cohort of 65 patients by Raghu et al [71]. This study 
demonstrated that GOR was present on 24-hour pH monitoring in 87% of their subjects. 
Interestingly Raghu et al showed abnormal oesophageal acid exposure in 63% of their 
patients who remained on a proton pump inhibitor during their pH studies. A recent 
case-control study [75] aimed to evaluate reflux in patients with IPF by analysing the 
scores from a validated cough questionnaire, the Hull airway reflux questionnaire 
(HARQ). The authors also used an exhaled breath condensate (EBC) to detect pepsin in 
suspected extraoesophageal reflux and Helicobacter Pylori (H.Pylori) serology to 
evaluate for the prevalence of this bacterium in the upper gastrointestinal tract of IPF 
patients. For the three aspects of the study the cases and control groups were not 
matched in numbers. For the HARQ component of the study, 40 IPF patientswere 
evaluated against 50 controls, EBC was collected from 17 IPF patients and 6 controls 
and H.pylori antibody detection was performed in 34 IPF patients and 23 controls. 
Significantly higher HARQ scores were recorded in patients with IPF compared with 
controls (p<0.001). This questionnaire is targeted towards non-acid reflux 
(larynopharyngeal reflux), but without objective impedance-pH monitoring it is not 
possible to be certain as to the nature of the refluxate in this patient group. The EBC 
measurements of pepsin showed no difference between the patients and controls. As the 
EBC was used in clinic at a set point in time it may have easily missed reflux episodes. 
The study did not show any significant difference in H.Pylori serology between patients 
and controls. The lack of correlation with the HARQ scored can be expected as H.Pylori 
colonisation is often associated with a reduction in acid reflux [25]. However, a further 
study from Fahim et al [75] clearly reinforces the hypothesis that reflux and IPF may 
have a causal relationship. 
Idiopathic pulmonary Fibrosis patients with marked asymmetry of their lung disease on 
high-resolution CT (HRCT) have an increased prevalence of acute exacerbations, with 
increased reflux symptoms [76].The most recent guidelines (BTS, 2008) from the 
British Thoracic Society on ILD, recognises the potential of GOR to complicate IPF but 
since then the ATS/ERS/JRS/ALAT 2011 IPF [6] statement has also reiterated the lack 
of understanding of any link between GOR and IPF. It encourages further studies to 
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determine the exact nature of the reflux. This is not only important to improve our 
understanding but to ensure patients receive the correct therapy.  
There is conflicting evidence of the role of proton pump inhibitor (PPI) therapy in IPF 
patients, with some studies claiming inadequate acid suppression with standard doses of 
PPI e.g. omeprazole 20mg once daily [71]. A single case study of a 60 year old patient 
with IPF demonstrated symptomatic improvement of IPF with treatment (high dose) PPI 
e.g. 20mg omeprazole twice daily. However, in this study they also made dietary and 
behavioural changes including abstinence from alcohol as well as sleeping in a slightly 
elevated position; it is therefore difficult to conclude from a single case report that the 
improvements are as a result of the PPI therapy alone [77]. More recently from the 
Mayo clinic, PPI therapy has been shown to improve survival and lower radiological 
evidence of fibrosis [78]. Interestingly 5% of patients still received anti-reflux surgery 
despite these findings. 
1.5.3 GORD and Cystic Fibrosis (CF) 
Cystic fibrosis is a multisystem disease which can have profound effects on the 
functioning of the digestive, endocrine, reproductive and respiratory systems. Cystic 
fibrosis transmembrane conductance regulator (CFTR) is a 1480 amino-acid 
glycoprotein that in humans is encoded by the CFTR gene expressed on chromosome 7. 
CFTR is a member of the ATP-binding cassette (ABC) transporter superfamily. All 
ABC transporters bind to ATP and use its energy to transport molecules across the cell 
membrane. Mutations in ABC genes have been linked to many diseases; one of the most 
common in the West is Cystic Fibrosis. Approximately 1 in 20 Caucasians are carriers 
for mutations in CFTR and the disease affects 60000 individuals worldwide [79]. This 
disease can present as exocrine pancreatic insufficiency, an increase in sweat sodium 
chloride concentration, male infertility and most commonly airway disease. The CFTR  
plasma-membrane cyclic AMP-activated chloride channels is found in the epithelial 
cells of many organs including the lung, liver, pancreas, digestive tract, reproductive 
tract, and skin. In addition to mediating the secretion of chloride ions, CFTR also 
regulates several transport proteins including the epithelial sodium channel (ENaC).  
Mutations of the CFTR gene affect the number of CFTR channels in the membrane, 
channel activity and intracellular trafficking of CFTR. This reduces the functional levels 
of CFTR in the plasma membrane resulting in a defect of chloride ion secretion, 
hyperabsorption of sodium and other changes affecting a number of organs, leading to 
cystic fibrosis. It is the effect on the respiratory system and the reduced capacity of the 
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cilia to clear bacteria from the airway which accounts for the morbidity and mortality 
associated with the disease. The major respiratory manifestations include chronic 
bacterial colonisation with Pseudomonas aeruginosa, cough and emphysema [80]. 
GOR has been reported as early as the 1970s in patients with CF and currently the 
prevalence is estimated to be between 35-81% [81]. Over the last 30 years advances in 
the care of patients with CF have results in a growing adult population with CF. There is 
a higher incidence of GOR in children with CF than in the general population [82], 
about 1 in 5 newly diagnosed CF infants have pathological reflux, [22] but there are 
very few comparable studies in the adult CF population. It is unclear whether GOR is 
increased in CF as a primary effect of the disease, or is prompted by non-GORD 
manifestations of CF and its treatments [83].  
Several mechanisms have been suggested for the GOR seen in patients with CF 
including a reduced pressure of the lower oesophageal sphincter, the presence of 
increased number of transient LOS relaxations, delayed gastric emptying and the 
increased abdominal-thoracic pressure gradient often secondary to cough and postural 
drainage physiotherapy [81]. Although the role of physiotherapy exacerbating reflux in 
patients with CF is unclear as several studies have demonstrated no change in the 
number of reflux episodes, including proximal events when assessed in the 20º head 
down position [84]. A recent study [85] attempted to determine the relationship between 
the type of reflux, (GOR or duodeno-gastroesophageal reflux) with gastric emptying 
and demonstrated a positive correlation between the rate of gastric emptying and 
severity of duodenal reflux (n=5). However, the study used very small subgroups to 
determine the above relationship and so its application to a CF population in general is 
limited.  
Most of the studies performed so far in this population use 24 hour pH monitoring 
which only allows the detection of acidic GOR. However, the nature of the refluxate in 
CF, that is, the volume and acidity maybe altered and simple pH monitoring may not 
effectively characterise the GOR [81]. GOR is thought to be highly prevalent in CF but 
has not been systematically studied with up to date methods such as impedance pH 
monitoring. This method of assessment allows the detection of acidic, weakly acidic 
and non-acid reflux which will provide better characterisation of GOR in CF [41]. There 
have been limited studies performed using pH impedance in CF patients [81] with 
interesting results. Blondeau et al performed pH impedance studies on 23 CF patients 
and demonstrated that up to 80% had acid GOR with subgroup having increased weakly 
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acid reflux. However, it must be noted that in this study the patients had been on long 
term PPI which was only stopped for 7 days prior to the assessment. This may have lead 
to under-detecting some patients with acid reflux, as depending on the PPI, acid 
suppression effects can last up to 7 days from stopping the treatment [86]. Another 
hypothesis suggested for the presence of acid reflux in CF patients is due to delays in 
acid clearance. Reduced bicarbonate secretion from the stomach, duodenum and 
pancreas may delay neutralisation and this could account for the acidic refluxate [83]. 
The studies above illustrate the importance of understanding the nature of the reflux as 
well as determining the underlying mechanism. Although weakly acid GOR is 
uncommon in CF, acid GOR can be prevalent as early as infancy [87], and this 
highlights the importance of early management of GOR in CF. Fathi et al [80] 
demonstrated that laparoscopic fundoplication was highly effective in controlling reflux 
in a small selection of CF patients, where medical treatment had failed. Further open 
studies which indicate the potential for anti reflux treatments to impact on the natural 
history of lung disease come from studies of lung allograft. This includes evidence from 
Davis et al, in 2003 [88], demonstrating that anti-reflux surgery may lead to increased 
survival post lung transplantation by preventing lung damage through reflux and 
aspiration. 
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1.6 Aspiration and Gastrooesophageal Reflux 
1.6.1 Background to Microaspiration  
The term aspiration is defined as the inhalation of oropharyngeal or gastric content into 
the larynx and lower respiratory tract[89].  When aspiration occurs at a sub-clinical 
level and the aspirate consists of tiny droplets it is termed microaspiration[90]. 
Depending on the frequency of these microaspiration episodes and the underlying 
medical condition patients may manifest with cough, wheeze or a decline in pulmonary 
function.  
 Lung transplant survival is reduced when compared to heart, liver and kidney 
transplant [65]. Death post lung transplant is commonly due to chronic allograft 
dysfunction otherwise known as bronchiolitis obliterans syndrome (BOS)[65]. 
Brochiolitis obliterans syndrome generally begins to develop between 6 months and 2 
years following lung transplant [91] and affects 50-60% of patients at 5 years post-
transplantation. Reflux and microaspiration have been shown to be risk factors for BOS 
following lung transplant [58].  
Several studies have attempted to determine the incidence of microaspiration in lung 
transplant patients. Within our own research unit studies have shown that the lung 
epithelial lining fluid concentration of pepsin in lung allograft recipients was much 
higher than blood reference levels, with no detectable pepsin in controls [92].  D’Ovidio 
et al [93] examined the bronchoalveolar lavage (BAL) samples of 120 post-transplant 
patients and found elevated bile salts, normally found in gastro-duodenal tract in 17% of 
patients. The levels of these salts were higher in patients with more advanced BOS. A 
subsequent study [94] from the same authors concluded that the prevalence of 
microaspiration, as measured by bile salts, was as high as 43% at 3 months after lung 
transplant. Blondeau et al [95] used impedance-pH in order to characterise reflux in 
lung transplant patients. They also performed BAL analysis for pepsin and bile salts as 
markers of microaspiration. All lung transplant patients had increased levels of pepsin 
in BAL even those with normal impedance studies; bile acids were detected in 49% of 
samples. The authors concluded that reflux is detectible in lung transplant patients and 
that gastric aspiration occurs frequently as demonstrated by the elevated pepsin and bile 
salts in BAL.  From this evidence several studies have also suggested that treatment 
with proton pump inhibitor does not protect from the aspiration of gastric contents while 
early anti-reflux surgery improves survival and decreases chronic allograft rejection 
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after lung transplant, by reducing microaspiration [96, 97]. Although the studies above 
have demonstrated the presence of pepsin and bile salts in BAL, the techniques used for 
the measurements of these markers, in particular the use of enzymatic kits for measuring 
bile salts have limited accuracy when compared to more recent spectrophotometric 
assays [98]. 
With regard to advanced lung disease and microaspiration there is limited information 
from human studies. Experimental models in animals and some descriptive studies in 
humans do support the concept of microaspiration as a potential cause of pulmonary 
fibrosis ( 
Figure 1-１４).  Gastric juice has been detected in the lungs of dogs a short time after 
instillation into the main bronchus. In addition, when the lungs of rabbits and dogs are 
exposed to acid solution, they demonstrate histological manifestations consistent with 
fibrotic lung disease [90].  There is no direct data demonstrating that microaspiration 
leads to pulmonary fibrosis; much of the evidence to suggest it may be a causative 
factor comes from studies of gastro-oesophageal reflux in patients with IPF.  
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Figure 1-１４: Possible Pathogenetic Mechanism for Chronic Microaspiration in Idiopathic 
Pulmonary Fibrosis [90]. 
 
Legend: Gastric fluid can travel in a retrograde fashion through a weakened lower 
oesophageal sphincter(e.g. secondary to a hiatus hernia, traction from the diaphragm, or 
medications) up into the oesophagus. The gastric refluxate can travel as high up as the 
cricopharyngeal region and enter the airway. Normal host defences likely clear most 
gastric refluxate without clinical sequelae [90]. However, in some cases, components of 
the gastric refluxate (e.g. acid, bile, particulates) may directly injure the lung epithelium. 
In the genetically or otherwise predisposed patient, chronic microaspiration of gastric 
refluxate may cause repetitive injury over time leading to granulomatous pneumonitis, 
dysregulated wound healing, and eventual lung fibrosis. Additionally, progressive 
pulmonary fibrosis may lead to distortion of the mediastinal structures and traction on 
the oesophagus. This could cause additional weakening of the lower oesophageal 
sphincter, which could in turn lead to microaspiration, lung injury, and the accelerated 
decline and/or acute respiratory decompensation seen in some patients with idiopathic 
pulmonary fibrosis [90].  
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Lee at al [90] in their review highlight the difficulties in diagnosing microaspiration in 
IPF. Several approaches have been used but there are many limitations to each of these; 
 Patient Symptoms – On their own, symptom screening for extra-oesophageal 
symptoms of reflux is a poor diagnostic tool for microaspiration. In a study of 65 
patients with IPF over 50% had objective evidence of GOR but no symptoms 
due to clinically silent disease. [71].  Symptom screening for oesophageal reflux 
may only have sensitivity of 65% and specificity of 71% [99]. 
 Radiological studies – studies attempting to demonstrate microaspiration using 
barium swallows, computed tomography (CT) scans and radio-labelled nuclei 
scans are limited by poor sensitivities, inter-observer error and costs [90] 
 Oesophageal studies – The use of pH impedance studies to allow the detection 
of acid and non-acid reflux as well as allowing an assessment of proximal reflux; 
these measures can assess only the risk of microaspiration. 
Gastric microaspiration may be a common phenomenon in CF patients but the 
published evidence is scarce.  Ledson et al [100] studied 24-hour ambulatory tracheal 
and oesophageal pH monitoring in 11 CF patients with symptoms of GOR and 
demonstrated tracheal acidification in those patients with significant GOR, suggesting a 
high proportion of these patients suffered from microaspiration.  They showed that a 
longer period of tracheal acidification of 15-75 minutes correlated with longer periods 
of oesophageal reflux.  This study was performed off PPI for 48 hours. Stopping PPI for 
such a short time after long-term use may result in rebound acid hypersecretion (RAHS) 
[101], accounting for the high levels of tracheal acidification in this study. The study 
focuses on acid reflux and takes no account of non-acid refluxate that is increasingly 
been detected on impedance-pH. 
More recent studies have focused on demonstrating gastric microaspiration by analysing 
the presence of biochemical markers in both sputum and BAL. Blondeau et al [81] 
showed that a significant group of CF patients have evidence of microaspiration by 
showing elevated levels of bile salts detected in sputum and BAL. In this study they 
also demonstrated that half of the CF patients with increased GOR or microaspiration 
had no symptoms. They also showed a correlation between the CF genotype and levels 
of aspiration; bile aspiration was more prevalent in ΔF508 homozygotes. Although this 
study recruited 71 CF patients, 10 had received lung transplants, but this was the only 
group where oesophageal pH tests AND aspiration tests were performed allowing a 
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correlation to be made. However, methodological problems with bile salt assays 
illustrate the need for further studies and for consensus on the standardisation of bile 
salt measurements. Recent tests on the enzymatic bile salt kits have shown a failure to 
detect bile salts below 5µmol/L in BAL [102].  The majority of the studies above use 
these kits and suggest bile salt levels below this; but the evidence suggests the kits are 
simply not sensitive enough for detecting bile salts in BAL questioning the accuracy of 
the current consensus on markers of microaspiration. The process of transplantation 
involves denervating the donor lung thereby reducing the cough reflex and muco-cillary 
clearance; loss of these protective mechanisms may predispose to microaspiration [103]. 
Though this data supports a role for microaspiration in pathophysiological events in 
lung transplant recipients it has limited application in the pre-transplant CF population. 
The non-transplanted CF group were separated and a proportion had only oesophageal 
pH tests whilst the rest had aspiration testing. Therefore, correlation of the results 
cannot be made as there are two separate groups.  
A more recent study [104] attempted to elucidate the link between aspiration of gastric 
content and lung inflammation in children with CF. The authors recruited 31 patients 
with CF nad 7 controls and demonstrated in over half of the CF patients there were high 
levels of ‘pepsin’, a biochemical marker of aspiration (see next section). High levels of 
pepsin appeared to correlate with higher levels of IL-8, a marker of inflammation, 
suggesting  that chronic microaspiration may contribute to airways inflammation. 
Unfortunately, this study fails to objectively asses GOR in all the patients; only 6 
patients had pH tests performed. In addition, 9 patients were still on PPI and it is 
unclear from the results how this may have affected the levels of pepsin in the BAL of 
these patients.  
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1.6.2 Biomarkers of Aspiration 
Pepsin 
Pepsin is a proteolytic enzyme (Figure 1-１５) which is secreted by the chief cells in 
the stomach [24]. 
 
Figure 1-１５: The chemical structure of the macromolecular Enzyme Pepsin  
Pepsin can be detected at low levels in the lungs of healthy individuals as a small degree 
of aspiration may occur during sleep in healthy individuals [105].  In addition, 
individuals with GOR will not necessarily have elevated pepsin levels in their BAL. 
This suggests that simply identifying gastro-oesophageal reflux is not sufficient for 
diagnosing microaspiration [90] and a distinction between high and low levels of pepsin  
in BAL is important in identifying those patients at a significant risk of microaspiration 
[104]. Pepsin has been used as a marker of gastric aspiration, mainly through its 
detection in the BAL of lung transplant recipients [106]. Pepsin is measured using an 
ELISA, but assay variability between units can lead to marked variability in 
concentrations of pepsin detected (Table 1-4). Some papers suggest the lower limit of 
detection is 1ng/ml, but BAL can dilute the actual alveolar fluid by up to 200 fold 
reducing the concentration to as low as 0.5ng/ml potentially missing aspiration events 
[107]. Also with the process of performing a  BAL further variability in the ability to 
detect pepsin is introduced by differences in the exact volume of fluid recovered and in 
the volumes of saline used for the lavage. This makes comparison of the various studies 
difficult.
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Table 1-4: Variability in Pepsin levels detected in aspiration studies [36]: 
Study Instilled Volume Pepsin levels 
Ward, Forrest et al, 2005 [92] 180ml 35-1375ng/ml 
Stovold, Forrest et al, 2007 [108] 180ml 0-51.7ng/ml 
Blondeau, V. Mertens et al, 2008 [109] 100ml 0-2000ng/ml 
Starosta, Kitz et al, 2007 [110] Unknown 0-2500ng/ml 
 
Bronchoalveolar lavage pepsin levels in clinically stable lung transplant patients were 
shown to be hundred times higher than control subjects (109ng/ml vs. <1ng/ml) 
suggesting gastric aspiration. Levels were 10-1,000 times higher than the serum 
reference ranges and pepsin was still detected in lung transplant patients taking high 
dose PPI; suggesting that aspiration can occur even when attempts are made to control 
acid secretion [92]. Detection of pepsin in BAL is a reliable method for diagnosing 
reflux associated pulmonary aspiration and can be highly specific (100%) and highly 
sensitive (80%) [111]. High levels of pepsin have also been shown to correlate with the 
number of proximal reflux events as detected with 24 hour pH monitoring [110]. In IPF 
elevated levels of pepsin in the BAL were seen in patients at the onset of an acute 
exacerbation of the disease [112]. This indicates that the contents of the gastrointestinal 
tract are capable of reaching the lung without an overt aspiration event and that 
microaspiration may even be a trigger to acute lung injury. Although detection of pepsin 
in BAL has been used as a biomarker of microaspiration, detection of pepsin in sputum 
would be a useful non-invasive tool for diagnosing reflux associated aspiration [113]. 
Bile Salts 
Bile salts are steroids synthesised in the liver by hepatocytes during the metabolism of 
cholesterol. These are normally conjugated with glycine or taurine before secretion and 
release [114]. Their role is to aid digestion and absorption of lipids in the small intestine. 
The main bile acids present are the glycine and taurine conjugates  
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Table 1-5) [115]. Bile salts are later  reabsorbed in the  ileum and colon [114]. Bile 
acids exist as mixtures, and due to their detergent status, they will influence each other’s 
solubility[36].  
 
 
Table 1-5: Composition of bile and biochemical properties [115]: 
Bile Acid Solubility in water 
(µM/L) 
pKa % in Bile 
Free Bile Acids 
Cholic Acid 
Deoxycholic Acid 
Chenodeoxycholic Acid 
 
 
242 
100 
142 
 
5.2 
5.02 
4.98 
 
Trace 
Trace 
Trace 
Glycine Conjugates 
Glycocholic Acid 
Glycodeoxycholic Acid 
Glycochenodeoxycholic 
Acid 
 
53 
17.5 
17.6 
 
3.88 
3.88 
3.87 
 
30 
15 
30 
Taurine Conjugates 
Taurocholic Acid 
Taurodeoxycholic Acid 
Taurochenodeoxycholic 
Acid 
 
14x10
3
 
82x10
3
 
n/a 
 
<2 
<2 
<2 
 
10 
10 
5 
 
As with the detection of pepsin, there is considerable variability in the levels of 
detection of bile salts in reflux studies. This is not only due to the different methods of 
detection but variability between individuals and the time of day samples were collected.  
A common assay is the 3α hydroxylase method described by Fausa & Skalhegg [116]. 
This assay is not affected by pH but the presence of food or colorants can interfere with 
results [117]. There is considerable variability in agreement about the lower limit of 
detection of  mass spectrophotometric assays; Collins et al suggested 62.5µmol/L [118], 
Klokkenburg et al claims 5µmol/l [114], Biostat, who produce the commercially 
available assay claim a lower limit of detection 1µmol/L and the Leuven group have 
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claimed an accuracy of 0.2µmol/L [81, 109]. These levels are lower than serum bile salt 
levels (<8µmol/L) [119]. One group have found this type of assay to be unreliable [120]. 
Certain operations can affect the concentration of intra-gastric bile salt concentrations; 
90% of the normal population will have intra-gastric bile salts concentrations of less 
than 250µmol/l [121]. Intra-gastric levels up to 34,260µmol/l have been reported after 
the formation of a gastro-jejunostomy [122]. 
Duodenogastric reflux is a physiological event that occurs most often after a meal and in 
the early mornings [114]. Levels of bile salts in the oesophagus are rarely over 
1000µmol/L and are usually between 0 and 200 µmol/L even in Barrett’s oesophagus. 
Approximately 25% of patients with reflux will have no detectable bile salts in the 
oesophagus [123]. Duodenal reflux events will combine with gastric refluxate by 
mixing with gastric contents and therefore bile reflux normally occurs on a background 
of weakly acid reflux (pH 4-7). Detection of bile salts above the level of the stomach 
signifies gastric as well as duodenal reflux. 
Detection of bile salts in BAL as a marker of gastric aspiration has been used in the in 
patients post lung transplant and in those in whom BOS has started to develop. BOS has 
been shown to be associated with abnormal pH studies, the presence of bile salts in 
BAL and microaspiration. [94]. Bile acids have also been analysed in the sputum of 
patients in order to diagnose reflux associated aspiration [124]. In this study the authors 
induced sputum in patients with GOR and measured bile acid concentration and 
compared values to levels of TGF-beta 1. Patients with GOR had higher levels of bile 
salts in their sputum compared to controls (p<0.005) and this correlated with higher 
levels of TGF-beta 1 which has the potential to promote fibroblast proliferation. More 
recently Blondeau et al, 2008 demonstrated the presence of bile acid in sputum of over 
50% of CF patients they tested. They also showed that in these patients it was 
associated with exacerbations of respiratory infections and an increased requirement for 
intravenous antibiotics [125]. Other studies have analysed bile salt levels in the saliva of 
patients with CF and have shown that one-third of children with CF have bile salts in 
the saliva [87], which may indicate an increased risk of aspiration. However, as saliva is 
not a direct representation of lung aspirate like BAL and to some extent sputum, these 
measurements of bile salts maybe less clinically meaningful. Bile salts can predispose 
patients to lung injury due to disruption of the lung mucosa and also their effects on the 
lipids in surfactant. They also lead to down-regulation of the innate immunity 
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mechanisms in the lung hence predisposing patients to infection and further lung injury 
[94].  
The major limitations to the measurements of biomarkers such as bile salts and pepsin 
in BAL, sputum or saliva is the lack of standardised methodology and unknown half-
life clearance from the lower respiratory tract of these compunds [90]. However, based 
on currently available data the specificity of bile salts and pepsin to the gastrointestinal 
tract makes measurements from lung aspirates a useful diagnostic tool for 
microaspiration. 
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1.7 Lung Transplant and Reflux 
1.7.1 Bronchiolitis Obliterans Syndrome (BOS) 
Compared to other allograft transplantation, survival form lung transplantation is poor 
with only 60% of patients alive 5 years after their lung transplants [97]. One of the main 
reasons for this is the development of Bronchiolitis Obliterans which is believed to be 
the pathological process of chronic rejection [126].  Bronchiolitis Obliterans Syndrome 
generally develops between 6 months & 2 years post transplantation [91] and affects 50-
60% of patients at 5 years post-transplantation. The 5 year post-transplantation survival 
is 20-40% lower than average in patients with BOS [119]. Bronchiolitis Obliterans 
Syndrome is a significant process which leads to decreased quality of life by causing 
graft failure and as a result leads to an increased mortality [65].  
The pathology behind this process involves progressive fibrosis of the small airways, 
leading to complete obstruction with sclerosis of the airways, intimal thickening and 
destruction of the pulmonary vasculature (Figure 1-１６)[126]. BOS is thought to be 
mediated by a number of risk factors including the process of acute allograft rejection, 
HLA mismatch, cytomegalovirus and more recently the development of GORD and 
microaspiration [36, 65].  
Figure 1-１６: Model of Non-alloimmune Lung Allograft Injury and Inflammation in BOS 
pathogenesis from Robertson et al Am J Trans 2009 [126]. 
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Clinically the ISHLT definition of BOS is a decrease in FEV1 from the best post-
operative value in the absence of anastomotic strictures, infection or other complication 
and is categorised by a simple scoring system (Table 1-6): 
Table 1-6:  Bronchiolitis Obliterans Syndrome (BOS) scores [36, 127]  
1993 Classification 2002 Classification 
BOS 0 FEV1: 80% or more of baseline FEV1: >90% of baseline and 
FEF25-75 >75% of baseline 
BOS 0 
 
 FEV1: 81-90% of baseline and/or 
FEF25-75 ≤75% of baseline 
BOS 0p 
BOS 1 FEV1: 66-80% of baseline FEV1: 66-80% of baseline BOS 1 
BOS 2 FEV1: 51-65% of baseline FEV1: 51-65% of baseline BOS 2 
BOS 3 FEV1: ≤50% or more of baseline FEV1: ≤50% or more of baseline BOS 3 
 
1.7.2 Reflux post Lung Transplant 
Chronic microaspiration, secondary to extra-oesophageal reflux, may plausibly 
contribute to bronchiolitis obliterans syndrome (BOS) post-lung transplant. Up to 75% 
of lung transplant patients have demonstrable gastro-oesophageal reflux disease (GORD) 
[36, 128-132]. Elevated biomarkers, pepsin and bile salts, have been documented in the 
BAL fluid post-transplant, suggesting microaspiration[108, 109, 119]. A number of 
reasons for this have been suggested including damage to the Vagus nerve leading to 
delayed gastric emptying and dysmotility of the distal oesophagus promoting reflux 
after lung transplantation [133]. In addition, it has been suggested that a large 
proportion of patients (63-68%) with end-stage lung disease suffer from reflux prior to 
their transplantation [65]. 
Anti-Reflux surgery has been demonstrated to improve lung function as early as 2000 
[91]. However in was not until 2003 that evidence from Duke University provided a 
better understanding of the possible role of fundoplication in lung transplant patients 
and hence the possible role of microaspiration. Their study involved 43 patients 
undergoing anti-reflux surgery after lung transplantation. An improvement of FEV1 was 
demonstrated in 24% of patients with reversal of BOS in some patients [88]. From the 
same centre only one year later a study involving 76 lung transplant patient undergoing 
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fundoplication demonstrated a similar success of anti-reflux surgery particularly in the 
first 90 days post-transplant (Figure 1-１７) [65]. 
 
Figure 1-１７: Freedom from Bronchiolitis Obliterans Syndrome [65] 
 
Legend: A Kaplan Meier survival graph showing freedom from BOS at 1 and 3 years. 
The horizontal plotted line at the top of the graph indicates the group with reflux who 
received early fundoplication. The other plotted lines represent 4 groups; those with 
normal pH studies, those with reflux that did not receive fundoplication, those with 
reflux who received late fundoplication and those with unknown reflux status. There is 
a significant difference between those that underwent early fundoplication and the other 
groups (p=0.01) [65].
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The limitations of the studies performed so far examining the role of fundoplication 
after lung transplantation is that they are mainly from a single centre and there is a lack 
of basic information regarding the assessments of quality of life after anti-reflux surgery 
in these patients [97]. Such information is important because physiological post-
operative complications are common following fundoplication, and may lead to a 
reduction in quality of life, despite resolution of reflux symptoms.  Specific 
complications include temporary dysphagia, nausea[134], discomfort from gas bloat and 
increased flatulence [126].  There is very little evidence on the effects of fundoplication 
on quality of life in this population. Additional surgery may put these patients at risk of 
physiological dysfunction and reduced quality of life after surgery. To date no studies 
have been performed assessing the response of extra-oesophageal reflux symptoms to 
fundoplication and quality of life improvements of this intervention in the transplant 
population.  
1.7.3 Fundoplication and lung Transplant – Work from the Unit 
Between June 2006 and October 2009 lung transplant patients were referred to the 
Northern Gastro-Oesophageal Unit at Newcastle’s Royal Victoria Infirmary [36]. A 
laparoscopic fundoplication was offered to those patients with symptomatic reflux and 
for those with reflux associated with a decline in lung function. Quality of life 
questionnaires including Gastrointestinal Quality of Life Index (GIQLI), Demeester and 
Reflux Symptom Index (RSI) were performed prior to surgery and then in the early and 
later post-operative period. Pulmonary function was monitored regularly in these 
patients throughout the study. 
In total 9 patients had a laparoscopic fundoplication performed. There were no major 
complications secondary to the surgery. There were significant improvements in the 
quality of life score both at 6 weeks and 6 months after surgery and median FEV1 
increased from 2.35 litres to 2.68 litres at the latest follow-up. Although, the numbers in 
this study were very small, the work illustrates the importance of objective reflux 
assessment after lung transplant allowing the option of surgical management in this 
patient group. Further work and results will be presented in the later sections of this 
thesis. 
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2 Purpose and Theory behind the Study 
2.1 Hypothesis 
I propose that both symptomatic and asymptomatic reflux is a common feature in 
patients with advanced lung disease. I hypothesise that, in patients with idiopathic 
pulmonary fibrosis and Cystic fibrosis, this reflux together with the subsequent (micro) 
aspiration of stomach contents into the lungs can lead to long term deterioration of lung 
function. Detection of reflux using established techniques combined with laboratory 
measurements of biomarkers in refluxate will identify both the extent and severity of 
gastro-oesophageal reflux (GOR) in these patients. The translational significance of this 
is that there are both surgical and non surgical treatments available for reflux. The 
subsequent treatment of GOR identified patients could preserve long-term lung function 
and improve their quality of life. 
In this study I will test the hypothesis that in IPF and CF there is objective evidence of 
GOR. Subsequent aspiration represents a potential mechanism through which GOR may 
lead to lung damage and may be denoted by increased lung levels of pepsin and bile 
salts. This will represent a potential explanation for an association between GOR, 
aspiration and impaired lung function. 
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2.2 Aims of the Study 
2.2.1 Purpose & Theory 
The overall aim of this study is to evaluate the prevalence of gastro-oesophageal reflux 
(GOR) in patients with idiopathic pulmonary fibrosis (IPF) and cystic fibrosis (CF) and 
its potential role in the development of chronic lung dysfunction. Many patients with 
advanced lung disease are considered to suffer from gastro-oesophageal reflux (GOR), 
but this has not been systematically characterised. This GOR may be symptomatic or 
asymptomatic and in some cases can lead to microaspiration which significantly injures 
the patient’s lungs and affects their quality of life.  
In order to determine potential associations between impaired lung function and gastro-
oesophageal reflux, I will perform a range of specialised investigations for which the 
centre has international recognition. In order to determine the degree of reflux, patients 
will be invited to attend for both oesophageal manometry and impedance pH 
measurements.  This will provide a detailed objective assessment of both acid and 
weakly acid reflux (refluxate pH >4) in these patients; Pulmonary function tests 
including spirometry will be used to identify impairment of lung function. This will be 
related to the patient’s impedance pH test results, testing for association between GOR 
and reduced lung function. 
Both groups of respiratory patients (CF and IPF) will have lung samples analysed in the 
lab for bile salts and pepsin; two biochemical markers of aspiration. The IPF group of 
patients will have provided samples through bronchoalveolar lavage (BAL). The CF 
group of patients will have daily physiotherapy where they would be encouraged to 
clear their airways. A small amount of this induced sputum will be taken at this stage 
and analysed for markers of aspiration (Figure 2-1). 
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2.2.2 Aims  
 To measure impedance pH in patients with IPF and CF to objectively assess reflux  
 To measure patient symptoms of reflux disease, using validated questionnaires 
 To compare objective assessment of reflux (impedance pH) with patient experience 
of symptoms (questionnaire) 
 To compare objective and clinical assessments of reflux and symptoms with 
markers of aspiration(pepsin, bile salts); using BAL samples (IPF group) and 
sputum samples (CF group) 
 To correlate the above investigations of reflux with lung function 
 To identify patients suitable for specialist referral and subsequent management of 
reflux disease; and assess the effect of the intervention with regular lung function 
assessment 
The study will provide a subjective assessment of symptoms, objective evidence of 
GOR physiology and laboratory based assessments of markers of aspiration in patients 
with IPF and CF. The information gathered from the studies above will be used to 
develop our understanding of the association between these lung diseases and gastro-
oesophageal reflux.   
Potential development from the study: Those patients with significant reflux that could 
warrant treatment may be offered referral to an upper GI specialist for the most 
appropriate management.  
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Figure 2-１: Summary of Study Protocol 
 
IPF1 PATIENTS 
N=30 
Cystic Fibrosis 
Patients 
N=30 
          BAL3 Sputum Samples 
      Lab based assays for bile salts and pepsin 
Collation of Results 
Base Line PFTS2 
Manometry, 24h pH Impedance and Reflux 
Questionnaires 
1. IPF = Idiopathic Pulmonary Fibrosis 
2. PFT = Pulmonary Function Tests 
3. BAL = Bronchoalveolar lavage 
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3 Methods 
3.1 Ethical Approval 
Ethical approval was obtained from County Durham and Tees Valley 2 Research Ethics 
Committee (Appendix 3). Approval for the research to be carried out at the Newcastle 
upon Tyne Hospitals NHS foundation Trust was granted by the Research and 
Development department at the Royal Victoria Infirmary. (Appendix 3) 
3.2 Patient Recruitment 
Patients with IPF were recruited with the aid of a national interstitial lung disease 
specialist, already closely involved in the study. From the start of the study in the 
summer of 2010 until the current day a rapid expansion of the interstitial lung clinics 
took place. Initially at the Royal Victoria infirmary, ILD clinics were organised twice a 
month and recruitment of IPF patients was by the primary investigator, directly from 
these clinics. As the clinics expanded due to practicalities IPF patients who were 
suitable for the study were selected by the specialist and communication was made over 
the phone to recruit the patient. 
CF patients were recruited directly from designated specialist clinics. There are 
currently two specialists at the Royal Victoria infirmary, and patients were approached 
directly by the primary investigator and provided with a patient information leaflet. The 
recruitment of CF patients was also through the help of the CF specialist nurse or the 
patient’s clinician. 
3.2.1 Inclusion & Exclusion Criteria 
All IPF patients were identified from ILD clinics. Idiopathic pulmonary fibrosis in new 
and known patients had to fulfil the internationally accepted definitions as proposed by 
the European Respiratory Society (ERS) and American Thoracic society (ATS) [5]: 
Major Criteria: 
 Exclusion of other known causes of ILD such as certain drug toxicities, 
environmental exposures and connective tissue disease 
 Abnormal pulmonary function studies that include evidence of restriction 
(reduced VC, often with an increased FEV1/FVC ratio) and impaired gas 
exchange (increased P(Aa)O2, decreased PaO2 with rest or exercise or decreased 
TLCO) 
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 Bibasilar reticular abnormalities with minimal ground glass opacities on HRCT 
scans 
 Trans-bronchial lung biopsy or BAL showing no features to support an 
alternative diagnosis 
Minor Criteria: 
 Age> 50 years 
 Bibasilar inspiratory crackles (dry or ‘Velcro’ type in quality) 
 Insidious onset of otherwise unexplained dyspnoea on exertion 
 Duration of illness > 3 months 
The CF group of patients would include all adult patients (age >16 years). The principal 
exclusion criteria are: 
 Patients in respiratory failure 
 Patients with a coexisting respiratory disorder 
 Patients with overt congestive cardiac failure 
 Patients regarded unfit for any other clinical reason by their respiratory 
physician 
3.2.2 Sample Size 
The recruitment targets were 20 IPF and 20 CF patients. This was based on the number 
of patients attending clinic and the incidence within the region. This is an empirical 
sample size suggested from previous studies as there is insufficient data available to 
calculate formal sample size through power calculations. The results will be collated by 
the research team and simple descriptive statistics produced. A statistician will then be 
consulted with regard to the most appropriate method of analysis. 
3.2.3 Consent and Information 
All patients that agreed to be recruited into the study were provided with an information 
pack. This was either given to them in the clinic if they were recruited from the clinic or 
sent in the post if they were recruited over the phone. The information pack provided a 
detailed explanation of the investigations and the consent form, which was returned at 
the time the patient returned to the hospital for their investigations. 
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3.3 Oesophageal Investigations 
3.3.1 8-Channel Manometry 
Patients underwent manometry after a minimum four hour fast from solids and at least 
two hours free from liquids [135]. Patients were able to take their regular medication on 
the morning of the test with a sip of water only. The system consisted of a 3.9mm eight 
lumen single-use catheter, a water perfused manometry system (MMS system) and data 
displayed on a computer using the MMS programme. The catheter consisted of 4 radial 
ports arranged at the same level and 4 lateral ports spaced 4cm apart. The 4 radial ports 
are used to characterise the lower oesophageal sphincter (LOS).  Before the start of the 
investigation each of the eight lumens were flushed and the catheter assembly was 
connected to the 8 channels of the air pneumo-hydraulic low compliance perfusion 
pump. The system pumped distilled water through the catheter at a constant rate of 
0.6ml/s and the system was calibrated with the ‘zero’ pressure point being at the level of 
the a patient’s sternal angle. A transducer system was connected to the MMS computer, 
a Windows compatible computer. 
8-Channel manometry standard technique [36] 
Patients attended a specific oesophageal physiology laboratory based at the Royal 
Victoria Infirmary. After discussing the procedure once again with the patient, patients 
were asked to sit upright on the bed and the catheter, lubricated at the tip was passed 
horizontally through the nostril into the nasopharynx [135]. The patient was asked to tilt 
their head forward with their chin touching their chest. As the catheter was advanced the 
patient was asked to take a few sips of water through a straw and swallow. This 
technique helps the catheter progress through the cricopharyngeus and into the 
oesophagus. Whilst the patient was positioned upright the catheter was advanced into 
the stomach to a distance of 70cm from the nostrils. The patient was then asked to lie in 
a semi recumbent position as this is the validated position for taking manometry 
measurements. The presence of all the channels in the stomach is confirmed by a 
positive deflection in the channels in response to the patient taking a deep breath. 
8-Channel manometry LOS position 
The catheter was withdrawn at 1cm intervals every thirty seconds [136] until the high 
pressure zone of the LOS was reached. The lower margin of the LOS was detected first. 
The catheter was then withdrawn by a further 1cm and a 5ml bolus of water was given 
to the patient to assess the LOS activity, in particular paying attention to the degree of 
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relaxation. As the catheter was withdrawn the top of the LOS was represented by a drop 
in pressure as the catheter exits the high pressure zone. The length and resting pressure 
were calculated manually using the trace on the MMS programme. The lower 
oesophageal sphincter end expiratory pressure was defined as the difference between 
basal tone pressure and the average of the end-expiratory resting pressures found in 
each port whilst in the high pressure zone.  
8-Channel manometry oesophageal peristalsis 
With the catheter positioned 5cm above the top of the LOS, ten swallows consisting of 
5ml boluses of water were performed. The motility was evaluated for normal peristalsis, 
simultaneous contractions, aperistalsis or non-specific dysmotility. Mean distal 
oesophageal peristaltic amplitude was calculated based on the average of all swallows 
performed at 5cm. mean proximal peristaltic amplitudes were based on the average of 
all swallows performed at 15cm above the lower oesophageal sphincter. Traces were 
analysed and categorised using the definitions in the table below. Figure 3-１illustrates 
a section of an 8-channel manometry trace. 
Table 3-1: Classification of Oesophageal Peristalsis [36] 
 
Normal Peristalsis Normal peristalsis >70% of the time 
Mild Ineffective Oesophageal Motility Abnormal peristalsis 30-70% of the time 
Severe Ineffective Oesophageal Motility Normal peristalsis <30% of the time 
Aperistalsis Abnormal peristalsis 100% of the time 
Diffuse Oesophageal Spasm >10% of swallows simultaneous with mean 
amplitudes over 30mmHg  
Nutcracker Oesophagus Mean amplitude of peristalsis >180mmHg 
Hypertonic Lower Oesophageal Sphincter >45mmHg but relaxing 
Hypotonic Lower Oesophageal Sphincter <10mmHg 
Achalasia Hypertonic LOS, absent or incomplete 
relaxations >70-80% of the time. Simultaneous 
contractions or aperistalsis in the oesophageal 
body 
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3.3.2 High Resolution Manometry 
Patients underwent High Resolution Manometry (HRM) after a minimum four hour fast 
from solids and at least two hours free from liquids [135]. Patients were able to take 
their regular medication on the morning of the test with a sip of water only. The system 
consisted of a manometric catheter connected to a series of pressure transducers which 
were all connected to a water perfused manometry system (MMS system) and data 
displayed on a computer using the MMS programme. As with the 8-channel manometry 
the principles of the system are identical. The pressure in the oesophagus is converted to 
an electrical signal by the pressure transducers. The computer programme then 
amplifies and filters the signals so that it can be displayed on the screen in an 
interpretable manner. In the case of HRM, the measurements are presented as a 
spatiotemporal Oesophageal Pressure Topography plot as in Figure 3-２. This allows 
more accurate and efficient placement of the catheter [137].  
Two main types of manometric catheters can be used for HRM studies, solid state and 
water-perfused. We used single-use water perfused catheters. The catheter is an 
extruded silicone catheter containing 20 individual channels spaced 1cm apart in a 
unidirectional sensor orientation (measuring the pressure at the point of the channel 
hole). As with the 8-channel manometry, the catheter is perfused with distilled water 
driven by a pneumatic pressure pump. Each channel opens into the oesophageal lumen 
at different points and pressures from each of the points is transmitted back to the 
transducers to be interpreted by the computer. Water perfused catheters are less 
sensitive to rapidly changing pressures like those found in the upper oesophageal 
sphincter (UES) and interpretation of pressure changes at the UES have to be treated 
judicially.  
HRM standard procedure 
 Equipment preparation – Prior to the arrival of the patient, the perfusion reservoir 
and the pump were filled with water and the reservoir is pressurised to drive the 
water through the catheter capillaries. This allows the clinician to check that all the 
channels are perfusing to ensure an accurate trace. The catheter was perfused with 
water for several minutes until the pressures in all the channels were stable. Before 
the study the recording channels were referenced to atmospheric pressure by placing 
the catheter at the level of the subject’s oesophagus, and the system was ‘zeroed’. 
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 Subject Preparation – As with the traditional 8-channel manometry, subjects were 
fasted for 4 hours prior to the study. Clear instructions were provided to the patient 
in order to be able to tolerate the procedure including an awareness of some minor 
discomfort on intubating the nostrils 
 Introduction of the catheter - The HRM catheter was introduced through the nostrils 
in an identical manner to the 8-channel probe. The HRM catheter was lubricated and 
slowly introduced into one of the subject’s nostril whilst the subject was sat upright. 
A glass of water was available with a straw to aid the insertion of the catheter. The 
subject was asked to take sips and swallow continuously with their chin placed close 
to the chest whilst the catheter was inserted in a steady manner through the upper 
and lower sphincters until it is in the stomach. 
 Positioning of the catheter and completion of the study – The catheter was 
positioned correctly for HRM when both the upper and lower sphincters can be 
recognised and when at least 2 pressure sensors are in the stomach. The position of 
the diaphragm can be determined by examining the pressure inversion point (PIP). 
During inspiration, pressure in the thorax decreases as abdominal pressure increases. 
The point where the pressure changes with inspiration meet is the PIP and is 
generally located at the diaphragm [137].  
After the catheter was correctly placed it was secured in this position with tape as a 
pull-through technique is not required with HRM. The subject was asked to lie 
down in the semi-recumbent position.  Once the patient wass comfortable, the LOS 
resting pressure was assessed over 30 seconds with the patient asked not to swallow. 
After this, standard evaluation of oesophageal motility was performed with 10 ‘wet’ 
swallows using 5ml boluses of water given to the subject via a syringe body.  
Swallows should be recorded at 20-30 second intervals as this is when the previous 
peristaltic wave has terminated and the LOS has returned to baseline pressure. After 
the 10 swallows have been recorded, the catheter was removed.  
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HRM Analysis 
The analysis and interpretation of the 10 swallows HRM test are based on a set of 
measurements and normal values. These are then classified into groups defined by the 
Chicago classification criteria [138].  The terms necessary to use the classification a 
described in the table below: 
Table 3-2: HRM measurements  
Integrated Relaxation Pressure (IRP - mmHg) The mean pressure at the O-G junction measured 
over 4s in the 10 seconds following UOS 
relaxation. Equates to LOS relation pressure in 
conventional manometry 
Distal Contractile Integral (DCI – mmHg/s/cm) Amplitude x duration x length of the distal 
oesophageal contraction. Equates to peristaltic 
amplitude in conventional manometry 
Contractile Deceleration point (CDP) The inflection point along the swallow where 
propagation speed slows down and is the point of 
transition between oesophageal peristalsis and 
oesophageal emptying. 
Contractile Front Velocity (CFV – cm/s) The gradient of the peristaltic body representing 
the speed of the swallow. 
Distal Latency (DL – s) Interval between UOS relaxation and the CDP 
Peristaltic Breaks (cm) Gaps in the HRM peristaltic contraction between 
the UOS and LOS 
 
Figure 3-２on page 80 illustrates a single peristaltic wave on HRM with the anatomical 
landmarks and measurement points. After these individual measurements are made they 
are analysed with the normal values and each swallow is characterised in terms of the 
integrity of the contraction and the contraction pattern as summarised in the table below: 
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Table 3-3: Table illustrating the components of the peristaltic contraction that help define the 
nature of the swallow 
Integrity of Contraction Contraction Pattern 
Intact – No peristaltic breaks 
Weak – Large (>5cm) or small (2-5cm) peristaltic 
breaks 
Absent – Minimal integrity of contour plot 
Premature (DL < 4.5s) 
Hypercontractile (DCI > 8000mmHg/cm/s) 
Rapid Contraction (CFV > 9cm/s) 
Normal Contraction (none of the above apply) 
The individual characterisation each swallow is used to compute an overall diagnosis as 
defined by the Chicago classification using the algorithm in Figure 3-３. 
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Figure 3-１: A normal peristaltic wave demonstrated by 8-channel manometry [36].  
 
Legend: The propagation of the wave is illustrated from channel P1 to P4 in the 
oesophageal body and the radial 4 channels mark the position of the LOS. The time 
(GMT) is on the horizontal axis.  
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Figure 3-２: A High Resolution Manometry trace illustrating a normal peristaltic wave with the 
landmarks and measurement points identified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: An HRM trace for a normal peristaltic swallow where UOS is the upper 
oesophageal sphincter and LOS is the lower oesophageal sphincter. As time progresses 
on the horizontal axis the swallow migrates from the UOS toward the LOS as a 
peristaltic wave represented in a topographic form. The contractile deceleration point 
(CDP) marks the point where the swallow decelerated between the lower oesophageus 
and LOS prior to emptying into the stomach. The distal contractile integral (DCI) is 
represented by the red box and is a measure of the amplitude of the wave form 
(swallow). The speed of the swallow is represented by the gradient of the wave (red 
arrow) also know as the contractile front velocity (CFV). 
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Figure 3-３: Flow diagram illustrating the analysis algorithm according to Chicago 
classification[138] 
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3.3.3 Ambulatory impedance/pH Studies 
After performing the oesophageal manometry, the information was used to determine 
the location of the lower oesophageal sphincter. Combined 24-hour ambulatory. 
Multichannel Intraluminal Impedance is a technology that measures changes in 
oesophageal intraluminal resistance and bolus transit. It consists of a catheter with 
several metal rings (Figure 3-４). Changes in resistance between these rings are 
detected. Gas causes an increase in resistance and liquids cause a decrease in resistance. 
The direction of these changes allows the direction of movement of the bolus to be 
determined. This device also has a pH probe that allows reflux events to be classified as 
acidic, weakly acidic or non-acid (Figure 3-４)  
Impedance-pH standard technique [36] 
Ambulatory impedance-pH was performed using the MMS Ohmega device and a 
Pharsiflex (Z61A\ZNIS-8R) catheter. The Ohmega device is simply a portable 
recording box and the catheter is a 1.9mm diameter single-use catheter consisting of 6 
impedance rings (3,5,7,9,15 and 17cm) and a pH probe. The impedance rings at 15 and 
17cm were used to identify proximal reflux. 
The catheter is initially connected to the Ohmega device and calibrated in a standardised 
fashion. This begins with a ten-minute pre-soak of the probe in de-ionised water and 
then the pH probe is calibrated with pH 4 and pH 7 buffer solutions at room temperature. 
The Impedance-pH catheter was inserted in a similar manner to the manometry catheter 
and secured so that the pH probe was located 5cm above the upper border of the LOS 
the location of which was determined from manometry. 
During Impedance-pH monitoring, patients were encouraged to maintain their usual 
eating habit but avoid fresh citrus juices (i.e. very acidic) and chewing gum. The 
Ohmega device has several buttons allowing the patients to record symptoms, meals and 
position (upright or supine). They were also given a standardised patient diary to 
complete. After the 24 hour period, patients returned to the lab and the catheter was 
removed from the patient. The Ohmega box was then connected to a Windows 
compatible computer with the MMS software and uploaded. The trace was reviewed 
manually and the electronic diary was verified with the paper diary and edited 
appropriately. After the trace was reviewed the MMS software provided an automatic 
analysis and summary of impedance-pH events and symptoms scores.  
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The table below shows the main components of analysis provided by the Ohmega 
device. 
Table 3-4: The components of the 24 hour pH-impedance analysis 
pH Analysis pH results are analysed by comparing them to 
normal values as defined by Johnson and 
Demeester [10]. 
An abnormal study is defined as a pH < 4 for 
more than 4.5% of the study duration. 
Impedance Analysis Impedance traces were manually analysed by the 
research clinician and compared to normal values 
as defined by Zerbib [139] 
An abnormal study is defined as volume 
exposure >1.2% 
Symptom Index (SI) This is calculated using the number of 
symptomatic episodes associated with a reflux 
event as a percentage of the total number of 
symptomatic episodes.  
50% is the defined threshold for a positive 
result [15]. 
Symptom sensitivity index (SSI) This is calculated as the number of reflux events 
associated with symptoms as a percent of acid 
reflux events. It accounts for the limitation of the 
symptom index [15]. 
A positive result is an SSI > 10%. 
Symptom Associated Probability (SAP) A statistical calculation using the data recorded. It 
uses a Fisher exact test based on 4 distributions 
(Symptom with reflux/Symptom without 
reflux/reflux with symptoms/Reflux without 
symptoms). The test evaluates whether the 
distribution occurs by chance. 
SAP >95% is a positive result. The test provides 
a more accurate understanding of the association 
between reflux and symptoms [15]. 
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The overall analysis of the pH trace used several impedance-pH indices to determine if 
the patient had pathological reflux. The important distal reflux parameters were 
oesophageal acid exposure and oesophageal volume exposure. Oesophageal acid 
exposure is defined as the percentage of time that the pH is less than 4, 5cm above the 
lower oesophageal sphincter over a 24-hour period (normal <4.5%). Oesophageal 
volume exposure is defined as the percentage of time that impedance detects refluxate 
within the oesophagus over a 24-hour period (normal < 1.2%). Distal reflux was present 
when either the oesophageal acid exposure or oesophageal volume exposure was 
abnormal. Patients with abnormal oesophageal volume exposure but normal 
oesophageal acid exposure were likely to have weakly acid reflux [36]. 
Impedance-pH provides a valuable assessment of proximal reflux i.e. reflux events 
reaching the impedance ring located 17cm above the LOS. Patients with more than 17 
of these events were deemed to have significant proximal reflux. 
Figure 3-４: A weakly acidic liquid reflux event on impedance-pH. 
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3.4 Reflux Questionnaire Assessments 
Questionnaires have been designed to detect symptoms suggestive of both oesophageal 
and extra-oesophageal reflux (appendix 6). These were used to assess severity of 
symptoms and responses to treatment. Three questionnaires have been validated for the 
assessment of patient symptoms and were used in this study: 
 The DeMeester Reflux Questionnaire is a validated straightforward tool to 
assess basic reflux symptoms [57]. It is based on a score of 0-3 for symptoms of 
reflux, regurgitation and dysphagia.  
 A validated questionnaire which focuses on extra-oesophageal reflux symptoms 
is the reflux symptom index (RSI). This is a 9-item questionnaire which is easily 
administered and highly reproducible. A limitation of this questionnaire is that 5 
points can be attributed to heartburn. Thus, the RSI is not limited to extra-
oesophageal reflux symptoms but can be elevated in patients with typical reflux 
symptoms. A RSI score of greater than 13 is abnormal[56].  
 The gastrointestinal quality of life index (GIQLI) was developed by Eypasch et 
al in Germany. It is a well established, tested and validated tool which has been 
shown to be reproducible [140]. The use of GIQLI is recommended for the 
assessment of anti-reflux surgery by the European Association for Endoscopic 
Surgery and has been validated for this purpose [141]. A normal score is 
between 121 and 130. 
The questionnaires were performed at the time of recruitment, therefore, if patients are 
on PPI therapy this was accounted for by a repeat questionnaire assessment at the time 
of the oesophageal studies before which the patient had stopped their PPI therapy for 
two weeks.  
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3.5 Patient Sample Collections 
3.5.1 Bronchoscopy 
Bronchoscopy was performed on the day the patient returned following their 24-hour 
pH study, providing continuity and minimal imposition on the patient. The patient was 
provided with an information leaflet prior to the procedure and requested to fast for 4 
hours prior to the test. After receiving informed consent, the patient was taken to the 
procedure room and intravenous access with a blue venflon was gained.  
Adequate sedation was achieved with up to 10mg intravenous midazolam. In addition, 
local anaesthetic was applied in the form of 4% lignocaine to the nose, pharynx and 
larynx and just below the vocal cords. Oxygen saturations were monitored with a pulse 
oximeter and supplemental oxygen was administered via nasal cannulae. 
Bronchoscopy was then performed in a supine position and intubation was achieved 
through one of the nares. A 4.9mm external diameter, 2mm internal diameter fibre-optic 
bronchoscope was used for the procedure and passed through the nostrils into the larynx 
and trachea. Three photos were taken of the larynx and vocal folds and were externally 
reviewed. The bronchoscope was then passed into the lingular bronchus or the bronchus 
of the right middle lobe. 
3.5.2 Bronchoalveolar Lavage 
Bronchoalveolar lavage (BAL) was performed in a standardised manner in accordance 
with BTS guidelines [142]. Three samples of 60ml of sterile saline were injected into 
the lobe and whilst the standardised lavage was being performed, a series of receptacles 
connected to the system was used to collect the retrieved lung fluid. The majority of the 
retrieved BAL was retained for research with a small amount (10ml) reserved for 
clinical purposes.  
3.5.3 Sputum: 
CF patients provided a sputum sample on the day of their oesophageal investigations. 
3.6 Laboratory Investigations 
3.6.1 BAL processing: 
The BAL sample was processed immediately after collection using a validated standard 
operating procedure [143]. This has been produced and extensively used in clinical 
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practice at the Freeman Hospital’s Sir William Leech Centre. The principles of this 
procedure are to: 
 Measure the volume of BAL fluid received and establish the initial cell count 
 Prepare 12 cytospins onto glass slides to allow staining and differential cell 
counts 
 Prepare 25 x 600µl aliquots (stored at -20 ºC) to allow pepsin and bile salt 
assays to be performed 
 Storage of cell pellets with up to 6 x 3 million cells (stored at -20 ºC). 
The BAL fluid was first filtered through a thin layer of gauze into 2 x 50ml centrifuge 
tubes and the total volume recorded. The two centrifuge tubes were filled to the same 
level and then placed into a centrifuge for 6 minutes at 4°C at a speed of 1250rpm. The 
supernatant was then divided equally into 2 x 50ml centrifuge tubes, being careful not to 
disturb the cell pellet. The supernatant was placed back in the centrifuge for a further 
6mins at 4°C but at a speed of 2500rpm. The resultant supernatant was then further 
divided into twenty-five 600μl micro centrifuge tubes and the excess divided into 5ml 
tubes and stored at -20°C for further analysis. 
The cell pellets in the two centrifuge tubes were combined and mixed with Dulbecco’s 
PBS to give an opaque suspension. A small aliquot of the suspension was placed on a 
Neubauer counting chamber and the total cell concentration calculated by counting all 
the cell in the 4 large squares. Using the information from the cell concentration 
calculation the suspension was made up to 0.5million cell/ml. Twelve cytospins were 
then prepared using 100μl of the re-suspended cells at 300rpm for 3 minutes at room 
temperature. Two cytospins were fixed in acetone for 10 minutes and allowed to air dry. 
3.6.2 Sputum processing:  
The sputum collected was processed immediately after collection using a validated 
standard operating procedure [144]. This has been produced and extensively used in 
clinical practice at the Freeman Hospital’s Sir William Leech Centre. The principles of 
this procedure are to: 
 Produce a sputum plug that can be processed 
 Produce 25 x 600µl aliquots (stored at -80 ºC) to allow pepsin and bile salt 
assays to be performed 
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 Process the cell pellet to determine an initial cell count (viable and non-viable 
cells) 
 Prepare 12 cytospins onto glass slides to allow staining and differential cell 
counts 
Once the sputum had been collected and taken to the lab, time was invested in the initial 
processing to produce a decent sputum plug. The processing of the sputum was where 
possible by me but much of the processing was completed by a PhD student, Miss. 
Gemma Crossfield. The sputum was transferred to a petri dish and using a blunt forceps 
the thick mucus strands were condensed into a dense plug. The weight of this plug was 
then measured and the plug suspended in Dulbeccos PBS, using a vortex machine to 
form a suspension. 
The suspension was then centrifuged at 2500rpm for 10 minutes at 4°C and the 
supernatant is decanted off into a new tube being careful not to displace the sputum 
pellet. The supernatant is then centrifuged in the same conditions at 2500rpm and the 
resultant supernatant is divided into 600μl to store at -20°C for future studies. 
The sputum pellet was suspended in 0.2% sputolysin, which has to be prepared as 
detailed in the standard operating procedure (appendix 1). The sputum pellet was 
thoroughly mixed with the sputolysin using the vortex machine. A small volume of 
Dulbeccos PBS was added and a further mix in the vortex machine was performed. The 
suspension was filtered through a thin nylon gauze and the resultant solution 
centrifuged at 2000rpm for 10 minutes at 4°C. The supernatant was then discarded and 
the remaining pellet suspended in a small volume of Dulbeccos PBS to form an opaque 
suspension and 20μl of this was mixed with the same volume of Trypan Blue dye. A 
small aliquot of the suspension was placed on a Neubauer counting chamber and the 
total cell concentration calculated by counting all the cell in the 4 large squares. The 
cells were recorded as viable (colourless) or non-viable (blue) leucocytes and squamous 
cells. The total cell count per gram of sputum was calculated. The suspension was 
centrifuged at 800rpm for 10 minutes at 4°C and the supernatant discarded. A further 
small volume of Dulbeccos PBS was added to the cell pellet to form a solution in which 
the cell concentration was 0.5 million cells per ml. Twelve cytospins were then prepared 
using 100μl of the re-suspended cells at 450rpm for 3 minutes at room temperature. 
Two cytospins were fixed in acetone for 10 minutes and allowed to air dry. 
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3.6.3 Pepsin ELISA 
The pepsin assay used was developed and extensively calibrated, tested and verified 
[145]. The principle steps to the pepsin ELISA were: 
 100μl of standards diluted in phosphate buffered saline (PBS) or 20μl of sample, 
added to 80μl of PBS were added to coat a 96 well micro-plate (Maxisrop, 
Nunc). The plate was sealed and incubated overnight at room temperature.  
 The following day each well was aspirated and washed with 400μl wash buffer 
repeating the process twice for a total of three washes, followed by two more 
washes of 1% PBS. The plate was then blocked by adding 300μl of block buffer 
(1% bovine serum albumin in PBS) to each well and incubated at room 
temperature for 1 hour. Aspiration and wash were repeated.  
 Primary antibody (antipepsin, Biodesign International, USA) was diluted to a 
working concentration (1 in 2000) in reagent buffer (0.1% BSA, 0.05% Tween 
20 in PBS) and 100μl was added to each well. The plate was covered with 
parafilm and incubated for 2 hours at room temperature. Aspiration and wash 
were repeated.  
 100μl of the secondary detection antibody (horse radish peroxidase-conjugated 
anti sheep/goat antibody, Sigma, UK), diluted in reagent dilutant (1 in 10,000), 
was then added to each well. This was covered and incubated for 2 hours at 
room temperature. Aspiration and wash were repeated.  
 100μl of substrate solution (2,2’-azino-bis(3-ethylbenzothiazoline-6-) sulfonic 
acid) was added to each well. This was incubated for 20 minutes at room 
temperature, avoiding direct light.  
 100μl of stop solution (1% sodium dodecyl sulphate) was added to each well.  
 Optical density of each well was determined immediately using a microplate 
reader set to 405nm [145].  
 Negative controls were analysed. These samples were analysed identically apart 
from omitting the primary antibody. In addition a correction factor is used to 
correct for the difference in primary antibody affinity to human compared to pig 
pepsin [145]. 
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Figure 3-５: Standard curve produce with pepsin ELISA 
 
3.6.4 Bile Salt analysis 
Because bile salts were likely to be essentially undetectable by spectrophotometric 
based approaches, a more sensitive tandem mass spectrometry method was used at a 
nationally accredited external laboratory, blind to the study; Sheffield Children’s 
Hospital, UK. Tandem mass spectrometry is a technique that allows the analysis of 
metabolites and proteins in blood samples. The lower limit of detection limit was 
0.01μmol/l but the procedure was further modified to improve the assay sensitivity to 
1nmol/l using an extraction based protocol as follows [36]:  
450μl of BAL was added to 10ml of distilled water containing 150μl of deuterated 
taurocholate (internal standard). This solution was loaded onto a C18SPE column 
(Supelco LC-18) washed with 5ml water and 2ml hexane. The bile salts were eluted 
with 10ml of methanol and evaporated to dryness. They were then reconstituted in 1ml 
of 90% acetonitrile. 30μl was injected directly onto tandem mass spectrometry with 
50% acetonitrile as running buffer. The bile salts were measured using negative ion 
mode and multiple reaction monitoring scans, giving sensitivity down to 1nmol/l. 
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3.7 Cell Staining and Counting  
3.7.1 Giemsa 2 (Romanovsky) stain  
The principle of this stain is to identify the nucleus of all types of inflammatory cells 
allowing a differential cell count to be performed. 
The method of staining each of the cytospins was through a standard operating 
procedure (appendix 2). The cytospins used for the Romanovsky stain were fixed in 
acetone. The working stain solution is produced by mixing two stock solutions which 
were produced as follows: 
Stock Solution A:  Azure B thiocyanate 1.5g with DMSO 200mls. This mixture was 
warmed to 37°C until the Azure B has dissolved 
Stock Solution B: Eosin Y (VWR BDH 341972Q) 0.5g with methanol 300ml. 
Stock solution A was slowly added to stock solution B. This is a concentrated mixture 
and a 10:1 dilution using PBS/Tween 20 (pH7.4) producing the working dye.  
The acetone fixed cytospin was flooded with the dye solution and left for 10 minutes. 
After this, distilled water was used to wash the slide and it was left to air dry. Once dry, 
DPX was used to mount the cover slip and the differential count can be performed 
under a microscope. The table below (Table 3-5) summarises the colours seen for the 
individual cell components: 
Table 3-5: Differential cell count key 
Nuclei Purple 
Cytoplasm Shades of Blue 
Cytoplasmic Granules Shades of Pink 
Eosinophilic Granules Red 
Mast Cells Metachromatic purple red 
 
The diagram on the following page (Figure 3-６) illustrates the appearance of a Geimsa 
stained cytospin under high power magnification with the various cell types identified. 
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Figure 3-６: BAL samples stained with Giemsa stain to visualize cell morphology 
 
 
3.7.2 Oil Red O   
The principle of this stain is to demonstrate intracellular lipid within the macrophages. 
The staining mechanism of this polyazo dye is a function of the physical property of the 
dye being more soluble in the lipid than in the solvent. The presence of lipid in alveolar 
macrophages may be the result of microaspiration secondary to GOR [146]. 
The method of producing cytospins correctly stained with Oil Red O is through 
following the standard operating procedure (appendix 2). This stain requires the 
cytospin to be fixed in formalin which takes 10-15minutes at the start of the procedure. 
The Oil Red O stock solution was produced by dissolving 0.5 grams of Oil Red O in 
100mls of 60% isopropanol using very gentle heat.  
The working Oil Red O solution was made by diluting the stock solution with distilled 
water in a 3:2 ratio and filtering the resultant mixture prior to staining. Once the 
cytospins have been fixed they were washed, first in water and then 60% isopropanol. 
The cytospin was then flooded with the Oil red O stain and left for 15 minutes. A 
second wash with water followed by 60% isopropanol was performed before a light 
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application of Harris Haematoxylin counterstain was added to the slide. After a final 
rinse with water the cover slip was mounted using a glycerin based aqueous mount. 
Under the microscope the nuclei appear blue and the lipid appears red. 
Counting the macrophages and achieving a lipid-laden alveolar macrophage (LLAM) 
score is performed using the method as described by Colombo and Hallberg [147]. 
Using the system described by the authors, a total of 300 macrophages are screened for 
cytoplasmic lipid granules, and the macrophages are graded to their content of lipid 
stained: 0 = cytoplasm not opacified, 1 = up to ¼ opacified, 2 = up to ½ opacified, 3= 
up to ¾ opacified and 4 = totally opacified cytoplasm. Thus LLAM scores could be a 
maximum of 1200. The percentage of LLAM can then be calculated for 300 
macrophaes. 
 
3.7.3 Hemosiderin (Perls Prussian Blue)  
The principle of this stain is to specifically stain the released ferric iron from protein 
bound tissue deposits which in the presence of ferrocyanide ions is precipitated as 
potassium ferric ferrocyanide Prussian Blue. Detection of chemically active iron 
released from ferritin stores and nitric oxide-derived radicals maybe an indication of 
oxidative stress in these cells [148]. More specifically elevated levels of haemosiderin 
laden macrophagesmaybe a sign of occult alveolar haemorrhage secondary to 
pulmonary veno-occlusive disease, a form of pulmonary hypertension seen in IPF [149]. 
The method of producing cytospins stained with Perls Prussian Blue was through 
following the standard operating procedure (appendix 2). This stain requires the 
cytospin to be fixed in acetone which takes 10-15minutes at the start of the procedure. 
The Perls reagent was produced by mixing 2% hydrochloric acid with 2% potassium 
hexacyanoferrate (II) trihydrate (potassium Ferrocyanide). A counterstain is also 
required to provide a neutral control. This was 1% neutral red and is a combination of 
Industrial methylated spirit and Xylene.  
The working solution must be made fresh. Once the cytospins have been fixed and 
allowed to air dry for 15 minutes they were washed first in distilled water. The cytospin 
was then flooded with the Perls reagent and left for 15 minutes. A second wash with 
water followed by the 1% neutral red was performed and left for 30 seconds. A final 
wash with distilled water is required before the cytospin is mounted in DPX. Under the 
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microscope the nuclei appear red and the ferric iron appears blue. Red blood cells 
appear yellow. 
A haemosiderin score (HS) was calculated as described by Reid et al [148]. In total, 200 
macrophages were examined on each slide and each cell was ranked for haemosiderin 
content using a scale from 0 to 4 as follows: 0 = no colour, 1 = faint blue, 2 = deep blue 
in a minor portion of the cell, 3 = deep blue in most of the cytoplasm and 4 = deep blue 
throughout the cell. The total value for all cells was calculated and divided by 2 to 
obtain a score for an average of 100 cells. In addition, the simple percentage of cells 
staining positive was also recorded. 
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3.8 Pulmonary Function Tests 
During the assessment of patients in clinic, pulmonary function tests were performed by 
clinical physiologists in accordance with the standardised European guidelines [138].  
During the tests patients were seated with a specialised mouthpiece and nose clip to 
prevent air escaping during expiration.  After a period of a few minutes of adjustment, 
the patient was asked to take a maximal breath in followed by a hard fast breath out to 
full expiration. In order for the test to be accurate it was essential that expiration was 
both forceful and prolonged [36]. The test was repeated for a minimum of three and a 
maximum of eight times to improve the accuracy.   
The simple spirometry provided a graph of volume against time from which the FEV1 
and FVC were calculated. These measurements are defined below in Table 3-6. The 
FEF25-75 was extrapolated from the graph by taking the points at 25% and 75% of the 
vital capacity and drawing a line between them. The gradient of this line gives the mid 
expiratory flow FEF25-75. (Figure 3-７). 
The flow-volume curves were measured using a Collins Owl body plethysmography 
connected to pnemotach device to give a flow signal (Figure 3-8)) which was then 
integrated with Raptor software to provide volume measurements as defined in the table 
below: 
Table 3-6: Definitions of pulmonary function tests [36] 
 
FVC (litres) Maximal volume of air exhaled with maximally 
forced effort from a maximal inspiration, 
expressed in litres at body temperature and 
ambient pressure saturated with water vapour 
(BTPS) 
FEV1 (litres) Maximal volume of air exhaled in the first second 
of a forced expiration from a position of full 
inspiration, expressed in litres at BTPS. 
FEV1/FVC (%) Ratio of FEV1 as a percentage of FVC 
FEF25-75 Mean forced expiratory flow between 25 and 75% 
of FVC – known as maximal mid-expiratory flow 
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Figure 3-７: Volume-time graph for a normal subject. The red line shows the FEF 25-75 [36]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-８: Flow-volume curve for a normal subject and subject with obstructive air flow disease. 
Legend: [36]. 
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3.9 Statistical analysis 
All the data was recorded onto an excel spreadsheet and the statistical analysis 
performed on Minitab 16 (State College, Pennsylvania, USA). Due to the very small 
sample sizes used basic descriptive statistics were extrapolated from the data and for the 
IPF and CF results Pearson correlation tests was performed to provide a correlation 
coefficient and p value for the relationship. For the lung transplant patients before and 
after surgery a non-parametric paired t-test (Wilcoxon) was performed on the data. 
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4 Idiopathic Pulmonary Fibrosis Results Section 
4.1 Introduction 
A potential relationship between idiopathic pulmonary fibrosis (IPF) and gastro-
oesophageal reflux (GOR) was first demonstrated by Mays et al [73] when they noted 
that hiatus hernia is more common in IPF patients. Tobin et al [74] demonstrated in 17 
patients with biopsy-confirmed IPF, that 94% had reflux confirmed with 24-hour 
manometry, 75% of these patients reported no reflux associated symptoms. Recently 
this has been confirmed in a larger cohort of 65 patients by Raghu et al [71]. Their study 
demonstrated GOR was characterised on 24-hour pH monitoring in 87% of their 
subjects. Interestingly Raghu et al showed abnormal oesophageal acid exposure in 63% 
of their patients who remained on a proton pump inhibitor during the pH studies. The 
most recent guidelines from the American Thoracic Society, 2011 [6] regarding the 
diagnosis and management of IPF, recognised the complication of GOR in IPF, and 
encouraged further studies to determine the exact nature of the reflux. The role of 
microaspiration in IPF is not clearly understood as very few human studies exist looking 
in particular at this disease.  
This section aimed to identify the incidence and nature of reflux in IPF patients and 
develop an understanding of the role of microaspiration in this patient group. 
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4.2 Methods 
Patients diagnosed with IPF as defined by the internationally accepted criteria attended 
a specialist ILD clinic at the Royal Victoria Infirmary. Between July 2010 and March 
2012 all patients with IPF from this clinic that fulfilled the inclusion criteria as defined 
in the previous chapter were approached to be recruited to the study. 
My protocol was to comprehensively assess for GOR using assessments of symptoms, 
objective physiological assessments of reflux and putative markers of aspiration . I used 
a set of validated reflux questionnaires, oesophageal manometry and pH/impedance 
measurements. In tandem with these assessments a bronchoscopy and lavage was 
performed to assess markers of aspiration and airway inflammation. Those patients on 
proton pump inhibitor (PPI) therapy were requested to stop their medication 2 weeks 
prior to the investigations. In addition, they were asked to complete a set of 
questionnaires whilst they were taking the PPI.  Results were then compared with 
markers of aspiration in the bronchoalveolar lavage (BAL) samples and differential cell 
counts from the BAL cytospins. Pulmonary function tests were also available over the 
time the patient had attended the ILD clinic and these were used in the comparison 
analysis. 
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4.3 Results 
4.3.1 Recruitment 
This is summarised in Figure 4-１. 
The recruitment of IPF patients was initially instigated via the specialist clinic. In July 
2010, a specialist IPF clinic was held every 2 weeks with approximately ten patients. 
Suitable patients for recruitment were selected by the specialist through the study 
inclusion criteria described in the previous chapter. The principal researcher would 
approach these patients individually in another clinic room to discuss recruitment into 
the study. In total 19 patients were approached in this way and 11 consented to the 
study. After the start of 2011, clinics were reorganised and took place on a weekly basis 
with several specialists. In this setting it was no longer practical to have the researcher 
in the clinic setting and the specialist would inform the patient that they would be 
contacted via telephone. Through this method of referral 19 patients were contacted and 
only one patient did not consent. In total 29 patients consented to the study. 
Of the 29 patients that consented to the study, 4 patients dropped out before an 
appointment was given for their investigations. Two of the four patients dropped out 
after family concerns having discussed the study at home. One patient relocated outside 
the region and was no longer able to participate in the study. The last patient to drop out 
at this stage was actually a cancellation by the specialist who felt the patient’s frailty 
deemed him unfit for the study investigations 
Of the 25 patients given appointments, 3 dropped out and 2 did not attend (DNA). Of 
the 3 drop outs, two died prior to their appointment date and one patient had their 
diagnosis changed from IPF to obstructive airway disease and was therefore no longer 
eligible. Of the 2 DNAs, one was due to a disagreement with the taxi company on the 
day they were due to attend for their investigations. 
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Figure 4-１: Consort Diagram of IPF patient 
recruitment
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4.3.2 Demographics 
Twenty patients were therefore studied (Table 4-1) (14men, 6 women) with a median 
age of 69 years (range 44-81). Two patients were active smokers at the time of 
recruitment, six patients stated that they had never smoked and the majority were ex-
smokers with a Fangerstorm score of 5-6. This scoring system indicates the level of 
nicotine dependence with a score over 5 indicating moderate to severe dependence [33].  
Only four patients had documented evidence of gastro-oesophageal reflux. Median 
forced expiratory volume in one second (FEV1) was 1.94L (Range 1.4-3.55L) and 
median vital capacity (VC) was 2.53L (Range 1.65-4.35L). Five patients were on 
steroids and six patients were taking N-acetylcysteine as part of their active IPF 
treatment. 15/20 patients were taking a proton-pump inhibitor (PPI). All 20 patients 
completed the investigations. 
Table 4-1: Demographics of study patients
 
Age Sex Smoking 
status 
Fagerstrom 
Score  (SCA) 
Known 
GORD 
PPI Steroids N-
Ace 
FEV1 VC 
IPF1 61 male Current 3 YES YES YES YES 2.45 2.85 
IPF2 44 male Ex-
smoker 
5 NO YES YES YES 1.95 3.05 
IPF3 71 femal
e 
Ex-
smoker 
6 NO YES NO NO 1.85 2.1 
IPF4 81 femal
e 
Ex-
smoker 
6 NO YES NO NO 1.5 1.65 
IPF5 58 male  Ex-
smoker 
6 YES YES NO NO 3.55 4.35 
IPF6 58 male  Never 1 NO YES NO YES 1.82 2.1 
IPF7 72 femal
e  
Ex-
smoker 
6 NO YES NO NO 1.85 2.3 
IPF8 47 femal
e 
Ex-
smoker 
5 NO YES YES NO 1.65 1.9 
IPF9 69 male Never 1 NO YES YES YES 1.4 2.3 
IPF10 78 femal
e 
Never 1 YES YES NO YES 1.86 2.23 
IPF11 74 male Ex-
smoker 
6 NO YES NO NO 2.79 4 
IPF12 66 male Ex-
smoker 
6 NO NO NO NO 2.99 3.34 
IPF13 77 femal
e 
Ex-
smoker 
6 NO YES NO NO 1.93 2.21 
IPF14 72 male Ex-
smoker 
6 NO NO NO NO 2.7 3.1 
IPF15 73 male Never 1 YES YES NO NO 1.85 2.16 
IPF16 47 male Never 1 NO YES YES YES 2.31 3.5 
IPF17 80 male Never 1 NO NO NO NO 1.82 2.41 
IPF18 65 male Ex-
smoker 
6 NO NO NO NO 2.8 3.13 
IPF19 65 male Current 4 NO YES NO NO 2.91 3.38 
IPF20 73 male Ex-
smoker 
6 NO NO NO NO 2.17 2.64 
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4.3.3 Oesophageal Manometry 
8-channel manometry 
11 patients underwent traditional 8 channel manometry as described in the previous 
chapter. Overall  64% of patients (7/11) had normal oesophageal physiology. No 
complications were attributed to the procedure. 
 Lower oesophageal Sphincter 
The median lower oesophageal sphincter length was 4cm (range 3-4cm). Sphincter 
pressure was within normal limits (6-25mmHg) in the majority of the patients (8/11) 
with an average sphincter pressure of 21.9mmHg (Range 13-32mmHg). Three patients 
had a hypertonic LOS and the remaining patients had a normotonic sphincter. Only one 
patient had complete relaxation of the LOS on swallowing with a median percentage 
relaxation of 32% (range 0-100%). 
 Oesophageal Peristalsis 
The median percentage of normal swallows was 90% (range 11-100%). In total 7 
patients had normal peristaltic activity (two of these had hypertonic oesophageal 
peristalsis characterised by high pressure amplitudes), four had non-specific 
oesophageal dysmotility with 3 of these patients having simultaneous oesophageal 
contractions in over 20% of the swallows (Figure 4-２) 
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Table 4-2: Oesophageal peristaltic amplitudes 
 Median 
(mmHg) 
Range (mmHg) Normal Values 
(mmHg) 
Minimum Oesophageal Amplitude 23 12-51  
Maximum Peristaltic Amplitude 157 104-282  
Average Peristaltic Amplitude 65 40-44 30-180 
Distal Oesophageal Amplitude (5cm 
above the lower oesophageal 
sphincter) 
53 32-109 30-180 
Proximal Oesophageal Amplitude 
(15cm above the lower oesophageal 
sphincter) 
68 22-282 30-180 
 
Median peristaltic amplitudes are shown in Table 4-2. One patient had a hypotonic 
proximal oesophagus but had a normotonic distal oesophagus. Another patient had a 
hypertonic proximal oesophagus but they had a normotonic distal oeosphagus. All the 
other patients had proximal and distal amplitudes within the normal range. 
4.3.4 High Resolution Manometry (HRM) 
9 patients underwent HRM as described in the previous chapter. Overall 44% of 
patients (4/9) had normal oesophageal physiology as defined by the Chicago 
classification. No complications were attributed to the procedure. 
 Lower oesophageal Sphincter 
The median lower oesophageal sphincter length was 3.9cm (range 2.8-4.3cm). Sphincter 
pressure was within normal limits (10-45mmHg for HRM) in the majority of the 
patients (6/9) with an average sphincter pressure of 17.9mmHg (Range 1.7-51mmHg). 
Two patients had a hypotonic LOS, one patient had a hypertensive LOS and the 
remaining patients had a normotonic sphincter. In addition, HRM provided details of 
the intra-abdominal length of LOS and the presence of a hiatus hernia. The median 
intra-abdominal length of LOS was -1.8cm (a negative value simply implies that the 
LOS lies above the true pressure inversion point i.e.  Suggestive of a hiatus hernia and 
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is thus NOT intra-abdominal). Six patients (66.7%) had hiatus hernias detected on HRM 
with a mean hernia length of 2.8cm. 
 Oesophageal Peristalsis 
The characterisation of the oesophageal peristalsis was determined by a set of 
measurements taken on HRM as described in table 3.3. The median percentage of 
normal swallows was 93% (range 7 -100%). In total 4 patients the contraction pattern 
was normal in 80-100% of swallows. The remaining 5 patients had a mixture of rapid 
and premature contractions. In four patients there was intact peristalsis in 100% of 
swallows. The Chicago classification of the oesophageal motility in these 9 patients is 
shown below (Figure 4-３).  
Table 4-3: HRM key results 
 Median  Range  Normal Values  
Distal Latency (DL) - s 6.4 5 – 7.8 >4.5 
Distal Contractile Integral (DCI) – 
mmHg.s.cm 
488 160 – 2088 <8000 
Peristaltic Breaks - cm 0.7 0 – 5.7 <2cm 
Integrated Relaxation Pressure 
(IRP4s) - mmHg 
5 -3.8 – 15.1 <15 
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Figure 4-２: Oesophageal Peristalsis 
 
 
Figure 4-３: HRM Oesophageal Peristalsis 
 
 
In summary just under half the patients (9/20) with IPF demonstarted abnormal 
oesophageal motility on manometry 
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4.3.5 Reflux Data 
Reflux Questionnaires 
Fifteen of the twenty IPF patients were taking PPIs at the time of recruitment. The doses 
are listed below in Table 4-4. Patients were requested to stop their PPI for 2 weeks prior 
to the oesophageal physiology investigations. All 15 patients were compliant with this 
request. Questionnaires were completed by the patient ‘ON’ and ‘OFF’ PPI. The 
median daily dose of lansoprazole was 30mg (Range 15 – 60mg) and omeprazole was 
20mg (Range 10-80mg). The total daily dose of PPI were compared to reflux 
questionnaire scores having adjusted the dosages for lansoprazole to omeprazole 
equivalents for purpose of comparison; 15mg lansoprazole = 20mg omeprazole, 30mg 
lansoprazole = 40mg omeprazole and 60mg lansoprazole = 80mg omeprazole [150]. 
Table 4-4: The variation of PPI dosage in study patients 
PPI or H2 Receptor Antagonist Dose Number of Patients 
No Medication 5 
lansoprazole 30mg od 6 
lansoprazole 15mg od 1 
lansoprazole 15mg bd 1 
lansoprazole 30mg bd 2 
omeprazole 10mg od 1 
omeprazole 20mg od 3 
omeprazole 40mg bd 1 
The RSI questionnaires were completed by 19 patients prior to their investigations. One 
patient did not complete this questionnaire and so was excluded from the analysis. All 
15 patients who were on PPI therapy completed the RSI questionnaire before the 
investigation having stopped their medication for 2 weeks before. Eight patients (42%) 
had a positive RSI score (RSI>13).The median RSI score was 10 (Range 0 to 39). The 
15 patients on PPI therapy completed a questionnaire whilst on their treatment. Whilst 
on their PPI nine patients (60%) had a positive RSI score. The median score was 18 
(range 4 to 32).  The differences in RSI score ‘on’ and ‘off’ PPI did not reach statistical 
significance (p=0.45).Therefore, a greater proportion of patients had symptomatic reflux 
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as determined by the RSI despite taking PPI medication. Figure 4-４i shows the RSI 
scores for the IPF patients ON and OFF their PPI. For these patients the median 
difference of the RSI score on and off PPI was +1 (range -30 to 17). For the 15 patients 
on PPI no significant relationship was demonstrated between RSI score and the daily 
dose of PPI (P = 0.645). The scatter plot (Figure 4-５i) demonstrates no clear 
relationship to indicate higher PPI dose reduces RSI score. 
The Demeester questionnaires were completed by all 20 patients prior to their 
investigations. All 15 patients who were on PPI therapy completed the Demeester 
questionnaire before the investigation having stopped their medication for 2 weeks 
before. The median Demeester score was 2 (Range 0 to 7). The 15 patients on PPI 
therapy completed a questionnaire whilst on their treatment. Whilst on their PPI the 
median score was 2 (range 0 to 5). Therefore, the patients on PPI gained no additional 
symptom improvement as determined through the Demeester questionnaire. Figure 4-４
ii shows the Demeester questionnaire scores for the IPF patients ON and OFF their PPI. 
For these patients the median difference of the Demeester score on and off PPI was -1 
(range -4 to 5). Figure 4-５ii shows that for these 15 patients on PPI no significant 
relationship was demonstrated between Demeester score and the daily dose of PPI (P = 
0.231).  
The GIQLI questionnaires were completed by all 20 patients prior to their investigations. 
All 15 patients who were on PPI therapy completed the GIQLI questionnaire before the 
investigation having stopped their medication for 2 weeks before. Fifteen patients (75%) 
had a score below the normal range (121-130). The median GIQLI score was 95 (Range 
49 to 138), indicating health-related quality of life specific to the gastrointestinal system 
was much lower in the IPF patient group. The 15 patients on PPI therapy completed a 
questionnaire whilst on their treatment. Whilst on their PPI Thirteen patients (87%) had 
a GIQLI score below the normal range (121-130). The median score was 108 (range 60 
to 135). The differences in GIQLI score ‘on’ and ‘off’ PPI did not reach statistical 
significance (p=0.41). Therefore, PPI therapy makes very little difference to the quality 
of life of these individuals. Figure 4-４iii shows the GIQLI scores for the IPF patients 
ON and OFF their PPI. For these patients the median difference of the GIQLI score on 
and off PPI was 16 (range -41 to 51). Figure 4-５iii shows that for the 15 patients on 
PPI no significant relationship was demonstrated between GIQLI score and the daily 
dose of PPI (P = 0.595).  
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Figure 4-４: Dot plots showing: i) RSI score (y-axis) for IPF patients ON and OFF PPI therapy (x-
axis). The dotted line indicate the upper limit of mormal, abovbe this indicate abmormal RSI scores.  
ii) Demeester Score (y-axis) for IPF patients ON and OFF PPI therapy (x-axis) iii) GIQLI score (y-
axis) for IPF patients ON and OFF PPI therapy (x-axis) The dotted lines indicate the upper and 
lower linits of the normal GIQLI score, and values below the lower line are abnormal.   
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Figure 4-５: Scatterplots showing: i) the relationship between the daily dose of PPI (x-axis) and RSI 
score (y-axis) ii) the relationship between the daily dose of PPI (x-axis) and Demeester score (y-axis) 
iii) the relationship between the daily dose of PPI (x-axis) and GIQLI score (y-axis) 
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pH – Impedance 
All twenty IPF patients completed the 24 hour recordings. Of the twenty patients, 60% 
patients had evidence of reflux as determined by an abnormal Demeester score (Figure 
4-６). A summary of the median reflux indices per 24 hours for the pH part of the study 
are shown in the table below (Table 4-5). Most refluxes were in the upright rather than 
supine position (62% vs. 38%). 
Table 4-5: Median Reflux Indices for pH part of study 
 Median Range Normal 
Values 
No. of patients 
with abnormal 
results 
Demeester Score 20.7 0.2-
201.6 
<14.72 12/20 
Acid Exposure (%). (% of time pH<4, in 24hrs) 7 0-60 <4.2 12/20 
Number of Reflux Periods in 24 hours 58.1 0-326.7 <50 11/20 
Number of long Refluxes /24hours (>5min) 4.15 0-39.4 <4 10/20 
Longest Reflux  15.5 0-164.3 <9.2 14/20 
 
A summary of the median reflux indices as detected by oesophageal impedance is 
shown in table 3-6. Just over half the patients (60%) had reflux on impedance. Seven 
patients had weakly acid reflux. Two patients had abnormal amounts of both acid and 
weakly acid reflux. Six of the twenty patients had abnormal proximal (Figure 4-７) 
oesophageal reflux (30%). Of these six, four had abnormal Demeester scores.  
The majority of reflux events confirmed from impedance analysis were in the upright 
rather than in the supine position (medians 33.15 vs. 3.4), but these are within the 
normal range for a 24 hour period. However, in these 20 patients nine had an abnormal 
number of supine events compared to only 5 patients with an abnormal number of 
upright events. Most proximal reflux events were in the upright position 8.6 (0-37.3) vs. 
1.1 (0-10.6). The majority of reflux events were mixed (liquid and gas) 26.3 (7.5-89.8) 
vs. 8.75 (0-42.1) for liquid reflux alone. There is a positive correlation between the 
proximal reflux score and the number of liquid and mixed reflux events (Figure 4-８). 
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The correlation is significant for the number of mixed events and proximal reflux score 
(p<0.005). 
Table 4-6: Median Reflux Indices as demonstrated by Oesophageal Impedance  
 Median Range Normal Values No. of patients 
with abnormal 
results 
Oesophageal Volume Exposure (%)  0.63 0.15-
1.75 
0.4 -1.2 4/20 
Total Number of Reflux events/24hours 37.45 10.8-
119.20 
25-58 6/20 
Number of Acid Refluxes/24 hours 17 0-86.8 10-35 5/20 
Number Weakly Acid 
Refluxes/24hours 
11.25 0-89.8 5-18 7/20 
Bolus Clearance Time (s) 11.5 5.5-
17.5 
8-13 6/20 
Proximal Reflux Events 11.15 0-44.5 4-17 6/20 
Liquid Reflux Events 8.75 0-42.1 10-32 1/20 
Mixed Reflux Events 26.3 7.5-
89.8 
11-26 10/20 
Upright Reflux Events 33.15 0-101.1 23-52 5/20 
Supine Reflux Events 3.4 0-22.7 1-6 9/20 
 
Two patients with a positive RSI score (RSI>13) had pathological proximal reflux; Six 
patients with a positive RSI had no pathological proximal reflux. Four patients with a 
negative RSI score had abnormal proximal reflux and eight patients had a negative RSI 
score and a  proximal reflux score which fell within the normal range (<17) (Table 4-7). 
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Table 4-7: The predictive value of the RSI score for proximal reflux 
 Proximal Reflux No proximal reflux  
RSI positive 2 6 PPV= 25% 
RSI negative 4 8 NPV= 67% 
 Sensitivity= 33% Specificity= 43%  
PPV= Positive Predictive Value, NPV=Negative Predictive Value 
No correlation existed between RSI and the Demeester score (P = 0.419) (Figure 4-９i). 
In addition, no significant correlation existed between RSI score and proximal reflux 
measured on oesophageal impedance (P = 0.971). (Figure 4-９ii). 
Manometry to reflux indices 
No significant relationship was demonstrated between the length of the LOS and both 
distal and proximal reflux scores (P= 0.863 and P= 0.712 respectively) (Figure 4-１０). 
The correlations between the LOS resting pressure and Demeester or proximal reflux 
(Figure 4-１１) were not significant (P = 0.801 and P = 0.466 respectively). Of the nine 
IPF patients who had HRM, distal and proximal reflux did not appear to correlate to 
intra-abdominal LOS length (P = 0.765 and P = 0.286 respectively). 
Relationship between use of PPI therapy and reflux symptoms  
Automatic symptom analysis using the MMS software could not be performed due to 
poor compliance of patients with the symptom button and diary. Symptoms were 
studied using the questionnaires only. Of the 15 patients who completed the initial 
symptom questionnaires whilst taking PPI therapy, 60% had an elevated RSI score 
(>13). No difference was seen in the Demeester questionnaires scores when these 
patients completed the questionnaire ‘on and ‘off’ their PPI. GIQLI assessment showed 
85% had below normal scores whilst on their PPI. The indications from the symptom 
scores suggest very little improvement whilst taking the PPI.  
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Figure 4-６: Graph Showing Patient Demeester Scores 
 
 
Figure 4-７: Graph showing proximal Relfux scores 
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Figure 4-８: Scatter plots showing: i) the relationship between liqid reflux events (x-axis) and 
proximal reflux (y-axis) ii) the relationship between mixed reflux events (x-axis) and Proximal 
Reflux (y-axis). 
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Figure 4-９:  Scatter plots showing: i) the relationship between the RSI score (x-axis) and distal 
reflux as defined by Demeester score (y-axis) ii) the relationship between the RSI score (x-axis) and 
ProximalReflux (y-axis). 
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Figure 4-１０: i) The relationship between LOS length (x-axis) and distal reflux as indicated by 
Demeester score (y-axis); ii) the relationship between LOS length (x-axis) and proximal reflux (y-
axis) 
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Figure 4-１１:  i) The relationship between LOS pressure (x-axis) and distal reflux as indicated by 
Demeester score (y-axis); ii) the relationship between LOS pressure (x-axis) and proximal reflux (y-
axis) 
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4.3.6 Lavage Processing Data 
Cell Counts 
All 20 patients with IPF successfully completed a bronchoalveolar lavage (BAL) under 
sedation as a day case patient with no complications post procedure. All lavages were 
performed with a standard 3 x 60ml (180ml) 0.9% saline solution. The median volume 
of BAL return was 90ml (Range 45 -120ml). All lavages were successfully processed 
and the differential cell counts performed and shown in the table below (Table 4-8). 
Table 4-8: The median total cell and differential cell count 
 IPF patients Normal Values [151] 
Total BAL cell count (cellsx10
4
/ml) 16.8 (1.8–236) 14 (12-16) 
Neutrophils (%) 7.5 (1-56) 2.1 (1.6-2.6) 
Lymphocytes  (%) 3 (1-58) 20 (14-26) 
Macrophages (%) 83 (34-97) 73 (66-80) 
Eosinophils (%) 2.5 (0-12) 1.1 (0-2.2) 
There were increased percentages of neutrophils, macrophages and eosinophils but 
decreased levels of lymphocytes when compared to stable controls [151]. No correlation 
existed between the percentages of neutrophils, macrophages or eosinophils and 
proximal reflux score (P= 0.705, P= 0.620 and P=0.449 respectively).  
Cell Stains 
Table 4-9: Haemosiderin and Oil Red stain median values  
       IPF patients Normal Values [148, 152] 
Haemosiderin stained macrophage %  20 (2-98.5) 0 (0-1.5) 
Haemosiderin Score 31.8 (3 -236.5) 0 (0-2) 
Oil Red (lipid laden macrophage) % 3.3 (0-47) 2.63 (0-20) 
Oil Red Positive Macrophage Score 15.5 (0-310) 5.47(0-49) 
 
All 20 IPF patients had an elevated haemosiderin (HS) score outside the range seen for 
normal subjects as described by Reid et al [148] (Table 4-9). However, there was no 
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significant correlation to either proximal or distal reflux scores (P= 0.734 and P= 0.295 
respectively) or total reflux episodes detected on impedance (P= 0.405) or pH analysis 
(P= 0.444). (Figure 4-１３) 
All 20 IPF patients were also scored with regard to lipid laden macrophages as detected 
by Oil Red staining. The median percentage of Oil Red positive macrophages and 
median score were both above the values observed in a control population [152] (Table 
4-9). However, only 5/20 patients had a lipid laden macrophage score outside the 
normal range. There was no significant correlation to either proximal or distal reflux 
scores (P= 0.592 and P= 0.942 respectively) or total reflux episodes detected on 
impedance (P= 0.781) or pH analysis (P= 0.678) (Figure 4-１４). 
In summary, all 20 IPF patients successfully completed bronchoscopy and lavage. All 
BAL samples were processed to produce cytospins and differential cell counts and 
specific stains as described above were performed on all patient samples. Table 4-9 
summarises the individual patient results and Figure 4-１５illustrates the Haemosiderin 
(HS) and Oil red (OR) percentages found in the IPF patient group when compared to 
normal controls (median values). Actual slide photos are shown in Figure 4-１６. 
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Table 4-10: Summary of cell processing, differential counts and stain scores for IPF 1-20. 
Patient No BAL Vol/ml  
vo/ml/mlused/ml 
Cell 
Count(x10
4
/ml) 
%M %L %N %E HS score OR-score 
IPF1 35 32.5 48 2 38 12 19.5 52 
IPF2 90 22 86 4 8 2 236.5 23 
IPF3 80 16 84 3 9 4 4.5 6 
IPF4 75 2.5 41 18 31 10 19.5 8 
IPF5 90 23.3 89 3 3 5 9.5 139 
IPF6 80 13.6 88 9 2 1 8 0 
IPF7 90 46.75 82 10 6 2 67 13 
IPF8 77.5 17.5 91 2 7 0 115.5 57 
IPF9 95 236 57 28 15 0 89 12 
IPF10 47 22 43 31 24 2 11.5 34 
IPF11 55 14.32 36 58 3 3 109.5 30 
IPF12 85 15.3 89 1 3 7 9 0 
IPF13 105 8.6 74 9.5 16 0.5 207.5 73 
IPF14 40 27.25 54 5 36 5 6.5 0 
IPF15 75 5.55 86 3 5 6 44 7 
IPF16 45 5.86 78 1 9.5 11.5 3 18 
IPF17 86 19.3 94 2 3 1 46.5 11 
IPF18 52 1.82 34 1 56 9 71.5 5 
IPF19 75 30.13 97 2 1 0 4.5 310 
IPF20 82 6.71 96 1 3 0 74.5 24 
KEY: %M=macrophages, %L=lymphocytes, %N=neutrophils, %E=eosinophil 
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Figure 4-１２: Dot Plot to illustrate the haemosiderin score and Oil Red score in IPF patients 
(n=20) with the upper limit of the normal values indicated. 
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Figure 4-１３: Scatter plots of reflux parameters versus percentage of Haemosiderin stained 
macrophages (in % 200 macrophages; n =20) i) distal reflux as defined by Demeester score versus 
% Haemosiderin stained macrophages; ii) proximal reflux score versus % Haemosiderin stained 
macrophages; iii) Total reflux periods on impedance versus % Haemosiderin stained macrophages; 
iv) Total reflux periods on pH analysis versus % Haemosiderin stained macropahges. 
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Figure 4-１４: Scatter plots of reflux parameters versus percentage of Oil Red stained 
macrophages (in % of 300 macrophages; n =20) i) distal reflux as defined by Demeester score 
versus % Oil red stained macrophages; ii) proximal reflux score versus % Oil red stained 
macrophages; iii) Total reflux periods on impedance versus % Oil red stained macrophages; iv) 
Total reflux periods on pH analysis versus % Oil red stained macrophages. 
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Figure 4-１５: i) Graph showing percentage of Oil Red positive macrophages (y-axis) for each IPF 
patient compared to the percentage seen in a control population [152]; ii) Graph showing 
percentage of Haemosidderin positive macrophages (y-axis) for each IPF patient compared to the 
percentage seen in a control population [148]  
  
 i) 
  
 ii) 
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Figure 4-１６: Slide pictures showing Geimsa, Haemosidderin and Oil Red Staining for IPF 1-20 
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4.3.7 Markers of aspiration 
Bile Salts 
BAL samples from all 20 IPF were analysed using a combination of tandem mass 
spectrometry allow the sensitivity of detecting bile salts to be increased to a minimum 
level of 0.01µmol/L [98]. Our samples were also processed using a specialised 
extraction technique and the lower limit of detection was 0.001µmol/L. Concentrations 
of the individual bile salts (glycodeoxycholate, glycocholate, taurodeoxycholate and 
tauracholate) were added together to give the total bile salt concentration. The 
concentration of free lithocholate was also available using the extraction technique 
described in the previous chapter. The table on the following page (Table 4-11) shows 
the concentration of bile salts identified in the BAL of IPF subjects 1-20 and four 
normal controls. 
All 20 patient samples showed ‘detectable’ bile salts and 17/20 showed detectable free 
lithocholate. The highest bile salt concentration was 0.7449µmol/L and the highest free 
lithocholate concentration was 0.05µmol/L. The median value for bile salts in the 20 
IPF patients was 0.0087µmol/L which was similar to the median level detected in the 
four normal controls (0.0065µmol/L). One patient had much higher levels 
(0.745µmol/L) than the other patients. The median free lithocholate concentration in the 
twenty IPF patients was 0.012µmol/L which was lower than the levels detected in the 
normal controls (0.025µmol/L). It is clear from the table that although levels were 
detectable, the amounts identified in most patients were in the region of the lower limit 
of detection (0.001µmol/L) and is essentially a negligible concentration. 
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Table 4-11: Bile salt concentration in the BAL for IPF 1-20 and four normal controls 
 G-DHC 
µmol/l 
G-THC 
µmol/l 
T-DHC 
µmol/l 
T-THC 
µmol/l 
Total Conc. 
µmol/l 
Free Lithocholate 
µmol/l 
IPF1 0.003 0.003 0.003 0.003 0.012 ND 
IPF2 0.006 0.002 0.005 0.003 0.016 ND 
IPF3 0.003 0.001 0.050 0.004 0.058 0.02 
IPF4 0.010 0.003 0.008 0.004 0.025 0.05 
IPF5 ND ND 0.004 0.002 0.006 ND 
IPF6 0.460 0.145 0.111 0.029 0.745 0.016 
IPF7 0.002 0.001 0.002 0.000 0.005 0.020 
IPF8 0.004 0.001 0.011 0.001 0.017 0.012 
IPF9 0.000 0.000 0.003 0.001 0.005 0.008 
IPF10 0.000 0.001 0.006 0.001 0.007 0.033 
IPF11 0.003 0.001 0.000 0.001 0.004 0.012 
IPF12 0.004 0.002 0.002 0.002 0.010 0.011 
IPF13 0.002 0.000 0.001 0.001 0.004 0.008 
IPF14 0.006 0.001 0.001 0.001 0.010 0.014 
IPF15 0.004 0.001 0.002 0.001 0.008 0.017 
IPF16 0.002 0.001 0.002 0.001 0.006 0.006 
IPF17 0.015 0.004 0.003 0.000 0.022 0.012 
IPF18 0.035 0.012 0.007 0.003 0.057 0.013 
IPF19 0.002 0.001 0.000 0.000 0.004 0.009 
IPF20 0.004 0.001 0.001 0.001 0.006 0.012 
Normal 1 0.013 0.020 0.003 0.005 0.041 0.01 
Normal 2 0.001 0.001 ND 0.001 0.003 ND 
Normal 3 0.004 0.002 0.002 0.002 0.010 0.06 
Normal 4 0.001 ND 0.002 ND 0.003 0.04 
KEY: G-DHC = glycodeoxycholate, G-THC = glycocholate, T-DHC = 
taurodeoxycholate, T-THC = taurocholate. ND = not detected 
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Figure 4-１７: Dot plots showing i) Bile salt concentration (y-axis) in the BAL of IPF patients 
compared to normal subjects (x-axis) ii) Free lithocholate concentration (y-axis) in the BAL of IPF 
patients compared to normal subjects (x-axis) 
i) 
NormalsIPF
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
T
o
ta
l 
b
ile
 S
a
lt
 C
o
n
c
e
n
tr
a
ti
o
n
Total bile salt concentration in IPF patients (n=20) and normal subjects (n=4)
 
ii) 
NormalsIPF
0.06
0.05
0.04
0.03
0.02
0.01
0.00
L
it
h
o
c
h
o
la
te
 C
o
n
c
e
n
tr
a
ti
o
n
Free Lithocholate Concentration in IPF patients (n=20) and normal subjects (n=4)
 
 
 
133 
 
Pepsin 
BAL samples from all 20 IPF were analysed using an ELISA technique to detect pepsin. 
Table 4-12 shows these pepsin values compared against reflux study results and lung 
function decline. 11/20 patient samples showed detectable pepsin. The highest pepsin 
concentration was 35ng/ml. The median pepsin concentration in the 20 IPF patients was 
9.0ng/ml which was higher than the median level detected in normal controls 
(1.1ng/ml)[106].  
Table 4-12: Pepsin concentrations in BAL samples for IPF1-20 
 Pepsis 
Concentration 
ng/ml 
 
Demeester 
Score 
(<14.72) 
Total Reflux 
Time 
(<4.2%) 
Proximal 
reflux Score 
(4-17) 
% Decline 
FEV1   
% Decline of 
vital Capacity 
in 12 months 
IPF1 0 55.63 16.00 38.7 -6.7 4.5 
IPF2 25 37.15 11.00 12.4 N/A N/A 
IPF3 7 54.47 18.00 9.5 -7.2 -5.3 
IPF4 0 7.79 2.00 4.2 1.7 3.9 
IPF5 16 30.29 8.00 4.8 -4.1 0.4 
IPF6 14 128.92 37.00 44.5 -0.5 -5.8 
IPF7 19 6.56 2.00 6.4 -5.4 -10.4 
IPF8 0 6.78 2.00 14 -1.1 -1.3 
IPF9 11 2.03 1.00 18.6 5.1 -11.6 
IPF10 0 121.29 39.00 15.2 -21.7 -12.7 
IPF11 0 201.56 60.00 3.2 -5.1 -8.5 
IPF12 35 45.88 17.10 19.6 -15.2 -16.8 
IPF13 0 18.5 6.00 25.7 -16.8 -21.2 
IPF14 0 0.2 0.00 28.3 -6.0 -12.8 
IPF15 26 22.84 7.40 9.9 -29.6 -62.8 
IPF16 14 78.22 20.00 5.2 -12.7 2.4 
IPF17 11 13.21 3.10 0 -10.3 -34.9 
IPF18 19 2.85 0.70 2.2 -8.5 -15.5 
IPF19 0 4.03 0.90 5.6 -8.8 -16.6 
IPF20 0 18.51 6.60 14.3 3.9 -7.4 
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Figure 4-１８: Dot plots showing i) pepsin concentration (y-axis) in the BAL of IPF patients 
compared to normal subjects (x-axis) 
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Eleven out of the 20 IPF patients had elevated pepsin concentrations in the lavage 
compared to pepsin concentrations in BAL of normal controls. Of these eleven patients, 
7 had high Demeester scores indicating significant reflux and 3 patients had proximal 
reflux. Ten of the eleven IPF patients with elevated pepsin levels also had lung function 
data available. Nine patients showed a decline in FEV1 and eight showed a decline in 
vital capacity. Pearson’s test showed no correlation between pepsin levels and either 
Demeester and proximal reflux scores. The regression analysis shows a small degree of 
association between decline in vital capacity and pepsin levels (p=0.085) and this is 
illustrated in Figure 4-１９ 
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Figure 4-１９:  Scatter plot showing pepsin concentrations (x-axis) for IPF 1-20 against percentage 
decline of lung vital capacity (y-axis). 
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4.3.8 Lung Function 
Serial lung function results were collected for 19 of the 20 IPF patients. IPF 2 was only 
seen in the specialist clinic on one occasion and therefore serial lung function tests 
could not be used to illustrate the rate of decline of lung function. The individual FEV1 
and VC (vital capacity) were plotted against the time period in weeks to reveal a 
regression line with a formula in the format y=mx+c. The values of t=0 and t=52 (1year) 
were re-inputted into the regression formulas and the percentage decline of lung 
function per year was calculated for each patient (Table 4-13). 
The FEV1/FVC ratio was greater than 80% in 15/20 people at the time of recruitment. 
The decline in lung function showed predominantly a greater reduction in FVC over 
time resulting in abnormal restrictive function. (median loss of vital capacity = 10%/yr). 
Table 4-13: Summary of lung function decline as measured using FEV1and VC with corresponding 
reflux scores for IPF 1-20. 
Patient No Yearly % 
Decline FEV1   
Yearly % Decline 
of vital Capacity 
Demeester 
Score (norm 
<14.72) 
Proximal 
Reflux Score 
(norm 4-17) 
IPF1 -6.7 4.5 55.63 38.7 
IPF3 -7.2 -5.3 54.47 9.5 
IPF4 1.7 3.9 7.79 4.2 
IPF5 -4.1 0.4 30.29 4.8 
IPF6 -0.5 -5.8 128.92 44.5 
IPF7 -5.4 -10.4 6.56 6.4 
IPF8 -1.1 -1.3 6.78 14 
IPF9 5.1 -11.6 2.03 18.6 
IPF10 -21.7 -12.7 121.29 15.2 
IPF11 -5.1 -8.5 201.56 3.2 
IPF12 -15.2 -16.8 45.88 19.6 
IPF13 -16.8 -21.2 18.5 25.7 
IPF14 -6.0 -12.8 0.2 28.3 
IPF15 -29.6 -62.8 22.84 9.9 
IPF16 -12.7 2.4 78.22 5.2 
IPF17 -10.3 -34.9 13.21 0 
IPF18 -8.5 -15.5 2.85 2.2 
IPF19 -8.8 -16.6 4.03 5.6 
IPF20 3.9 -7.4 18.51 14.3 
*IPF 2 was excluded from analysis as only a single lung function was performed on this patient 
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Decline of FEV1 
The median percentage decline of FEV1 per year was 7% with the largest decline of 
FEV1 being 30%. There was no significant correlation between the percentage decline 
of FEV1 and proximal reflux score (Pearson correlation = 0.114, p=0.642). There was 
no significant relationship between the percentage decline of FEV1 and Demeester score 
(Pearson correlation = -0.209, p =0.391). In addition, there was no significant relation 
between the reflux symptom index (RSI score) and decline of FEV1 (p=0.158). 
Decline of Vital Capacity (VC) 
The median percentage decline of VC per year was 10.4% with the largest decline of 
FEV1 being 62.8%. There was no significant correlation between the percentage decline 
of VC and proximal reflux score (Pearson correlation = 0.054, p=0.825). There was no 
significant relationship between the percentage decline of VC and Demeester score 
(Pearson correlation = 0.314, p =0.19). In addition, there was no significant relation 
between the reflux symptom index (RSI score) and decline of VC (p=0.152). 
Although TLco (Transfer factor of the lung for carbon monoxide) is a more useful 
measurement in assessing lung function in IPF patients this was not measured in all 
patients at their lung function tests and so the data was not available for analysis. 
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4.3.9 Reflux Finding Scores  
The reflux finding score (RFS) is an 8-item clinical severity scales based on the visual 
findings during bronchoscopy (Figure 4-２０). The scoring allows another mode of 
assessing potential laryngopharyngeal reflux (LPR). The scoring was performed by Dr. 
Julian Mcglashan at Nottingham University based on the validated RFS system 
produced and validated by Belafsky et al in 2001[153] and are documented with RSI 
score in the table below. The RFS for the IPF group is also illustrated in the dot plot 
(Figure 4-２１). The Normal RFS score is 7. Seven out of twenty patients had abnormal 
RFS scores. 
Table 4-14: RFS and RSI scores for IPF patients 1-20 
Patient 
No 
Vocal 
fold 
oedema 
Diffuse 
laryngeal 
oedema 
Posterior 
Commissure 
hypertrophy 
Granuloma/ 
granulation 
tissue 
RFS 
Total 
RSI 
Score 
IPF1 1 0 0 0 3 6 
IPF2 2 2 2 0 9 18 
IPF3 1 1 1 0 5 10 
IPF4 2 1 1 0 9 18 
IPF5 3 2 3 0 11 22 
IPF6 2 1 1 0 4 8 
IPF7 1 1 1 0 5 10 
IPF8 2 0 0 0 4 8 
IPF9 2 2 3 0 11 22 
IPF10 3 2 2 0 11 22 
IPF11 1 1 1 0 5 10 
IPF12 0 0 0 0 0 0 
IPF13 3 2 1 0 9 18 
IPF14 2 1 0 0 6 12 
IPF15 1 2 1 0 10 20 
IPF16 0 0 1 0 1 2 
IPF17 2 1 1 0 7 14 
IPF18 0 0 1 0 1 2 
IPF19 2 1 1 0 7 14 
IPF20 1 1 1 0 6 12 
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There was a positive correlation between the RFS scores calculated by an external 
source and the RSI scored from the research questionnaires but this was not significant 
(Pearson correlation = 0.289, p=0.217). There was no significant relationship between 
RFS scores and proximal reflux scores. 
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Figure 4-２０: Bronchoscopy images for RFS scoring  
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 Figure 4-２１: Dot plot of individual Reflux Finding Scores for IPF 1-20 with normal control score 
indicated 
12
10
8
6
4
2
0
R
FS
 T
o
ta
l
RFS in Control group = 7
 Reflux Finding Score for IPF 1-20
 
Figure 4-２２: Relationship between RFS scores and RSI scores in IPF patients 
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4.3.10 Radiological Information 
Table 4-15: HRCT information and reflux scores of IPF patients 1 to 20 
 
Patient 
No 
HRCT 
reviewed 
Hiatus hernia 
details 
IPF 
symmetry 
Demeester 
Score 
(norm<14.72) 
Proximal 
Reflux 
Score 
(norm 4-
17) 
IPF1 Yes Small Sliding Symmetrical 55.63 38.7 
IPF2 Yes Moderate Sliding Symmetrical 37.15 12.4 
IPF3 
Yes Small sliding 
Asymmetrical 
Left >right 
54.47 9.5 
IPF4 
Yes 
Large (most of 
stomach) 
Symmetrical 
7.79 4.2 
IPF5 Yes No Hiatus Hernia Symmetrical 30.29 4.8 
IPF6 Yes No Hiatus Hernia Symmetrical 128.92 44.5 
IPF7 Yes Moderate Sliding Symmetrical 6.56 6.4 
IPF8 Yes Small sliding Symmetrical 6.78 14 
IPF9 
No 
No hiatus hernia on 
Ba. swallow 
Symmetrical 
(CXR) 
2.03 18.6 
IPF10 Yes Small sliding Symmetrical 121.29 15.2 
IPF11 
Yes Small Hiatus Hernia 
Asymmetrical 
Right > left 
201.56 3.2 
IPF12 Yes No Hiatus Hernia Symmetrical 45.88 19.6 
IPF13 Yes Small sliding Symmetrical 18.5 25.7 
IPF14 Yes Small sliding Symmetrical 0.2 28.3 
IPF15 Yes Small Hiatus Hernia Symmetrical 22.84 9.9 
IPF16 
No 
No hiatus hernia on 
Ba. swallow 
Symmetrical 
(CXR) 
78.22 5.2 
IPF17 Yes Small Hiatus Hernia Symmetrical 13.21 0 
IPF18 Yes Small sliding Symmetrical 2.85 2.2 
IPF19 Yes Small sliding Symmetrical 4.03 5.6 
IPF20 Yes No Hiatus Hernia Symmetrical 18.51 14.3 
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An independent consultant radiologist (Dr. Hilary Spence, RVI) who was not involved 
in the initial CT diagnosis of IPF was asked to review the high resolution CT scan 
(HRCT) of the IPF patient group and comment on the presence of any hiatus hernia and 
the symmetry of the disease. Eighteen of the twenty patients had CT scans which were 
accessible on the local PACS system for review. However, the 2 patients who did not 
have a CT scan had a chest x-ray and barium swallow test in order for the radiologist to 
make comment. 
From HRCT evidence, 14/18 patients had evidence of a hiatus hernia. Of these, eight 
patients had objective evidence of reflux from pH-impedance. Two patients had 
evidence of asymmetrical IPF on HRCT. Both these patients had hiatus hernias and 
objective evidence of reflux. All four patients with no hiatus hernia visible on HRCT 
had objective evidence of reflux. 
The two patients who did not have a CT scan available for review (IPF 9 and IPF 16) 
both had symmetrical disease on their chest x-ray. A barium swallow had been 
performed on these patients during their attendance at the IPF centre and in both 
patients no hiatus hernia was present. Both patients did have objective evidence of 
reflux on pH-impedance.  
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4.4 Summary of IPF Results 
4.4.1 Clinical Results 
Between July 2010 and March 2012, twenty patients formally diagnosed with Idiopathic 
Pulmonary Fibrosis through a multi-disciplinary meeting were studied. This included 
fourteen males and six females who had a median age of 69 years. Baseline median lung 
function for the group was a FEV1 of 1.96 litres and a Vital Capacity (VC) of 2.53 litres. 
Fifteen patients were on proton pump inhibitor (PPI) therapy prior to their recruitment 
into the study; only four had documented evidence of gastro-oesophageal reflux (GOR) 
in their notes. 
All twenty patient successfully completed oesophageal manometry and Impedance-pH 
studies. Eleven patients demonstrated normal oesophageal peristalsis on either 
traditional 8-channel manometry or High Resolution Manometry (HRM). The most 
common abnormality detected on 8-channel manometry was simultaneous swallows but 
on HRM distal oesophageal spasm was seen most commonly in those patients with 
abnormal peristalsis. Of the twenty patients, twelve had objective evidence of reflux on 
impedance-pH. Seven patients had weakly acid reflux and six patients had evidence of 
abnormal proximal reflux. Most reflux events were mixed (liquid and gas). The 
incidence of reflux was not related to lower oesophageal sphincter (LOS) length or 
resting pressure. 
Patient symptoms and the effect on quality of life were studies using validated 
questionnaires. Fifteen patients were already on PPIs before they entered the study and 
the questionnaires were completed ‘on’ and ‘off’ PPI. Reflux symptom index (RSI) 
scores, assessing symptoms of extra-oesophageal reflux were higher for patients taking 
PPI with over 60% having a positive RSI score (RSI > 13). Demeester questionnaire 
scores for patients ‘on’ and ‘off’ PPI were identical. Quality of life scores were assessed 
with the Gastro-Intestinal Quality of Life Index (GIQLI). The median score was slightly 
higher for those patients on PPI therapy (108 vs. 95); however, over 85% of patients on 
PPI had GIQLI scores below the normal range. 
Lung function tests were performed on all 20 IPF patients but serial analysis of FEV1 
and VC were performed on nineteen patients. Using the raw lung function data, the 
percentage decline of FEV1 and VC over one year was calculated. 16/19 patients had a 
decline of FEV1 with the largest decline being 29.6%. Ten of these patients had an 
abnormal Demeester score and five patients had abnormal proximal reflux scores. 
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Fifteen patients demonstrated a reduction in VC. 8 patients with a reduction in vital 
capacity had elevated Demeester scores and five demonstrated abnormal levels of 
proximal reflux. The percentage decline of FEV1 and VC did not correlate directly with 
abnormal Demeester Scores or elevated levels of proximal reflux. Lung function was 
abnormal in 5/20 patients (FEV1/FVC ratio <80% predicted) and the disease 
progression was a rapid loss of FVC over time of over 10% per year.   
The reflux finding scores (RFS) were calculated for all the IPF patients using photos of 
the patient’s larynx taken at bronchoscopy. This score may indicate the presence of 
laryngopharngeal reflux.  The formal scoring was performed by an external specialist 
from another centre. Seven patients demonstrated abnormal RFS (>7) and all of these 
patients had elevated reflux symptom index (RSI) scores, a marker of extra-oesophageal 
reflux. Although a positive correlation was demonstrated between RFS and RSI scores 
the relationship did not reach statistical significance. There was no correlation between 
RFS scores and proximal reflux on impedance-pH.  
High resolution CT was used in the diagnostic assessment of the IPF patients. In 18/20 
of our patients the CT images were available for an independent radiologist to review 
the presence or absence of a hiatus hernia. Fourteen of these patients had a hiatus hernia 
on their CT scans and eight of these had objective evidence of reflux on Impedance-pH 
testing. Four patients had objective reflux in the absence of hernia. The two patients 
who did not have an accessible CT image had barium swallows. Neither patient was 
demonstrated to have a hiatus hernia but both had reflux on their impedance-pH studies. 
4.4.2 Laboratory based studies 
All 20 IPF patients had bronchoscopy performed with a standardised 3 x 60ml saline 
lavage. This was processed using a standard operating procedure so that a differential 
cell count could be performed. In addition, pepsin and bile salt assays were performed 
on the BAL supernatant. The principal cell type identified in the BAL was macrophages 
and these were stained with Prussian Blue (Haemosiderin) and Oil Red O (lipid-laden) 
stains. The percentages of cells that stained positive for these stains were higher than the 
percentages seen in normal controls. There was no correlation between the 
Haemosiderin or Oil Red scores and reflux levels for the IPF group. All 20 IPF patients 
showed detectable bile salt and the median levels were higher than the levels seen in 
normal controls. Free lithocholate was detected in 17/20 patients but the median levels 
were lower than those seen in normal controls. Eleven out of twenty IPF patients had 
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pepsin levels in the lavage samples higher than the normal controls, in some patients the 
levels were over ten times that of normal controls. 
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5 Cystic Fibrosis Results Section 
5.1 Introduction 
GOR has been reported as early as the 1970s in patients with CF and currently the 
prevalence is estimated to be between 35-81% [81]. Over the last 30 years advances in 
the care of patients with CF have resulted in a growing adult population with CF. There 
is a higher incidence of GOR in children with CF than in the general population [82], 
about 1 in 5 newly diagnosed CF infants have pathological reflux, [22] but there are 
very few comparable studies in the adult CF population. Most of the studies performed 
to date in this population use 24 hour pH monitoring which only allows the detection of 
acidic GOR The abnormal CFTR regulation in cystic fibrosis may influence the nature 
of the reflux including whether it is acidic or weakly acidic reflux. There have been 
limited studies performed using pH impedance in CF patients [81] with interesting 
results. Blondeau et al performed pH impedance studies on 23 CF patients and 
demonstrated that up to 80% had acid GOR with subgroup having increased weakly 
acid reflux. 
This section aimed to identify the incidence and nature of reflux in CF patients and 
develop an understanding of the role of microaspiration in this patient group. 
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5.2 Methods 
Adult patients with diagnosed CF are reviewed at specialist clinics at the Royal Victoria 
Infirmary. Several respiratory consultants who are specialists in cystic fibrosis work 
with a team of nurses and physiotherapists creating a multidisciplinary clinic setting. 
Between June 2011 and April 2012 all patients with typical (∆508) CF that fulfilled the 
inclusion criteria as described in the previous chapter were approached to be recruited to 
the study. 
My protocol was to assess for GORD using a set of validated reflux questionnaires, 
oesophageal manometry and pH/impedance measurements. At the same time as these 
assessments were made a sputum sample was requested. Those patients on proton pump 
inhibitor (PPI) therapy were requested to stop their medication 2 weeks prior to the 
investigations. In addition, they were asked to complete a set of questionnaires whilst 
they were taking the PPI.  Results were then compared with markers of aspiration in the 
sputum sample, microbiology, and differential cell counts from the sputum processing. 
Pulmonary function tests were also available over the time the patient had attended the 
CF clinic and these were used in the analyses. 
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5.3 Results 
5.3.1 Recruitment 
The recruitment of CF patients was initially instigated via the specialist clinic. In June 
2011, specialist CF clinics were being held regularly, normally a morning or afternoon 
clinic dependent on clinician. The CF lead’s clinic, held twice a week was chosen as the 
clinic where the research patients would be recruited from. This allowed confirmation 
that the inclusion criteria including genotype were strictly adhered to. Suitable patients 
for recruitment were selected by the specialist using the study inclusion criteria 
described in the previous chapter. The principal researcher would approach these 
patients individually in another clinic room to discuss recruitment into the study. In total 
40 patients were approached this way and 18 consented to the study. Further 
recruitment was done by the CF specialist nurse in the absence of the principal 
researcher. Through this method of referral 8 patients consented to the study. In total 26 
patients consented to the study (Figure 5-１).  
Of the 26 patients that consented to the study, 6 patients dropped out before an 
appointment was given for their investigations. Three of the six patients dropped out 
after reading the information leaflet. Three other patients were not contactable on the 
telephone numbers they had provided at the time of consent. 
Of the 20 patients given appointments, 8 dropped out which included 2 not attending 
(DNA), one patient becoming unwell and five patients changed their minds after the 
appointment was given. Of the 12 patients that did attend, 11 patients actually 
participated as one patient became extremely anxious on the day of the test and no 
longer wished to participate. 
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Figure 5-１: Consort Diagram of CF patient recruitment 
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5.3.2 Demographics 
Eleven typical CF patients (∆508 genotype) were therefore studied (Table 5-1) (6 men, 
5 women) with a median age of 29 years (range 44-81) and a median BMI of 22Kg/m
2
. 
Only four patients had documented evidence of gastro-oesophageal reflux either 
through clinical letters or a recent endoscopy. Median forced expiratory volume in one 
second (FEV1) was 1.86L (Range 0.86-3.08L) and median vital capacity (VC) was 
2.15L (Range 1.38-5.17L). All the patients had pancreatic insufficiency and 10/11 
patients were on azithromycin therapy. All the patients were colonised with 
Pseudomonas aeruginosa. Five patients had CF induced diabetes mellitus and were 
taking insulin. All patients were taking acid-suppression therapy at the time of 
recruitment. Nine of the eleven patients completed both oesophageal manometry and 
pH-impedance; two patients were unable to tolerate the manometry. 
Table 5-1: Demographics of study patients 
 Age Sex BMI 
Kg/m2 
Genotype Pancreatic 
Insufficiency 
Known 
GORD 
PPI On-
insulin 
On 
azithromycin 
Baseline 
FEV1 
Baseline  
VC 
CF1 24 Female 18.7 (∆508/-) 
 
YES NO YES YES YES 1.6 
 
2.15 
 CF2 22 Male 18.8 (∆508/∆508) 
 
YES NO YES NO YES 3.08 
 
5.17 
 CF3 29 Female 20.6 (∆508/N1303K) 
 
YES YES YES YES YES 1.2 
 
2.1 
 CF4 31 Male 23.4 (∆508/∆508) 
 
YES YES YES YES YES 1.86 
 
2.07 
 CF5 40 Male 26.65 (∆508/∆508) 
 
YES YES YES YES YES 2.26 
 
4.82 
 CF6 21 Male 19 (∆508/NMD) 
 
YES NO YES NO YES 3 
 
5 
 CF7 25 Female 22 (∆508/2184delA) 
 
YES NO H2A NO YES 1.31 
 
1.88 
 CF8 35 Male 22.16 (∆508) 
 
YES NO YES NO NO 2.25 
 
3.2 
 CF9 19 Female 29.7 (∆508/9551D) 
 
YES NO YES YES YES 2.46 
 
2.85 
 CF10 59 Female 20.4 (∆508/D1152H) 
 
YES YES YES NO YES 0.86 
 
1.38 
 CF11 32 Male 22.9 (∆508) 
 
YES NO YES NO YES 1.08 
 
2.15 
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5.3.3 High Resolution Manometry (HRM) 
9 patients underwent HRM as described in the previous chapter. Overall 66% of 
patients (6/9) had abnormal oesophageal physiology as defined by the Chicago 
classification (Table 5-2). No complications were attributed to the procedure. 
 Lower oesophageal Sphincter 
The median lower oesophageal sphincter length was 3.8cm (range 3.0-4.4cm). Sphincter 
pressure was within normal limits (10-45mmHg for HRM) in five patients with an 
average sphincter pressure of 14.54mmHg (Range 4.6-30.6mmHg). Four patients had a 
hypotonic LOS. In addition, HRM provided details of the intra-abdominal length of 
LOS and the presence of a hiatus hernia. The median intra-abdominal length of LOS 
was 1.3cm (Range -2.7- 4.1cm). Five patients (55.6%) had hiatus hernias detected on 
HRM with a mean hernia length of 2.12cm. 
 Oesophageal Peristalsis 
The characterisation of the oesophageal peristalsis was determined by a set of 
measurements taken on HRM as described in table 3.3. The median percentage of 
normal swallows was 87% (range 33 -100%). In 5 patients the contraction pattern was 
normal in 80-100% of swallows. The remaining 4 patients had a mixture of rapid and 
premature contractions. In four patients there was intact peristalsis in over 90% of 
swallows. The Chicago classification of the oesophageal motility in these 9 patients is 
shown below (Figure 5-２).  
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Table 5-2: HRM key results 
 Median  Range  Normal Values  
Distal Latency (DL) - s 7.1 5.8-9.0 >4.5 
Distal Contractile Integral (DCI) – 
mmHg.s.cm 
522 79-2314 <8000 
Peristaltic Breaks - cm 1.0 0.1-5.7 <2cm 
Integrated Relaxation Pressure 
(IRP4s) - mmHg 
4.9 1.5-22.3 <15 
 
Figure 5-２:  HRM oesophageal peristalsis 
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5.3.4 Reflux Data 
Reflux Questionnaires 
Ten of the eleven CF patients were taking PPI at the time of recruitment. One patient 
took Ranitidine, a histamine H2-receptor antagonist. The doses are listed below in Table 
5-3. Patients were requested to stop their acid suppression medication for 2 weeks prior 
to the oesophageal physiology investigations. Questionnaires were completed by the 
patient ‘ON’ and ‘OFF’ their medication. The median daily dose of lansoprazole was 
60mg (Range 15 – 60mg) and omeprazole was 40mg (Range 40-80mg). The total daily 
dose of PPI were compared to reflux questionnaire scores having adjusted the dosages 
for lansoprazole to omeprazole equivalents for purpose of comparison; 15mg 
lansoprazole = 20mg omeprazole, 30mg lansoprazole = 40mg omeprazole and 60mg 
lansoprazole = 80mg omeprazole [150]. 
Table 5-3: The variation of PPI dosage in study patients 
PPI or H2 Receptor Antagonist Dose Number of Patients 
lansoprazole 15mg once daily 1 
lansoprazole 30mg once daily 1 
lansoprazole 30mg twice daily 3 
omeprazole 20mg twice daily 3 
omeprazole 40mg once daily 2 
Ranitidine 300mg once daily 1 
 
The RSI questionnaires were completed by all 11 patients prior to their investigations 
and then repeated on the day of the oesophageal physiology having stopped their gastric 
acid suppression medication for 2 weeks. 8 patients (72%) had a positive RSI score 
(RSI>13).The median RSI score was 19 (Range 8 to 36). Whilst on their medication 6 
patients (55%) had a positive RSI score. The median score was 17 (range 5 to 32). The 
differences in RSI score ‘on’ and ‘off’ PPI did not reach statistical significance (p=0.34). 
Use of acid suppression did result in a reduction of the reflux symptom score, although 
over half the patients still had above normal symptom scores on medication.  Figure 
5-３i shows the RSI scores for the eleven CF patients ON and OFF their acid 
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suppression therapy. For these patients the median difference of the RSI scores on and 
off medication was -4 (range -15 to 8). Figure 5-４i shows that for the 10 patients on 
PPI acid suppression no significant relationship was demonstrated between RSI score 
and the daily dose of PPI (P = 0.287).  
The Demeester questionnaires were completed by all 11 patients prior to their 
investigations and then repeated on the day of the oesophageal physiology having 
stopped their gastric acid suppression medication for 2 weeks. The median Demeester 
questionnaire score was 3 (Range 1 to 7). Whilst on their medication the median score 
was 2 (range 1 to 8). The use of acid suppression medication makes minimal difference 
to the Demeester questionnaire score in these patients. Figure 5-３ii shows the 
Demeester questionnaire scores for the CF patients ON and OFF their medication. For 
these patients the median difference of the Demeester scores on and off medication was 
0 (range -3 to 3). Figure 5-４ii shows that for the 10 patients on PPI acid suppression no 
significant relationship was demonstrated between Demeester questionnaire score and 
the daily dose of PPI (P = 0.231).  
The GIQLI questionnaires were completed by all 11 patients prior to their investigations 
and then repeated on the day of the oesophageal physiology having stopped their gastric 
acid suppression medication for 2 weeks. Ten of the eleven patients (91%) had a score 
below the normal range (121-130). The median GIQLI score was 93 (Range 31 to 122). 
Whilst on their medication (82%) had a GIQLI score below the normal range (121-130). 
The median score was 102 (range 47 to 132). The differences in GIQLI score ‘on’ and 
‘off’ PPI did not reach statistical significance (p=0.39). Figure 5-３iii shows the GIQLI 
scores for the CF patients ON and OFF their medication. For these patients the median 
difference of the GIQLI score on and off medication was 10 (range -10 to 24). Figure 
5-４iii shows that for the 10 patients on PPI acid suppression no significant relationship 
was demonstrated between GIQLI score and the daily dose of PPI (P = 0.595).  
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Figure 5-３: Dot plots showing: i) RSI score (y-axis) for CF patients ON and OFF acid suppression 
therapy (AST) (x-axis)  ii) Demeester Score (y-axis) for CF patients ON and OFF acid suppression 
therapy (AST) (x-axis) iii) GIQLI score (y-axis) for CF patients ON and OFF acid suppression 
therapy (AST)(x-axis). 
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Figure 5-４: Scatter plots showing: i) the relationship between the daily dose of PPI (x-axis) and 
RSI score (y-axis) ii) the relationship between the daily dose of PPI (x-axis) and Demeester score (y-
axis) iii) the relationship between the daily dose of PPI (x-axis) and GIQLI score (y-axis) 
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pH – Impedance 
All eleven CF patients completed the 24 hour recordings. 9 of 11 patients (82%) 
patients had reflux determined by an abnormal Demeester score (Figure 5-５). A 
summary of the median reflux indices per 24 hours for the pH part of the study are 
shown in the table below (Table 5-4). Most refluxes were in the upright rather than 
supine position (median no of reflux periods 37 vs. 7). 
Table 5-4: Median Reflux Indices for pH part of study 
 Median Range Normal 
Values 
No. of patients 
with abnormal 
results 
Demeester Score 16.81 0.2-
45.55 
<14.72 9/11 
Acid Exposure (%). (% of time pH<4, in 24hrs) 6 0-16.5 <4.2 8/11 
Number of Reflux Periods in 24 hours 64.8 0-109.6 <50 9/11 
Number of long Refluxes /24hours (>5min) 2 0-6.4 <4 3/11 
Longest Reflux  6.9 0-55.7 <9.2 5/11 
A summary of the median reflux indices as detected by oesophageal impedance is 
shown in Table 5-5. Five patients had weakly acid reflux. Two patients had abnormal 
amounts of both acid and weakly acid reflux. Five of the eleven patients had abnormal 
proximal (Figure 5-６) oesophageal reflux (45%). Of these 5, all had evidence of distal 
reflux.  
The majority of reflux events confirmed from impedance analysis were in the upright 
rather than in the supine position (medians 50.1 vs. 8.1), but the median number of 
supine events for this group of patients is outside the normal range for a 24 hour period. 
In addition, in these 11 patients seven had an abnormal number of supine events 
compared to only 5 patients with an abnormal number of upright events. Most proximal 
reflux events were in the upright position 12.4 (0-32.2) vs. 2.2 (0-4.8). The majority of 
reflux events were mixed (liquid and gas) 44.4 (12.1-78.8) vs. 17.9 (0-47.3) for liquid 
reflux alone. There is a borderline positive correlation between the proximal reflux 
score and the number of liquid (r=0.391) and mixed reflux (r=0.573) events ( 
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Figure 5-７). The correlation is almost significant for the number of mixed events and 
the proximal reflux score (p=0.066). 
Table 5-5: Median Reflux Indices as demonstrated by Oesophageal Impedance  
 Median Range Normal Values No. of patients 
with abnormal 
results 
Oesophageal Volume Exposure (%)  0.76 0.02-
7.64 
0.4 -1.2 2/11 
Total Number of Reflux events/24hours 54.5 30.9-
96.8 
25-58 5/11 
Number of Acid Refluxes/24 hours 41.2 0-71.7 10-35 7/11 
Number Weakly Acid 
Refluxes/24hours 
17.1 0-44.1 5-18 5/11 
Bolus Clearance Time (secs) 10.0 7-17 8-13 0/11 
Proximal Reflux Events 15.8 0-32.2 4-17 5/11 
Liquid Reflux Events 17.9 0-47.3 10-32 1/11 
Mixed Reflux Events 44.4 12.1-
78.8 
11-26 9/11 
Upright Reflux Events 50.1 19.3-
96.8 
23-52 5/11 
Supine Reflux Events 8.1 0-23.4 1-6 7/11 
 
Three patients with a positive RSI score (RSI>13) had pathological proximal reflux; 
Five patients with a positive RSI had no pathological proximal reflux. 2 patient with a 
negative RSI score had abnormal proximal reflux and 1patient had a negative RSI score 
and a  proximal reflux score which fell within the normal range (<17) (Table 5-6). 
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Table 5-6: The predictive value of the RSI score 
 Proximal Reflux No proximal reflux  
RSI positive 3 5 PPV= 37.5% 
RSI negative 2 1 NPV= 33% 
 Sensitivity= 60% Specificity= 16.7%  
PPV= Positive Predictive Value, NPV=Negative Predictive Value 
No significant correlation existed between RSI and the Demeester score (P = 0.133) 
(Figure 5-８i). In addition, no significant correlation existed between RSI score and 
proximal reflux measured on oesophageal impedance (P = 0.433). (Figure 5-８ii). 
Automatic symptom analysis using the MMS software could not be performed due to 
poor compliance of patients with the symptom button and diary. Symptoms were 
studied using the questionnaires only. 
Comparison of manometry with reflux indices 
For the nine patients who were able to tolerate HRM, the findings of their manometry 
were compared to their reflux assessments. A sphincter length over 3.5cm appears to 
result in higher levels of both distal and proximal reflux but this relationship was not 
significant (P= 0.342 and P= 0.431 respectively) ( 
Figure 5-９). A larger intra-abdominal sphincter length appears to result in a lower level 
of reflux (A negative value simply implies that the LOS lies above the true pressure 
inversion point i.e.  Suggestive of a hiatus hernia and is thus NOT intra-abdominal). A 
longer intra-abdominal sphincter length was related to a lower Demeester score 
(p=0.004), but intra-abdominal sphincter length did not appear to determine proximal 
reflux extent (Figure 5-１０). Five patients had measurable hiatus hernias on HRM. 
There was no significant relationship between the LOS resting pressure and distal or 
proximal reflux (Figure 5-１１) (P = 0.932 and P = 0.308 respectively).  
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Figure 5-５: Dot plot Showing CF patient Demeester Scores (n=11) 
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Figure 5-６: Dot plot showing showing CF patient proximal Relfux scores (n=11) 
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Figure 5-７:Scatter plots showing: i) the relationship between liqid reflux events (x-axis) and 
proximal reflux (y-axis) ii) the relationship between mixed reflux events (x-axis) and Proximal 
Reflux (y-axis). 
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Figure 5-８: Scatter plots showing: i) the relationship between the RSI score (x-axis) and distal 
reflux as defined by Demeester score (y-axis) ii) the relationship between the RSI score (x-axis) and 
Proximal Reflux (y-axis). 
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Figure 5-９: i) The relationship between LOS length (x-axis) and distal reflux as indicated by 
Demeester score (y-axis); ii) the relationship between LOS length (x-axis) and proximal reflux (y-
axis) 
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Figure 5-１０: i) The relationship between intra-abdominal LOS length (x-axis) and distal reflux as 
indicated by Demeester score (y-axis); ii) the relationship between intra-abdominal LOS length (x-
axis) and proximal reflux (y-axis) 
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Figure 5-１１:i) The relationship between LOS pressure (x-axis) and distal reflux as indicated by 
Demeester score (y-axis); ii) the relationship between LOS pressure (x-axis) and proximal reflux (y-
axis) 
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5.3.5 Sputum Processing Data 
Cell Counts 
All eleven patients with CF were able to produce a sample of sputum prior to their 
oesophageal investigations and this was processed so that a differential cell count could 
be performed. Due to the quality of the sputum only ten samples were suitable for 
performing a differential cell count. 
Table 5-7:The median total cell and differential cell counts in sputum 
 CF patients Normal Values [154] 
Total Sputum cell count (cellsx10
6
/g) 23.1  
Neutrophils (%) 100 33.6  
Lymphocytes  (%) 0.6 1.25 
Macrophages (%) 0 57.8  
Eosinophils (%) 0 0.3  
The majority of cells in the sputum of CF patients were neutrophils. No additional 
staining was performed due to the low percentages of macrophages (See Table 5-7 and 
Table 5-8). 
Table 5-8: Summary of differential cell counts for CF 1-20. 
Patient 
No 
Sputum 
Vol/ml 
Cell 
Count(x10
6
/g) 
%Macrophages %Lymphocytes %Neutrophils %Eosinophils 
CF1 0.76 23.1 0 0 100 0 
CF2 0.69 123.36 0 0 100 0 
CF3 0.68 16.6 0 1 99 0 
CF4 0.49 32.52 0 0 100 0 
CF5 0.86 16.37 0 0 100 0 
CF6 0.43 2.03 0 0.6 99.4 0 
CF7 0.64 23.4 0 0 100 0 
CF8 1.22 38.79 0 0.6 99.4 0 
CF9 0.48 0.67 N/A N/A N/A N/A 
CF10 1.39 31.59 0 0 100 0 
CF11 1.6 2.29 0 0 99.6 0 
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5.3.6  Markers of aspiration 
Bile Salts 
Two sets of sputum samples were collected and processed for bile salts analysis. The 
sample taken on the days of the investigation, and a further sample taken 24hours later 
after the oesophageal investigation were complete. Sputum samples from all 11 CF 
patients were analysed using a combination of tandem mass spectrometry followed by a 
specialised extraction technique to allow the sensitivity of detecting bile salts to be 
increased to a minimum level of 0.001µmol/L. Concentrations of the individual bile 
salts (glycodeoxycholate, glycocholate, taurodeoxycholate and tauracholate) were added 
together to give the total bile salt concentration. The concentration of free lithocholate 
was also available using the extraction technique described in the previous chapter. The 
table below (Table 5-9) shows the concentration of bile salts identified in the sputum 
samples of CF. 
Of the 22 patient samples taken, twenty-one were suitable for analysis. All 21 samples 
showed detectable bile salts and 14/20 showed detectable free lithocholate (Figure 5-１
２). The highest bile salt concentration was 0.416µmol/L and the highest free 
lithocholate concentration was 0.072µmol/L. The median value for bile salts in the 21 
CF sputum samples analysed was 0.016µmol/L. The median free lithocholate 
concentration in the 21 CF sputum samples analysed was 0.027µmol/L. 
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Table 5-9: Bile salt concentration in the sputum samples of CF patients (n=11) 
 G-DHC 
µmol/l 
G-THC 
µmol/l 
T-DHC 
µmol/l 
T-THC 
µmol/l 
Total Conc. 
µmol/l  
Free 
Lithocholate 
µmol/l 
CF1 0.114 0.117 0.007 0.139 0.377 0.000 
CF1-2 0.041 0.286 0.011 0.079 0.416 0.072 
CF2 0.007 0.019 0.006 0.007 0.039 0.000 
CF2-2 0.001 0.000 0.004 0.015 0.020 0.032 
CF3 0.000 0.001 0.007 0.015 0.022 0.000 
CF3-2 0.000 0.001 0.002 0.003 0.005 0.000 
CF4 0.000 0.009 0.000 0.013 0.021 0.000 
CF4-2 0.005 0.005 0.001 0.004 0.015 0.044 
CF5 0.001 0.000 0.003 0.004 0.007 0.000 
CF5-2 0.000 0.001 0.000 0.002 0.003 0.016 
CF6 Insufficient 
Sample 
Insufficient 
Sample 
Insufficient 
Sample 
Insufficient 
Sample 
Insufficient 
Sample 
Insufficient 
Sample 
CF6-2 0.007 0.002 0.002 0.005 0.016 0.059 
CF7 0.007 0.002 0.004 0.003 0.015 0.000 
CF7-2 0.046 0.021 0.005 0.006 0.078 0.070 
CF8 0.024 0.030 0.004 0.006 0.064 0.046 
CF8-2 0.008 0.003 0.000 0.006 0.016 0.011 
CF9 0.001 0.000 0.010 0.005 0.016 0.027 
CF9-2 0.008 0.003 0.002 0.003 0.016 0.024 
CF10 0.005 0.001 0.003 0.004 0.013 0.070 
CF10-2 0.032 0.003 0.013 0.008 0.056 0.044 
CF11 0.005 0.000 0.002 0.006 0.013 0.044 
CF11-2 0.022 0.007 0.002 0.004 0.035 0.057 
KEY: G-DHC = glycodeoxycholate, G-THC = glycocholate, T-DHC = taurodeoxycholate, T-THC = 
taurocholate. ND = not detected 
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Figure 5-１２: Dot plots showing Bile salt concentration and free lithocholate concentration (y-axis) 
in the sputum samples of CF patients. 
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Pepsin 
Sputum samples from all 11 CF were analysed using an ELISA technique to detect 
pepsin. Table 5-10 shows theses pepsin values compared against reflux study results 
and lung function decline. 7/11 patient samples showed detectable pepsin . The highest 
pepsin concentration was 324ng/ml. The median pepsin concentration in the 11 CF 
patients was 88ng/ml which was higher than the median level detected in normal 
controls (7.7ng/ml) [137].  
Of the seven patients with elevated pepsin levels in the sputum 6 had high Demeester 
scores indicating significant reflux and 3 patients had proximal reflux. Five patients 
showed a decline in FEV1. Pearson’s test showed no correlation between pepsin levels 
and either Demeester and proximal reflux scores.  
Table 5-10: Pepsin Concentrations in the sputum samples of CF patients (n=11) 
Patient 
No 
Pepsin Conc 
(ng/ml) 
Demeester 
Score 
(<14.72) 
Total 
Reflux 
Time 
(<4.2%) 
Proximal 
reflux Score  
(4-17) 
%Decline 
FEV1   
CF1 0 14.84 4.10 4.9 -16.5 
CF2 152 43.65 16.50 27.4 -14.2 
CF3 88 14.95 4.70 31.7 -3.6 
CF4 0 45.55 13.50 26.5 -11.6 
CF5 0 22.24 6.00 25.2 -3.5 
CF6 324 28.95 8.4 8.9 -18.2 
CF7 196 16.18 7.5 32.2 -30.9 
CF8 112 6.81 1.6 5.1 -14.9 
CF9 0 0.2 0 0 -4.0 
CF10 80 16.81 5.7 2.3 1.2 
CF11 111 36.3 7.9 15.8 5.0 
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5.3.7 Lung Function 
Serial lung function results (3 per patient) were collected for all eleven CF patients. The 
individual FEV1 values were plotted against the time period in weeks to reveal a 
regression line with a formula in the format y=mx+c. Where y= FEV1 m= gradient of 
the plot created from serial lung function= and c= the constant .The values of t=0 and 
t=52 (1year) were re-inputted into the formulas and the percentage decline of lung 
function per year was calculated for each patient from the FEV1 values at t=0 and 1 year 
(Table 5-11). 
Table 5-11:  Summary of lung function decline as measured using FEV1 with corresponding reflux 
scores for CF 1-11. 
Patient No % Decline 
FEV1   
Demeester 
Score (norm 
<14.72) 
Proximal 
Reflux Score 
(norm 4-17) 
CF1 -16.5 14.84 4.9 
CF2 -14.2 43.65 27.4 
CF3 -3.6 14.95 31.7 
CF4 -11.6 45.55 26.5 
CF5 -3.5 22.24 25.2 
CF6 -18.2 28.95 8.9 
CF7 -30.9 16.18 32.2 
CF8 -14.9 6.81 5.1 
CF9 -4.0 0.2 0 
CF10 1.2 16.81 2.3 
CF11 5.0 36.3 15.8 
Decline of FEV1 
The median percentage decline of FEV1 per year was 11.6% with the largest decline of 
FEV1 being 30.9%. Two patients were shown to have an increase in FEV1/year with the 
largest percentage gain being 5.0%.  
There was no relationship between the percentage decline of FEV1 and Demeester score 
(Pearson correlation = 0.173, p =0.612).The degree of proximal reflux was not related 
with decline of lung function (Pearson correlation = -0.191, p=0.574). RSI score did not 
correlate with a larger percentage decline of lung function (Pearson correlation = -0.309, 
p=0.355) (Figure 5-１３). 
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Figure 5-１３: Scatter  plots showing: i) the relationship between the decline in lung function (y-
axis) and distal reflux as defined by Demeester score (x-axis) ii) the relationship between the decline 
in lung function (y-axis) and Proximal Reflux (x-axis) iii)  the relationship between the decline in 
lung function (y-axis) and RSI score (x-axis).  
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5.4 Summary of CF Results 
5.4.1 Clinical Results 
It was hard to get data in this population of 40 patients deemed to be suitable and the 26 
patients actually approached only 11 were successfully studied. Between June 2011 and 
March 2012, eleven patients with Cystic Fibrosis were studied. This included six males 
and five females who had a median age of 29 years. Baseline median lung function for 
the group was a FEV1 of 1.86 litres and a Vital Capacity (VC) of 2.15 litres.  
All 11 patients were on acid suppression therapy prior to their recruitment into the study; 
only four had documented evidence of gastro-oesophageal reflux (GOR) in their notes. 
All the patients studied were classified as having typical CF with a ∆508 mutation and 
all had pancreatic insufficiency. Five of the eleven patients had insulin dependent 
diabetes. 
Nine patients successfully completed oesophageal manometry and all eleven completed 
Impedance-pH studies. Three patients demonstrated normal oesophageal peristalsis 
High Resolution Manometry (HRM). The most common abnormality detected on HRM 
was rapid contractions. Of the eleven patients, nine had objective evidence of reflux on 
impedance-pH. Five patients had weakly acid reflux and five patients had evidence of 
abnormal proximal reflux. Most reflux events were mixed (liquid and gas). The 
incidence of reflux was not related to lower oesophageal sphincter (LOS) resting 
pressure but an increased intra-abdominal LOS length was associated with a lower 
Demeester score. 
Patient symptoms and the effect on quality of life were studied using validated 
questionnaires. All eleven patients were already on acid suppression before they entered 
the study and the questionnaires were completed ‘on’ and ‘off’ treatment for ten of the 
patients. Reflux symptom index (RSI) scores, assessing symptoms of extra-oesophageal 
reflux were abnormal (RSI > 13) in eight patients off therapy and abnormal in six 
patients whilst on their medication. Demeester questionnaire scores for patients ‘on’ and 
‘off’ were 3 and 2 respectively. Quality of life scores were assessed with the Gastro-
Intestinal Quality of Life Index (GIQLI). The median score was below the normal range 
(121-130) for patients ‘on’ and ‘off’ their treatment; whilst on acid suppression 
treatment 82% had a score below the normal range as opposed to 90% whilst off their 
treatment. Although all patients were on medical treatment to suppress gastric acid 
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production, nearly all had objective evidence of reflux and the symptom questionnaires 
indicate regular high dose acid suppression medication has very little effect. 
Lung function tests were performed on all 11 CF patients. Using the raw lung function 
data, the percentage decline of FEV1 over one year was calculated. 9/11 patients had a 
decline of FEV1 with the largest decline being 30.9%. Seven of these patients had an 
abnormal Demeester score and five patients had abnormal proximal reflux scores. The 
percentage decline of FEV1 did not correlate directly with abnormal Demeester Scores. 
Proximal reflux and RSI scores were not associated with a greater percentage decline of 
FEV1 in the low numbers of patients studied. 
5.4.2 Laboratory based studies 
All 11 CF patients had sputum samples taken and processed using a standard operating 
procedure so that a differential cell count could be performed. In addition, pepsin and 
bile salt assays were performed on the resultant supernatant. The principal cell type 
identified in the sputum was the neutrophil and the median percentages of these were 
much higher than found in normal controls (100% vs. 33.6%). 
Bile salt and pepsin analysis were performed on 22 samples taken in the 24 hour period 
the patients attended for their oesophageal tests. Of the 22 patient samples taken, 
twenty-one were suitable for analysis. All 21 samples showed detectable bile salts and 
14/20 showed detectable free lithocholate. The highest bile salt concentration was 
0.416µmol/L and the highest free lithocholate concentration was 0.072µmol/L. Elevated 
pepsin concentrations were detected in seven of the eleven CF patients with a median 
pepsin concentration of 88ng/ml, over 10 times higher than the concentrations of pepsin 
found in the sputum of healthy controls [137].  
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6 Anti-reflux surgery in lung transplant patients 
6.1 Introduction 
The previous sections of this results chapter focused on the assessment of reflux in the 
patients with idiopathic pulmonary fibrosis and cystic fibrosis. The latest data from the 
International society of heart and lung transplantation (ISHLT) suggests IPF patients 
represent 30.2% of all lung transplants performed in the adult population and CF 
patients represent 14.4% of all lung transplants performed between 2011 and 2012 [155].  
Newcastle data indicates that more CFs than this are transplanted, up to 30% [156]. 
Thus a considerable percentage of patients with IPF and CF make up the lung transplant 
population. This section comprises of work initiated by Robertson at al [36] and then 
completed by myself. The combined work and results in this section of the thesis have 
been presented in a peer-reviewed publication [97]. 
Up to 75% of lung transplant patients have demonstrable gastro-oesophageal reflux 
disease (GORD) [128-132].  In routine practice, anti-reflux surgery has been shown to 
improve symptoms and quality of life. In lung transplant recipients it is hypothesised 
that early anti-reflux surgery may also lead to protection of lung function and increased 
survival, through preventing microaspiration. Most of the current evidence of the effects 
of fundoplication in lung transplant patients originates from Duke University [132]. 
More recently in our unit work by Robertson at al [36] in a small number of patients 
demonstrated that anti-reflux surgery improves both reflux and extra-oesophageal reflux 
symptoms. 
However, there is a lack of basic information in this patient group including safety and 
assessments of quality of life. Such information is particularly important in this patient 
group who have already endured many years and months of chronic ill-health as well as 
the post-operative stresses after their transplantation.  Physiological post-operative 
complications of anti-reflux surgery include temporary dysphagia, nausea[134], 
discomfort from gas bloat and increased flatulence[129] and are common post-
fundoplication,  This puts these patients at risk of physiological dysfunction and 
reduced quality of life after surgery.  
Early data from our unit had demonstrated that fundoplication in a small group of  lung 
transplant patients had resulted in improved lung function [36] .This part of my thesis 
focuses on work which complements the study and initial findings of Robertson et al 
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[36] by assessing the safety of fundoplication in lung transplant recipients and its effects 
on quality of life and lung function. 
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6.2 Methods 
All lung transplant recipients referred to the Northern Oesophago-Gastric Unit for 
reflux assessment and consideration for anti-reflux surgery between 1
st
 June 2008 and 
31
st
 December 2010 were studied. Between June 2008 and December 2009 recruitment 
was performed by Mr. A.G.N. Robertson and continued by myself until December 2010. 
Surgery was considered for patients with symptomatic reflux alone, or for reflux 
associated with deteriorating lung function.  
Reflux status was assessed on proton pump inhibitor therapy, by oesophageal 
manometry, pH-impedance and endoscopy. Patients underwent a thorough pre-operative 
assessment to ensure fitness for surgery. Reflux status was defined by the presence of 
symptoms combined with objective evidence of GORD on pH-impedance and/or 
endoscopy. Pulmonary function tests and bronchoscopy were routinely performed in the 
preoperative work-up.  
Patients were followed up clinically with emphasis on lung function, satisfaction with 
treatment and quality of life. The validated questionnaires described in the previous 
chapter were used; the DeMeester Reflux Questionnaire, the Reflux Symptom Index 
(RSI) questionnaire and the Gastro-Intestinal quality of life index (GIQLI). These were 
completed pre-operatively, 6 weeks and 6 months post-operatively. Pre and post-
fundoplication BMI were recorded. Patient satisfaction was assessed by directly 
questioning of patients.  
Lung function was assessed in accordance with European standardised spirometry 
guidelines [157]. Bronchiolitis obliterans syndrome scores were calculated using FEV1 
in accordance with International Society for Heart and Lung Transplantation guidelines 
[127, 158].  
Surgical technique 
Laparoscopic Nissen fundoplication was performed using the same surgeon with the 
same operating technique as follows. A 4-port access technique was used with the 
epigastric incision allowing for the Nathanson retractor to retract the liver. The 
oesophageal hiatus was dissected to mobilise the oesophagus with care taken to 
preserve the posterior vagus nerve. A surgical window was created behind the 
oesophago-gastric junction to allow a loose 360
o
 wrap to be tailored. The wrap was 
secured with 3 sutures and the posterior crura were repaired to tighten the hiatus. One 
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further suture was used to anchor the wrap to the oesophagus and right crus. Local 
anaesthesia was inserted into the peritoneal cavity and infiltrated in the wounds at the 
end of the procedure [36].  
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6.3 Results 
6.3.1 Demographics 
Between the 1
st
 June 2008 and the 31
st
 December 2010, 109 lung transplants took place 
in total. 16 patients were referred to the Northern oesophagogastric unit for reflux 
assessments and consideration for anti-reflux surgery. Of the sixteen patients studied, 
ten were female and six were male with a median age of 38 years. The majority of 
patients had a background of cystic fibrosis as their condition requiring lung transplant 
(n=10). Patients with a background of fibrotic lung disease made up one-quarter of the 
lung transplant group studied (n=4). Thirteen patients had a single sequential lung 
transplant, one patient had left single lung transplant and two patients had right single 
lung transplants.  
Table 6-1: Demographics of the lung transplant group 
Demographics  
Age  Median 38years (range 24-63) 
Sex 
    -Male 
    -Female 
 
6 
10 
Underlying Pathology 
    -Cystic Fibrosis 
    -Pulmonary fibrosis 
    -COPD/Asthma 
 
10 
4 
2 
#Transplant 
    -SSLT 
    -LSLT 
    -RSLT 
 
13 
1 
2 
 
6.3.2 Oesophageal Manometry 
All 16 patients underwent traditional 8 channel manometry as described in the previous 
chapter. Overall 81.3% of patients (13/16) had normal oesophageal physiology on 
manometry. No complications were attributed to the procedure. 
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 Lower oesophageal Sphincter 
The median lower oesophageal sphincter length was 2.75cm (range 1.5-4.3cm). 
Sphincter pressure was within normal limits (6-25mmHg) in the majority of the patients 
(11/16) with an average sphincter pressure of 24.7mmHg (Range 9.3-55.36mmHg). 
Five patients had a hypertonic LOS and the remaining patients had a normotonic 
sphincter. The median of the mean distal amplitude of the swallows was 60.95mmHg 
(Range 18-165.9mmHg). 
6.3.3 pH-Impedance 
All sixteen lung transplant patients completed the 24 hour recordings whilst on PPI 
therapy. 15 of 16 patients (94%) patients had pathological distal reflux as determined by 
an abnormal Demeester score (Figure 6-１). Over half the patients had evidence of 
proximal reflux (Figure 6-２). A summary of the median reflux indices as determined 
by impedance monitoring is shown in the table below (Table 6-2).  
Table 6-2: Median Reflux Indices as determined by pH-impedance analysis 
 Median Range Normal 
Values 
No. of patients 
with abnormal 
results 
Demeester Score 52.8 7.47-
115.22 
<14.72 15/16 
Acid Exposure (%). (% of time pH<4, in 24hrs) 15.45 1.6-33.1 <4.2 14/16 
Total Reflux Events on impedance 62 10-125 25-58 9/16 
Proximal Refluxes 24 2-71 4-17 9/16 
Oesophageal Volume Exposure  1.09 0.16-
3.84 
0.4-1.2 6/16 
6.3.4 Lung function 
The rate of decline in FEV1 was calculated in standardised method [159] using serial 
FEV1 readings from the patient’s lung function tests before fundoplication up to the 
final FEV1 readings available after fundoplication. First of all the FEV1 values were 
plotted from the baseline FEV1 level to the time fundoplication was performed and the 
gradient between points was calculated in millilitres per month. The same was done for 
the FEV1 measurements after fundoplication.  
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6.3.5 Other Assessments 
All patients had a diagnostic gastroscopy (OGD). 15/16 patients had a hiatus hernia on 
OGD (2-6cm). 8/16 had oesophagitis (grade A n=4), (grade B n=3), (grade C n=1). 
Grade C is the most severe erosive oesophagitis. One patient had a small tongue of 
Barrett’s oesophagus confirmed on histological assessment. Three patients had 
oesophageal candidiasis which was treated pre-operatively.
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Figure 6-１: Dot plot Showing lung transplant patient Demeester Scores (n=16) 
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Figure 6-２: Dot plot Showing lung transplant patient proximal reflux scores (n=16) 
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6.3.6 Reflux Questionnaires 
There was a statistically significant improvement in symptoms and quality of life scores 
over the first six months post-fundoplication. Questionnaires were completed by 15/16 
patients. One patient, despite reporting high levels of satisfaction with their result, did 
not wish to spend time completing these questionnaires. 
Table 6-3: Median quality of life questionnaire scores before and after anti-reflux surgery 
 Pre-operative Six weeks Six months 
GIQLI 106 (65-132) 118 (63-133) 128 (75-142) 
DeMeester 4 (1-6) 1 (0-4) 1 (0-2) 
RSI 15 (8-23) 3.5 (2-18) 2 (0-18) 
 
Reflux Symptom Index questionnaire 
Pre-fundoplication RSI was positive on 8/15 patients and this decreased to 3/15 being 
positive for RSI by six weeks and 2/15 being positive at six months. The median RSI 
underwent a statistically significant improvement from 14 (range 1-23) pre-operatively 
to 4 (range 0-25) at six weeks post-fundoplication (p=0.01) and 2 (range 0-20) at six 
months (p=0.0005) (Figure 6-３i).  
DeMeester reflux questionnaire score 
There was a statistically significant improvement in median DeMeester reflux 
questionnaire score from 4 (range 1-6) pre-operatively to 1 (range 0-5) at six weeks 
(p=0.007) and 1 (range 0-3) at six months (p=0.001) (Figure 6-３ii).  
GIQLI 
There was an improvement in median GIQLI score from 106 (range 54-132) pre-
operatively to 116 (range 61-133) at six weeks (p=0.06). This was a statistically 
significant improvement by six months 127 (range 75-142) (p=0.004) (Figure 6-３iii). 
There was a statistically significant improvement from six weeks to six months (p=0.03). 
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Figure 6-３:Individual Dot plots showing: i) the change in RSI score (y-axis) 6 months after 
fundoplication ii) the change in Demeester questionnaire score (y-axis) 6 months after 
fundoplication iii) the change in GIQLI score (y-axis) 6 months after fundoplication 
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6.3.7 Body mass index 
Median BMI significantly decreased from 23.4 (range 18.5-33.2) pre-fundoplication to 
21.6 (range 17.6-32.9) at six months post-fundoplication (p<0.001) (Figure 6-４).  
6.3.8 Lung function 
Patients were followed up for a median of 502 days post-fundoplication (range 177-
923days). Median FEV1 was similar pre-fundoplication 2.05L (range 0.74-5.12L) and 
post-fundoplication 2.13L (range 0.73-5.21L) (p=0.09). Eight patients were operated on 
for deteriorating lung function. Of these eight, one patient had a reversal of BOS, two 
had a stabilisation of lung function and five had a decrease in the rate of deterioration. 
There was a statistically significant decrease in the rate of decline of FEV1 per day post 
fundoplication from a median change of -132.3ml/month (range -4.5 to -242.4ml/month) 
pre-fundoplication to a median change post fundoplication of +6.9ml/month (range -
22.5 to +117ml/month) post-fundoplication (p=0.008) (Figure 6-５).  
6.3.9 Operation parameters and patient satisfaction 
Fundoplication was performed at a median of 405 days post transplant (range 178-3235 
days). Median intra-operative time was 90minutes (range 60-125minutes). All patients 
had blood loss of less than 100ml. 5/16 patients were admitted electively to our High 
Dependency Unit for observation for 24 hours but none of the patients required an ITU 
stay. Median hospital stay was 2 days (range 2-4 days). Longer stays were due to post-
operative pain, peri-operative dysphagia (n=1), a return to theatre or difficulty arranging 
transport home.  
Morbidity and mortality  
There were no deaths or serious post-operative complications. Two patients developed 
post-operative dysphagia. One of these patients returned to theatre the following day 
and underwent a laparoscopy and minor revision of the wrap and subsequently made an 
uneventful recovery. In the other patient, barium swallow revealed no significant hold-
up and symptoms subsequently resolved spontaneously.  
Overall satisfaction with fundoplication 
Overall 15/16 patients reported being satisfied at 6 months follow-up. 
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 Figure 6-４: Individual dot plot showing the change in BMI (y-axis) after fundoplication 
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Figure 6-５: Individual dot plot showing the rate of change of FEV1 (y-axis) after fundoplication 
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6.4 Summary of lung transplant patient Results  
6.4.1 Reflux Findings 
Between the 1
st
 June 2008 and the 31
st
 December 2010, 16 lung transplant patients were 
assessed at the Northern oesophagogastric. Of the sixteen patients studied, ten were 
female and six were male with a median age of 38 years. 15/16 patients had evidence of 
reflux with an abnormal Demeester score and 9/16 had significant proximal reflux. 
Most patients (13/16) had normal oesophageal physiology when assessed with 8-
channel manometry. The significant incidence of reflux was confirmed on endoscopy 
with half the patients having visible signs of inflammation. 
6.4.2 Operative Outcomes 
All patients successfully underwent laparoscopic fundoplication with no permanent 
morbidity or mortality. 15/16 patients expressed their satisfaction with the operation 
when directly questioned. Reflux questionnaire assessments showed significant 
improvement of RSI, Demeester questionnaire and GIQLI scores after the operation. 
This improvement was seen as early as 6 weeks post fundoplication. In addition, the 
rate of decline of FEV1 was significantly reduced after fundoplication. 
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7 Discussion 
 
7.1 Idiopathic Pulmonary Fibrosis patients 
7.1.1  Recruitment to study 
Between July 2010 and March 2012 38 patients diagnosed with idiopathic Pulmonary 
Fibrosis (IPF) were approached to enter the study. Twenty nine patients initially 
consented to the study but in total nine patients dropped out.   In total, 20 patients were 
actually investigated. Despite this relatively high dropout rate, recruitment was 
considered to have been very successful. This provided experience of recruiting this 
specialised group of patients to a comprehensive “aerodigestive” investigation. To our 
knowledge this was the first such systematic study. I feel that the results of this study 
are timely, coinciding with increasing international calls for  research into  IPF in 
general and the potential role of aspiration in particular [90].  
The median age of our IPF group was 69 years, however, three patients who dropped 
out were in their eighth and ninth decades of life and although they had initially 
consented to the study in the discussion with the clinician, their relatives had influenced 
their drop out after the review of the information leaflet. Many relatives believed the 
investigations may have been too exhausting for their elderly family members.  
Although these patients were clinically suitable, the views of the relatives were taken 
very seriously and the patients left the study. This clearly indicates the nature of IPF as 
a disease principally affecting patients in the later decades of life has an influence on 
their ability to participate in the research.  
Idiopathic pulmonary fibrosis may be complicated by serious acute exacerbation 
resulting in acute hospital admission. One patient who had consented was admitted one 
week before their research appointment and subsequently died. Only two patients failed 
to attend their appointment after confirmation. This may be accounted by the fact that 
the disease is idiopathic and those suffering from it are keen to identify a cause. The 
majority of the patient group were just into their retirement and prior to the diagnosis 
had been quite well. The low ‘did not attend (DNA)’ rate indicates the desire for 
patients to return to their original level of fitness and thus their willingness to be 
recruited into the research. 
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7.1.2 Reflux in IPF – Clinical Findings 
Twenty patients attended and completed the oesophageal physiology tests, which 
included oesophageal manometry and pH impedance.  Only four patients had previously 
documented evidence of gastro-oesophageal reflux disease (GORD), but fifteen were on 
proton pump inhibitor (PPI) treatment at the start of the study. This was considerably 
more than the number of patients on steroid treatment which is often an indication to 
have PPI therapy for gastric lining protection (n=5). This implies many patients were on 
empirical PPI therapy without clear evidence of reflux. 
Our results showed 12 patients had evidence of reflux and in six there was evidence of 
proximal reflux. As early as the 1970s, reflux had been demonstrated in patients with 
IPF [73] with more recent studies demonstrating over 80% of patients having evidence 
of reflux [71]. Our study demonstrated slightly lower percentage of IPF patients with 
reflux (60%) but using pH impedance identified both acid and weakly acid reflux in 
patients with IPF. This is consistent with the findings of Salvarino et al, [160] who 
showed that 83% of IPF patients had abnormal distal acid exposure compared to 43% of 
non-IPF subjects but more importantly showed both acidic and weakly acidic reflux 
episodes were higher in IPF . This illustrates the value of impedance-pH monitoring.  In 
their study they observed a high frequency of both acid and non-acid reflux in the IPF 
group compared to non-IPF patients.  
In our study, 9 patients had some degree of oesophageal dysmotility identified either by 
traditional 8-channel manometry (n= 4) or high resolution manometry (HRM) (n=5). In 
almost all the patient (n=16) lower oesophageal sphincter pressure (LOS) resting 
pressure was within the normal range. However, HRM detected a hiatus hernia in 67% 
of IPF patients. These findings are consistent with other recent studies [160] comparing 
manometric studies in IPF patients and healthy volunteers.  In their study 55% of IPF 
patients had hiatus hernia detected on manometry compared to only 14% in healthy 
volunteers.   
Our study also used the HRCT images to identify hiatus hernias in the IPF patients. The 
presence of hiatus hernia is well known to be associated with increased reflux by 
affecting the integrity of the LOS [24]. For this reason we used a radiologist specialising 
in gastrointestinal imaging to review the HRCT images. In 78% of our IPF group, hiatus 
hernias were identified on their CT images. Over half of these patients had objective 
evidence of reflux on Impedance-pH.  Noth et al [161] identified 39% of IPF patients in 
their study had hiatus hernias on CT scans. Although modern CT has been recognised as 
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a method of diagnosing hiatus hernias barium swallows have been the standard method 
of determining the presence of hiatus hernias with clear identification of the LOS and its 
relationship to the diaphragmatic crus. As a result the high percentage of hiatus hernias 
diagnosed in our study must be interpreted with caution. In addition, the interpretation 
of a hiatus hernia on CT scans between radiologists varies considerably; the use of 
single radiologist reviewing our scans limits the interpretation of these results. A 
recommendation for further study out with my thesis would be the comparison of 
HRCT and barium swallows for assessing hiatus hernia in this patient group. 
Lee et al [19] retrospectively studied 204 patients with IPF of which 45% had a history 
of reflux and 34% reported symptoms of reflux. Of these 47% were taking anti-reflux 
medications. Using regression modelling they concluded that use of gastro-oesophageal 
reflux medication was associated with longer survival. In our study, only 4/20 patients 
had an established diagnosis of gastro-oesophageal reflux disease but 15/20 were 
already on PPI medication. Although oesophageal physiology was performed off-PPI 
medication, RSI scores for those patients when taking PPI were shown to be abnormal 
in 60% indicating extra-oesophageal reflux symptoms persisted despite use of PPI 
medication. In addition, Demeester questionnaire scores assessing classical reflux 
symptoms remained unchanged in PPI users once off their medication. To my 
knowledge this is the first study to prospectively evaluate reflux symptoms on and off 
PPI in this patient group. Although some studies suggest a survival benefit in long term 
PPI use in IPF patients [19], it is clear from work on lung transplant patients that PPIs 
may not reduce volume reflux and surgical treatment maybe more valuable [95]. 
There was no significant change in symptom scores with increasing dose of PPI. 
However, when PPI use is compared to the rate of decline of the vital capacity (VC), 
there is a positive correlation between the daily dose of PPI and the rate of decline of 
VC which reached statistical significance (p=0.003). The findings of my study suggest 
that a proportion of patients may not benefit from taking a PPI as the reflux they have is 
weakly acid or non-acid reflux. However, in our study some patients had acid reflux and 
PPI use may help these patients and control symptoms which in turn reduces the 
deterioration of lung function, particularly the vital capacity and as Lee et al [19] 
suggest contribute to long term survival. Finally quality of life scores for PPI users with 
IPF were only slightly higher than those not taking any anti-reflux medication, but more 
importantly 85% of PPI users had GIQLI scores below the normal range, questioning 
the overall efficacy of medically managed reflux disease in IPF patients. 
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In our study we also used a validated scoring system to identify laryngopharngeal reflux. 
Belafsky et al [56] validated the reflux finding score (RFS) by demonstrating excellent 
inter and intra observer reproducibility when assessing the effectiveness of PPI therapy 
in 40 patients clinically proven reflux. The score is an 8-item clinical severity scale 
based on findings from fibre optic inspection of the larynx. Scores range from 0 to 26, 
with an abnormal score being above 7. 
Nine out of the twenty IPF patients had an RFS score of 7 or above.  There was no 
relationship between objective reflux scores diagnosed on impedance and RFS scores. 
Unlike the above authors’ study, anti-reflux medication does not appear to have any 
relationship to the scores. However, all patients with an abnormal RSI score (>13) had a 
RFS score of 7 or above. Although the correlations between the two scores did not 
reach significance, this could simply be a reflection of the small sample sizes in this 
study; the findings of elevated RSI scores corresponding to possible changes at the level 
of the laryngopharynx may be evidence of refluxate irritating the upper airways raising 
the suspicion of microaspiration in these patients. 
7.1.3 Reflux in IPF – Cellular Findings 
Differential Cell Counts 
The clinical application of differential cell counts in BAL is widely accepted and 
recommended in the clinical guidelines [6] as a diagnostic tool for IPF in specialist 
centres. More recently the American Thoracic Society (ATS) produced guidelines for 
the inclusion of BAL in clinical practice [162]. The use of BAL differential cell counts 
alone cannot be used to make a diagnosis of IPF but knowledge of the cellular 
composition together with radiological and clinical information can help in the 
diagnosis and differentiating between the ILD subtypes. Meyer et al [162] suggest that a 
diagnosis of IPF can be associated with a BAL neutrophil count of >3%. From our 
patients (Table 4-8), the median neutrophil count is 7.5%, supporting the diagnosis of 
IPF as described in the guidelines. More specifically, the guidelines suggest when 
compared to differential counts in normal individuals, IPF is characterised by elevated 
alveolar macrophages, elevated neutrophils and possibly elevated eosinophils with a 
lack of prominent lymphocytosis or eosinophilia. The results of our BAL cell counts 
when compared to the normals [151] appears to support this description of an IPF 
diagnosis. However, when individual IPF patient BAL cell counts are reviewed, four 
individuals had a lymphocytosis (>15% lymphocyte) count. This may suggest a 
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different diagnosis including sarcoidosis. One individual demonstrated a 
lymphocytosis > 50% in combination with neutrophilia > 3% which maybe more 
consistent with acute hypersensitivity pneumonitis [162].  As the authors suggest, BAL 
cell counts alone cannot easily differentiate between the various subtypes of ILD and 
clinical and radiological correlation must be used. The majority of the cells within the 
lavage sample were macrophages, consistent with the findings in normal individuals. 
IPF patients did have a slightly higher percentage of neutrophils. Elevated neutrophil 
counts are most often associated with acute inflammation, but none of the IPF patients 
were on treatment for chest infections at the time of bronchoscopy. In our study the 
median age was 69 years and consisted of 12 individuals who were ex-smokers and two 
who were smoking at the time of the study. Elderly patients and asymptomatic smokers 
can have a higher percentage of neutrophils in the BAL [163] and may be another factor 
that accounts for the neutrophil distribution in the study group. 
In the guidelines Meyer at al [162] describes the recommended BAL procedure. They 
suggest that the volume of normal saline instilled should be between 100 and 300ml, 
divided into three to five aliquots. Optimal sampling should retrieve over 30%. We used 
3 x 60ml normal saline lavages and the median retrieval was 50% in our study. As 
recommended in the guidelines prompt processing of BAL provides optimal results and 
all of the study samples were processed within 30 minutes of the BAL. Although the 
methodology used in my study for the collection and processing of the BAL strongly 
adheres to the recommendations of the guidelines, we collected the lavage from the 
standard sites, the right middle lobe or lingual. Meyer et al [162] suggest using the 
HRCT to find a target site for the BAL as this is more likely to yield a diagnostic 
specimen and hence suggest BAL should be completed within 6 weeks of the HRCT. 
The use of the traditional site of BAL in my study may account for some of the cellular 
variations seen between individual patient samples. 
Oil Red O – Lipid Laden Macrophages 
Several studies have suggested the use of Oil Red O staining in BAL to identify 
exogenous lipid as a possible surrogate marker for GORD [146]. In their study of 34 
lung transplant patients, Hopkins et al performed 24-hour pH studies to diagnose GORD 
and used Oil red O staining of the macrophages to calculate the lipid index given as the 
lipid laden macrophage score.  They used a lipid index of >150 as being significant for 
reflux and showed 83.3% sensitivity and 76.4% specificity when compared to 24-pH 
study results.  Hayes et al [164] also demonstrate a relationship between clinically 
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occult reflux disease and lipid laden macrophage score. In their retrospective review of 
17 patients with cystic fibrosis they showed that surgical management of reflux resulted 
in reduction of the lipid index, supporting the evidence of Hopkins et al [146] that lipid 
laden macrophage score is a useful adjunct in assessing reflux disease.  
In our study, only 5 patients had a lipid laden macrophage score outside the upper limit 
seen in normal controls; only one individual having a score over 150.  Two patients 
with elevated scores did not have reflux on pH-impedance. There was no correlation 
between lipid-laden macrophage scores and proximal or distal reflux. Kitz et al [165], in 
their retrospective analysis of 448 children support this finding and showed no 
correlation between lipid laden macrophage scores and pH monitoring.  Contrary to the 
finding of Hayes et al [164], Rosen at al [166] assessed 50 children in which 
fundoplication had been performed in thirteen. They hypothesised that with treatment 
reflux should decrease and the lipid laden macrophage score should also decrease. 
However, after fundoplication, those patients without a symptomatic improvement had 
an increase in the lipid laden macrophage score, suggesting that lipid laden 
macrophages may be a marker of lung inflammation rather than specifically reflux 
related disease. It is clear that the lipid laden macrophage score cannot be used as a gold 
standard to assess reflux related aspiration. Not only do studies suggest variable 
findings, but lipid deposits in macrophages can be of endogenous origin as suggested in 
studies on patients with pneumonia [167] and may not be an accurate discriminator of 
aspiration in patients with reflux disease. 
Prussian Blue – Haemosiderin Laden Macrophages 
Oxidative stress and the effect this has on lung tissue has been investigated by Reid et al 
[148] in lung transplant patients. They suggested that the generation of free radicals and 
reactive oxygen species (ROS) by activated neutrophils contributes to the inflammatory 
process which may ultimately result in bronchiolitis obliterans syndrome (BOS). It is 
believed that the generation of free radicals and ROS originates from the release of ‘free 
iron’ from ferritin under inflammatory conditions. Alveolar macrophages (AM) attempt 
to protect against this iron-catalysed oxidative stress by scavenging the iron and 
sequestering it has an inert form called hemosiderin [148]. Therefore, the detection of 
hemosiderin laden macrophages can be used as a marker of oxidative stress and possible 
inflammation. In their study they showed the BAL cells from the lung transplant 
subjects and BOS subjects had a significantly higher hemosiderin score compared to 
normal subjects. In our study we found that IPF patients had a very high percentage of 
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hemosiderin stained macrophages and a hemosiderin score 15 times higher than the 
upper limit seen in normal individuals. However, the findings of elevated hemosiderin 
scores in IPF did not correlate to either distal or proximal reflux. This suggests as with 
lung transplant patients, IPF patients are subject to an inflammatory insult leading to the 
disruption of iron homeostasis and oxidative stress. Kim et al [168] suggested that 
increased alveolar septal capilleries and hemosiderin deposition may be useful predictor 
of pulmonary hypertension in IPF patients. They evaluated a cohort of 154 IPF cases, of 
which hemosiderin scores were calculated in 149 cases. They demonstrated that 
increased iron deposition was associated with elevated right ventricular systolic 
pressure, an early indicator of pulmonary hypertension. The mechanism of this is 
secondary to the remodelling of post-capillary pulmonary vessels in non-fibrotic areas 
of explanted lungs from IPF patients. They showed that hemosiderin scores provided a 
better predictor to the degree of pulmonary hypertension in IPF than either HRCT or 
lung function assessment. Important to note, the hemosiderin scoring system used by 
the authors is a variation of the standard scoring system described by Kahn et al and 
used by Reid et al [148] as well as in our study. Therefore, it limits the ability to directly 
compare with other studies and questions whether hemosiderin scores can accurately 
predict the degree of pulmonary hypertension. Puxeddu et al [149] studied 47 IPF 
patients against 14healthy controls.  They demonstrated higher levels of haemosiderin 
laden macrophages in the IPF patients with no significant differences between smokers 
and non-smokers. Previous theories had indicated high levels of iron-laden 
macrophages were assocaiated with tobacco smoke as a reaction to oxidative stress. 
Puxeddu et al [149]suggest high numbers of haemosiderin laden macrophages in the 
IPF group is indicative of occult alveolar haemorrhage secondary to pulmonary veno-
occlusive disease.  Elevated haemosiderin scores in IPF form an important tool in the 
diagnosis and management of the disease suggesting further discussion on the use N-
acetylcysteine (NAC), a tripeptide that scavenges oxygen free-radicals. The most recent 
ATS guidelines [6] only give a weak recommendation for NAC monotherapy in IPF but 
some studies have demonstrated both radiological and symptomatic improvements in 
IPF using aerosolised NAC which acts directly on the alveoli as an anti-oxidant.  
It is clear that the staining of cells to identify lipid laden macrophages and hemosiderin 
deposits can provide useful information in IPF patients as well as patients with other 
lung diseases. Many of the studies were based on a paediatric population, where the 
mechanisms of reflux as well as the extent of lung pathologies varies considerably to 
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the adult population, particularly the elderly patients as seen with IPF. Both types of 
stain may be more useful in the assessment of the lung disease rather than specifically 
being used to identify reflux disease. 
Bile Salts and Pepsin 
There are a limited number of studies attempting to identify the relationship between 
reflux and aspiration and many of these have focused on lung transplant patients. 
Elevated bile salts have been identified in patients post lung transplant [93], with up to 
43% having elevated bile salt levels 3 months after surgery. In addition to bile, pepsin 
has also been identified as a biomarker of gastric aspiration with elevated levels being 
identified in lung transplant recipients compared to normal controls [106]. Very few 
studies have clearly identified whether these markers of aspiration account for the 
pathophysiological changes seen in IPF. Lee et al [112] have compared pepsin levels in 
a case control study using 24 cases with acute exacerbation of IPF and 30 controls with 
stable IPF. They showed that the median level of BAL pepsin in the acute exacerbation 
group was higher than in the stable controls, (46.8ng/ml vs. 35.4ng/ml). Although the 
difference did not reach statistical significance the authors do conclude that elevated 
BAL pepsin is predictive of acute exacerbation of IPF, basing this on a subgroup of 8 
patients with very high pepsin levels (>70ng/ml). Secondly the authors showed in 7 
patients with an acute exacerbation, previous pepsin levels from lavages taken when 
these patients were diagnosed with IPF were no different in 6 out of the seven patients 
questioning the validity of the conclusion the authors have drawn. More importantly this 
study does not have any objective reflux assessment and this is a key component in 
ascertaining the possibility of gastric aspiration.  In my study BAL was not performed 
in patients with acute exacerbations. All of the study patients were clinically stable at 
the time of investigation. Many of the early studies assessing reflux and IPF used pH 
studies to assess reflux but very few also analysed BAL for biomarkers of aspiration.  
My study combined impedance-pH assessment of reflux with assessment of bile salts 
and pepsin in lavage samples. I demonstrated that more than half of the IPF patients had 
elevated pepsin levels in the lavage compared to normal controls; impedance-pH 
confirmed that eight patients of the eleven had reflux (5 distal reflux only, 2 both distal 
and proximal reflux, 1 proximal only). There was no correlation between reflux scores 
and pepsin when analysed for the whole group but a suggestion within the subgroup of 
eleven there appears to be a relationship between pepsin levels and reflux. Correlation 
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statistics on such small numbers of patients must be interpreted with caution and further 
work is indicated. 
Several studies more recently have also confirmed the presence of pepsin in the BAL of 
IPF patients. Savarino et al [160] comment that in a study of 40 consecutive IPF 
patients with IPF had a higher amount of pepsin than non-IPF patients (p>0.03). 
However, it is important to say that only 21 IPF patients had bronchoscopy and lavage 
not the forty described in the abstract. In addition, the authors have not used a 
standardised lavage; they used ‘at least 100ml of sterile saline’ which certainly alters 
the accuracy that these results can be interpreted with. I used a standardised lavage on 
all 20 patients which was 3x60ml sterile saline. The detection of pepsin is more 
accurately performed using an ELISA and this certainly supersedes the accuracy of 
commercially available kits e.g. Peptest
TM 
(lower limit of detection 16ng/ml), as used by 
Savarino et al. Interestingly, Fahim et al [75] only identified pepsin in 2/17 patients 
with IPF. Their study used an exhaled breath condensate and then a Peptest
TM
. Not only 
could the Peptest
TM
 affect the lower limit of detection but an exhaled breath condenser 
to detect pepsin relies on the sample being taken in conjunction with a reflux event 
which with single sample testing increases the chance of missing most events and 
questions the reliability of the authors result particularly with regard to pepsin 
measurement. In my study, using standardised lavages and an ELISA to identify pepsin 
indicates IPF patients have detectable pepsin levels within the lavage which may be 
affecting lung function. However, my results should also be interpreted with caution. 
Although our ELISA test produced accurate standard plot where R
2
= 0.981, further 
patients are required with repeated ELISA tests on the samples to support our initial 
findings. 
Using the technique of tandem mass spectometry the lower limit of detection of bile 
salts in 0.01µmol/L[102]. An extraction technique further increased the lower limit of 
detection to 0.001µmol/L. 17/20 of my study IPF patients had detectable, very low 
levels of bile salts.These levels are so close to the lowest level of detection, they can be 
regarded as negligible amounts. There was no relationship between bile salt 
concentrations in the BAL and reflux (both proximal and distal scores). In addition, bile 
salt concentration in BAL had no relationship to the decline of lung function. Very few 
studies have attempted to isolate bile salts in IPF patients to determine if it is a marker 
of microaspiration. Savarino et al [160] showed that 13/21 patients with IPF had bile 
salts in the BAL compared to no patients in the non-IPF group. The authors used a 
199 
 
commercial assay called Bioquant for the detection of bile acids, quoting the lowest 
level of detection as 0.2µmol/L. We evaluated the kit used by Savarino et al, while 
setting up our study design. The manufacturer of this kit actually claims a lower level of 
detection of 1.0 μmol/L. The results from our group and others indicate that outcomes 
of lower than 5 μmol/L may not be reliable [102]. This is in contrast to the latest work 
by Savarino et al which state sensitivities of 0.2umol/L [160]. 
In contrast my study using a sensitive analytical chemistry approach documented bile 
acid levels at orders of magnitude lower than the study by Savarino et al. These levels 
were not different to levels found in normal BAL [169] . Overall I would conclude that 
levels of bile acids were not raised in my series of patients and that appropriately 
sensitive methods are required for BAL analysis of bile aspiration rather than kits 
designed for reporting circulating levels of bile salts in pathology. 
Only two of the IPF patients had bile salt levels above the upper limit of normal. Only 
eight patients with reflux had bile salt levels above the median value seen in normal. we 
used a very accurate method of detecting bile salts the levels seen in our subjects and 
the relationship with refux indicate: 
1. Bile reflux (duodenogastric reflux) is not significant in IPF 
2. BAL measurement may not be the optimal method for this. My results 
demonstrated elevated haemosiderin scores which together with elevated protein 
in IPF BAL may mean that solute measurements are difficult to interpret due to 
loss of lung barrier function. 
3. Elevated pepsin levels may be important in IPF indicating gastro-oesophageal 
reflux. 
In summary my results illustrate that objective pH-impedance measurements can be 
performed safely and identify patients with both acid and non-acid reflux. 
Bronchoalveolar lavage was well tolerated in all our patients allowing cellular profile 
and stains to be performed as well labarotory analysis of markers of aspiration. Staining 
cells with both Oil Red O and Prussian blue may be a useful adjunct is assessing the 
inflammatory process taking place in IPF. Accuarate and standardised measurements of 
pepsin and bile salts are required to confirm the use of these markers in assessing 
microaspiration as a pathological process in IPF. 
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7.2 Cystic Fibrosis patients 
7.2.1 Recruitment to Study 
Between June 2011 and March 2012 40 patients diagnosed with Cystic Fibrosis (CF) 
were approached to enter the study. Initially 26 patients consented to participate in the 
research but less than half of this number actually attended (n=11). Of the eleven 
patients, two were recruited as inpatients from the CF ward. One patient who had 
consented in clinic became extremely anxious in the clinical setting of the lab and chose 
to withdraw from the study. Two patients withdrew their consent at the time of phoning 
to confirm their appointment. The other dropouts consisted mainly of patients failing to 
attend. The median age of the group was 29 years and all had the ΔF508 mutation.  
There are several reasons why the drop-out rate was high compared to the IPF group. 
This is a much younger population, many of whom were in work or higher education. 
With regular clinic appointments and attendance for lung function tests, many may not 
have the time for further attendance to hospital for research purposes. Cystic fibrosis 
centres are often conducting research and clinical trials and this relies on patients 
consenting to several studies at a time; thus precluding further participation in research. 
Having reviewed several patient forums it is apparent that many young patients with CF 
feel institutionalised, spending a significant proportion of their adolescent lives in 
hospital. This may have an impact of recruitment to research taking place within the 
hospital.  
Four patients rescheduled after their first appointment was given and then a further two 
patients rescheduled their second appointment. In all the cases it was secondary to chest 
infection requiring intravenous antibiotics either within the community or as an 
inpatient. It was therefore in the best interest of the patient to perform the research tests 
after their treatment was completed. 
7.2.2 Reflux in CF – Clinical Findings 
In total eleven patients attended the oesophageal physiology tests, nine patients 
completed oesophageal manometry and pH impedance, two were unable to tolerate the 
manometry and had impedance-pH studies only. Only four patients had previously 
documented evidence of GORD, but all eleven patients were on gastric acid suppression 
medication (10 on PPI, 1 on Ranitidine) at the start of the study. However, nearly all 
patients with CF have exocrine pancreatic insufficiency that requires pancreas enzyme 
replacement therapy. Therefore, the routine use of gastric acid suppression medication 
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was used to increase fat absorption despite the use of pancreas enzyme replacement 
[170]. 
Our results showed 9 patients had evidence of reflux and in five there was evidence of 
proximal reflux. Five patients had weakly acid reflux and in two there was significant 
volume reflux. This shows that reflux is far more prevalent that initially thought 
amongst patients attending a dedicated CF unit. Early studies demonstrated a high 
incidence of reflux in CF patients. Faithi et al [80] studied 30 adult CF patients. 
Eighteen were considered to have reflux. These patients were not all objectively studied 
and the information was based on a reflux questionnaire validated by the same unit. In 
fact only five patients were studied using 24-hour pH monitoring; four had a high 
Demeester score indicating reflux. This study uses a very small number of patients to 
objectively assess reflux. Ledson et al [100] used a similar number of patients as our 
study (n=11) and demonstrated 8/11 had reflux. Both these studies relied on pH 
monitoring only rather than pH-impedance and whilst our patients (10/11) stopped their 
acid suppression medication for 2 weeks, Ledson et al [100] only stopped the 
medication for 48 hours prior to the test. Blondeau et al [81] studied 33 patients with CF 
using pH-impedance as in our study and also demonstrated that the majority of patients 
had acid reflux (67%), slightly lower than in our study. They demonstrated both weakly 
acid reflux and proximal reflux in their study but the number of patients affected was 
slightly lower than our study (15% vs. 45% and 36% vs. 45% respectively). It is clear 
from both our study and the literature that reflux is common in CF. The reflux is mainly 
acid reflux but there is weakly acid reflux in a large proportion of patients and it is 
likely that refluxate is actually a mixture of acid and weakly acid content. Several 
studies have demonstrated elevated gastric acid secretion associated with the ΔF508 
mutation [171]. Other studies have suggested that the absence of CFTR-mediated 
bicarbonate secretion in the duodenum together with the CFTR protein on parietal cells 
causing gastric acid secretion via CFTR-modulated cAMP-dependent pathway in which 
K
+
 is exchanged for H
+
, leads to a drop in the pH, possibly contributing the incidence of 
acid reflux in CF [172]. 
All 9/11 patients had high resolution manometry (HRM) performed to ascertain the 
degree of oesophageal function. Only three patients had normal oesophageal motility as 
described in the Chicago classification for HRM. The majority of patients with 
abnormal oesophageal motility were categorised as having ‘rapid contractions with 
normal latency’, very similar in appearance to a simultaneous swallow. Five patients out 
202 
 
of the six with abnormal oesophageal motility had reflux, including 3 patients with 
proximal reflux. Two patients with normal oesophageal motility had reflux. Over half 
the patients (5/9) had a hiatus hernia detected on manometry. It is well understood that 
both significant oesophageal dysmotility and hiatus hernia can predispose to reflux [24].  
The two factors affecting the pathophysiology of reflux are the loss of the anti-reflux 
mechanism and diminished oesophageal clearance. An excess of transitory LOS 
relaxations (TLOSR) and a hypotonic LOS lead to loss of the anti-reflux mechanism. 
Development of a hiatus hernia with this exacerbates any reflux symptoms [173]. There 
are very few studies that describe the incidence of oesophageal dysmotility in CF, but it 
is a well known phenomenon in patients with chronic respiratory disease predisposing 
to poor oesophageal clearance and increased reflux symptoms[174]. As well as the 
functional integrity of the oesophagus contributing to reflux it is useful to remember 
that most of our CF patients had diabetes which either by causing autonomic neuropathy 
or smooth muscle dysfunction leads to an increase prevalence of oesophageal 
dysmotility.  
Sabati et al [175] prospectively studied 201 patients with CF using two validated 
questionnaires; the Mayo GER questionnaire (GERQ) to assess the prevalence and 
severity of reflux symptoms. The GERQ revealed 53% of patients suffered heartburn 
and 33% suffered acid regurgitation. Patients on acid suppression medication in fact had 
more symptoms than those not taking acid suppression tablets. We used three validated 
questionnaires to assess reflux in CF patients. The RSI score for extra-oesophageal 
reflux symptoms was abnormal in 72% of our patients and despite acid suppression, 
55% still had an abnormal RSI scores on PPIs. Typical reflux symptoms assessed using 
the Demeester questionnaire did not appear to be significantly affected by acid 
suppression treatment. The GIQLI assessment is abnormal in our CF patients both with 
and without treatment with use of medication resulting in only a small increase in the 
score. There was no significant change in symptom scores with increasing dose of PPI. 
The daily dose of PPI was not related to the rate of decline of lung function (FEV1). My 
results suggest that a proportion of patients may not benefit from PPI use and this may 
be due to the presence of weakly acid or non-acid reflux. However, in those patients 
who had acid reflux, PPI use may help control symptoms. Finally quality of life scores 
for PPI users with CF were only marginally higher than those not taking any anti-reflux 
medication, but more importantly 82% of PPI users had GIQLI scores below the normal 
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range, questioning the overall efficacy of medically managed reflux disease in CF 
patients. 
7.2.3 Reflux in CF – Cellular Findings 
Patients were asked to provide sputum prior to their oesophageal physiology tests 
having fasted for 4 hours. The sputum was processed with assistance from Miss. 
Gemma Crossfield, a PhD student, using the standard operating procedure (appendix2), 
carefully separating the sputum plug from the saliva. Despite using a meticulous 
methodology to process the sputum in order to provide a good quality cytospin for 
staining, only 10/11 samples could be analysed and all were heavily concentrated with 
neutrophils. This made further staining using Oil Red O and Prussian Blue impossible 
due to lack of macrophages within the sample. Blondeau et al [81] collected saliva from 
CF patients to analyse rather than sputum but saliva does not represent the fluid found 
in the large airway. As a result we used sputum but clearly the method of collecting 
sputum can influence the quality of the sample the differential counts. Spontaneous 
sputum analysis as in our study is a recognised technique for cytological diagnoses but 
the presence of large quantities of dead cells can affect the accuracy of the count [163]. 
Balbi et al [163] reviewed the literature regarding sputum collection and international 
guidelines on sputum collection studies suggest induced sputum as providing more 
representative cell counts, however they also conclude that the induced sputum 
technique can result in a neutrophilia and thus affect the overall accuracy of the cell 
differential counts. 
It is believed that duodenogastric reflux of bile is common in cystic fibrosis and is 
associated with cholelithiasis (gallstones), a common complication of CF [176]. 
Hallberg et al [176] investigated 8 adults with CF and compared them to 7 healthy 
volunteers without reflux disease. They collected gastric aspirates in these subjects and 
analysed them for bilirubin. Where the bilirubin concentration was high, a bile acid 
profile was performed using mass spectrometry. They showed that the median bile acid 
concentration of the gastric aspirates was nine time greater in CF patients than healthy 
subjects concluding that duodenogastric bile reflux is more common in CF. This is a 
very small study and more importantly, the healthy subjects did not actually have a bile 
acid profile performed as they did not have detectable bilirubin in the aspirate. The 
authors made the assumption that the bile acid concentration would be low or negligible 
as the bilirubin concentration had not been higher than 1.5μmol/L. The theory of bile 
reflux being more prevalent in CF patients have formed the basis of several other 
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studies attempting to detect bile salts in saliva, sputum or BAL samples from CF 
patients.  Blondeau et al [81] studied 71 CF patients concluding that reflux and 
aspiration was common in CF. However, this 71 consisted of 10 lung transplant patients 
with a background of CF. It is only these ten patients that had both reflux assessment 
using pH-impedance and BAL analysis of bile salts. Eight patients from this group had 
reflux and six had detectable bile in the lavage. From this small number it is not 
possible to accurately conclude that reflux and aspiration occur in CF. In addition, these 
were lung transplant patients post significant surgery and the findings may not be 
applicable to the more widespread non-transplanted CF patients. The authors did study a 
further 61 patients but separated them into two groups, analysing the saliva for bile 
acids in 38 patients and performing impedance-pH studies on a separate group of 23 
patients. They identified 20/23 patients to have reflux and 16/38 to have detectible bile 
acids in the saliva. As the authors have separated the groups it is difficult the 
relationship between the reflux and the detection of bile acids in saliva. Although the 
authors comment that the detection of bile acids in saliva may be a useful surrogate for 
proximal reflux, saliva is not representative of lung fluid and thus aspiration; the use of 
sputum or BAL analysis for the markers of aspiration are preferable [104, 177].  
In our study two separate samples of sputum were taken from the patients for bile salt 
analysis. Of the 22 samples taken, 21 were processed and used for analysis; there were 
detectable bile salts in all 21 samples. Two patients who did not have objective evidence 
of reflux still had detectable bile salts in their sputum. There was no significant 
relationship between bile salt concentrations and either Demeester or proximal reflux 
(p=0.554 and 0.337 respectively). The detection of these bile salts in the sputum is 
supported in the work by Pauwels et al [177]. In this prospective study they compared 
bile salt concentrations in the induced sputum samples of CF patients, healthy 
volunteers, asthmatics and chronic cough patients. 56% of CF patients compared to 
13% of healthy volunteers had elevated bile salt levels in the sputum. 28% of asthmatics 
also had elevated bile salt levels. In the CF patients they demonstrated that elevated bile 
salt levels were associated with a higher degree of lung function impairment. Although 
the authors comment on the median concentration of bile salts being significantly 
elevated in CF patients compared to the other groups, the dot plot of their results 
illustrated that the highest concentrations of bile salts were actually in the chronic cough 
group with many patients within the chronic cough and asthma groups having elevated 
levels; elevated bile salts in sputum may be common to patients with chronic respiratory 
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disorders and not only in CF patients. The groups were not matched in terms of patient 
numbers, therefore limiting the accuracy of comparing the groups. Finally, the authors 
conclude that the elevated bile salt levels are indicative of aspiration of duodenogastric 
contents. However, no objective evidence is available in this study to demonstrate 
duodenogastric reflux and the use of pH-impedance would have greatly added value to 
their study. In both the studies described above, the measurement of bile salts was 
performed using a commercially available enzyme assay (Bioquant). These kits are not 
as accurate or sensitive when compared to mass spectrometry and therefore the results 
should be interpreted with care. Our study is unique in providing detailed analysis of 
bile salts in sputum using mass spectrometry and having available the objective 
evidence of reflux assessment to determine if reflux and aspiration were responsible for 
deteriorating lung function in these patients. Although no significant statistical 
correlation was demonstrated between bile salt concentration and reflux scores or lung 
function and reflux scores, bile salts were present in all the patients with evidence of 
reflux and this could be very important for future studies. Correlation statistics have to 
be interpreted judicially when performed on such small patient groups. 
Very few studies have used sputum as a medium to detect pepsin. McNally et al [104] 
studied 31 patients with CF and compared the pepsin levels in bronchoalveolar lavage 
with 15 controls. The patients were all children with a mean age of 10.4 years. The 
lavage was performed with 1ml/Kg normal saline with an average return of 40%. The 
mean pepsin level in the BAL was higher in the CF group than the control group. 
However, pepsin was detected in the control group and 12/31 CF patients had pepsin 
quantities comparable to the control group. The authors therefore used the 95
th
 
percentile for the controls as the cut-off for elevated levels of pepsin (10.4ng/ml); levels 
above this were considered ‘high’ and seen in 19/31 CF patients. The authors suggest 
that these findings of elevated pepsin concentration in over half of their subjects are in 
keeping with aspiration. It is difficult to accurately confirm aspiration and as this study 
lacks objective reflux assessment it is difficult to determine the significance of the 
finding in this study. Although our study uses much smaller numbers we identified 
pepsin in the sputum of 7/11 CF patients with levels almost three higher than the pepsin 
concentrations detected in the study above. Six patients had objective evidence of reflux 
on pH-impedance assessment. Three patients had evidence of proximal reflux. In 
conclusion, although our  study uses small numbers of patients and there is no control 
group for comparison, it has been demonstrated that gastro-oesophageal reflux is 
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important in CF. In addition, the elevated concentrations of pepsin in sputum of CF 
patients who also have identifiable reflux provides much stronger evidence of 
microaspiration being an important pathological process in these patients.  
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7.3 Lung Transplant Patients 
7.3.1 Reflux in Lung Transplant patients 
Between June 2008 and December 2010, 16 patients who had undergone lung transplant 
were referred for reflux investigations. Nine patients were initially studied by Mr. 
A.G.N. Robertson as part of a PhD [36] and further recruitment continued by myself 
focusing on the safety and efficacy of fundoplication in lung transplant patients [97]. 
All 16 completed 8 channel manometry, thirteen having completely normal 
investigations.  Very little is published with regards to oesophageal motility after lung 
transplant but there is a high prevalence of foregut motility problems in patients with 
end-stage lung disease [132, 178]. D’ovidio et al demonstrated that up 80% (60/78) of 
these patients had oesophageal dysmotility and or a hypotensive lower oesophageal 
sphincter [179]. Basseri at al [180] demonstrated the problems with dysmotility seen in 
end-stage lung disease patients were as high as in the lung transplant candidates. This 
study evaluates oesophageal manometry post-lung transplant using HRM and shows 
76.7% of patients to have oesophageal dysmotility. Both hypotensive and aperistaltic 
swallows were six times higher in the 30 lung transplant candidates compared to the 10 
control subjects; this is in keeping with pre-transplant findings. Only 3/16 of our 
patients had abnormal peristalsis on 8-channel manometry and 5/16 had hypertonic 
lower oesophageal sphincters. The majority of our lung transplant patients had normal 
manometry and this discrepancy in results may be explained by different equipment and 
different reference values used particularly when trying to compare HRM and 8-channel 
manometry findings. 
We have used combined pH-impedance to assess these patients as this is the most 
accurate way currently to assess reflux [39]. All patients were assessed whilst on PPI 
medication [36]. The use of pH-impedance allowed the assessment of both mildly acidic, 
non-acid reflux events and proximal reflux events, which may be physiologically and 
pathologically important, especially if it leads to aspiration in this vulnerable population 
[108]. Previous studies have shown increased prevalence and severity of GOR post lung 
transplantation [181, 182] with up to 75% of patients having demonstrable reflux on pH 
monitoring [130, 181, 183].  In our 16 patients the post-transplant level of GOR was 
94% and 56% had proximal reflux on pH-impedance, despite the use of PPI. Davis et al 
[184] also demonstrated half of their subjects suffered from proximal reflux. Following 
endoscopy half of our patients had evidence of oesophagitis which is of concern 
considering the regular use of PPI medication and 15/16 had some evidence of a hiatus 
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hernia which is contrary to Davis et al [184] in which no patients were found to have a 
hiatus hernia. 
7.3.2 Fundoplication after Lung Transplant 
There is no consensus regarding fundoplication in lung transplant recipients [185]. We 
chose to operate in patients with symptomatic reflux and those with evidence of reflux 
and deteriorating lung function [97]. A laparoscopic Nissen fundoplication was 
favoured in our practice [36]. This study demonstrates that laparoscopic fundoplication 
in a transplant setting is safe. Of the sixteen patients operated on 15/16 patients reported 
a high level of satisfaction with the results of surgery at six weeks and at six months. 
This study also demonstrated that in this specialised patient population laparoscopic 
anti-reflux surgery is effective in reducing symptoms of GORD and improves quality of 
life. Our study also supports the possibility that fundoplication may impact positively on 
the loss of lung function seen in BOS, as 8/16 operations were performed for 
deterioration of lung function and all responded positively after surgery. 
With regard to safety our study had comparable results to the Duke’s group [186] with 
no significant mortality or morbidity experienced.  In addition, our operative times and 
blood loss figures were comparable to the Duke group[186]. Increased length of stay in 
the transplant population and a higher readmission rate, due to transplant co-morbidity 
are reported in some studies[186] . Our patients’ long post-operative stay may be 
partially explained by the fact that some transplant patients had to travel greater 
distances than a local population and for practical purposes spent longer in hospital. 
Overall our results suggest that laparoscopic fundoplication is safe in selected lung 
transplant recipients. 
In terms of patient outcomes, three questionnaires were used as described in the 
previous section; the European Association has recommended the GIQLI questionnaire 
for the assessment of quality of life after fundoplication[141]. The DeMeester Reflux 
Questionnaire is validated to assess reflux symptoms and the RSI has been validated in 
non-transplant patients as a marker of extra-oesophageal reflux and has been used to 
assess the effects of fundoplication on extra-oesophageal reflux [187, 188]. The median 
GIQLI, Demeester and RSI scores all showed considerable improvement over time 
reaching statistical significance. Median BMI significantly decreased from 23.4 pre-
fundoplication to 21.6 at six months post-fundoplication. The Melbourne group’s study 
[189] of fundoplication in lung transplantation described a decrease in mean BMI from 
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23kg/m
2
 six months pre-operatively to 21kg/m
2
 six months post-operatively. This may 
indicate the need for specialist dietary advice and intervention with this patient group. 
Lung function was assessed in accordance with European Respiratory Society 
guidelines. Eight patients were operated on for deteriorating lung function. Of these 
eight, one patient had a reversal of BOS, two had a stabilisation of lung function and 
five had a decrease in the rate of deterioration. There was a statistically significant 
decrease in the rate of decline of FEV1 per day post fundoplication which supports some 
of the work from the Duke University Transplant Group suggesting that anti-reflux 
surgery may lead to increased survival and improved lung function post-
transplantation[132].  
Our study shows that in this small group of lung transplant patients the intervention of 
laparoscopic fundoplication is safe and can result in an improvement of quality of life. 
Reflux may be contributing to the decline of lung function and the development of BOS 
and these results may indicate that anti-reflux surgery could play a role in reducing this. 
However, our current study has several limitations. The numbers involved were small 
and the study wasn’t randomised so there was no control group to compare and 
determine the true effect of the surgery. Fundoplication was performed at different 
times after transplant and no patients were operated on within 90 days of transplant, the 
suggested optimum time for intervention [65]. Further studies could include a focus on 
the effects of early fundoplication (within 90 days) on allograft function and long-term 
survival.  
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7.4 Conclusions and Future work 
I have studied three very specific groups of patients and have demonstrated that in 
patients with severe lung disease, reflux investigations can be performed safely. 
Working within a specialist upper gastrointestinal unit with sophisticated equipment for 
assessing reflux and oesophageal function we have shown that patients can be referred, 
counselled and investigated safely with close liaison with the CF, IPF and transplant 
clinics. Most patients are keen to attend for these investigations despite the invasive 
nature of the tests and certainly with the lung transplant patients the oesophageal 
physiology investigations have formed the basis of their surgical management. 
The use of pH-impedance and high resolution manometry have demonstrated that in 
both CF and IPF reflux can be identified in the majority of patients and can include acid, 
non-acid and proximal reflux. This is extremely important as recent evidence suggests 
that despite PPI use reflux can persist, in particular non-acid type, predisposing to 
Pseudomonas infection and a deterioration of lung function [190]. Our results indicate 
in all three groups of patients, objective evidence of reflux and symptoms of reflux 
persist despite PPI use. Further work is required to evaluate the role of medical 
treatment of reflux in advanced lung disease including identifying the role of 
dysmotiltiy agents such as dompridone and metochlopromide in controlling reflux 
symptoms. 
These groups of patients may have their deteriorating lung conditions treated with a 
lung transplant and considering that over 90% of the lung transplant patients we studied 
had reflux, this relationship could be very significant. It may indicate that patients with 
end-stage lung disease have reflux and consideration of surgical management in 
carefully selected patients prior to transplantation. Anti-reflux surgery prior to 
transplantation  may reduce the incidence of BOS in the allograft.  
It is clear that the laboratory studies attempting to identify microaspiration either 
through specialised stains or through bile salt and pepsin assays need much more 
development and global consensus. Certainly the results from this pilot study indicate 
that BAL fluid and sputum analysis can yield useful results but there are numerous 
improvements that can be made; the collection of sputum, the standardisation and 
accuracy of ELISA in order to develop reference ranges, the use of mass spectrometry 
for bile salts in other centres to ensure reproducibility of tests and comparisons to be 
made. 
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This study has managed to take three separate groups of clinical patients and safely 
recruit them, perform clinical tests and then incorporate that information into a host of 
laboratory tests. The patients were studied using the most up to date methods of 
assessing reflux including the use of HRM to provide better characterisation of 
oesophageal motility. The BAL was performed as recommended in the current 
guidelines and the close proximity of the endoscopy unit to the laboratory allowed the 
prompt processing of BAL ensuing good quality cytospins [162]. This study highlights 
the use of specialised cell staining, particularly Prussian Blue, both as a diagnostic tool 
as well as assessing the response to therapy. The positive findings of the research have 
altered the clinical management of lung transplant patients, improving their quality of 
life.  
There are clearly weaknesses to this study including the lack of a control group to 
compare with the IPF and CF patients. The poor recruitment in the CF group resulted in 
only 11 patients attending from a designated national unit. Clearly the CF patients are a 
vulnerable group with other comorbidities and closer liaison with a patient’s specialist 
nurse may aid recruitment and individual patient’s confidence in future reflux studies. It 
is clear that reflux is a problem in all three groups of patients. Only the transplant group 
were studied on PPI therapy but the findings from this study question the efficacy of 
PPI treatment in IPF and CF patients. Clearly objective assessment of reflux performed 
in these patients whilst they were on their medication would have been helpful in this 
study and would have answered important clinical questions on the role of PPI therapy 
in these patients. The processing of BAL was performed very efficiently but the 
diagnostic quality of the sample may have been improved with targeted BAL using the 
HRCT. The collection of sputum also needs to be improved to ensure that the quality of 
the sample is consistent between patients and to allow for more accurate cytological 
analysis.  
At our centre future work is focusing on the establishment of an aerodigestive unit in 
which the respiratory physicians, transplant team and upper gastrointestinal surgeons 
work closely in a multidisciplinary setting to enhance the clinical management of 
patients. In addition, a close liaison should be maintained with the university 
laboratories, trying to develop the techniques used to analyse the samples for a variety 
of markers and inflammatory proteins. Future work will inevitably include larger 
studies in IPF, CF and transplant patients with the aim to conduct randomised controlled 
trials of both medical and surgical treatment of reflux. We hope to develop clinical trials 
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that may elucidate the exact role reflux has in the pathophysiology of chronic lung 
disease and the importance of identifying markers of microaspiration early in the 
disease process. We believe early surgery may have a crucial role in the management of 
these patients. However, patients with advanced lung disease and those post lung-
transplants have to be carefully considered before surgical intervention is offered as 
many of these patients are frail, elderly and suffer multiple co-morbidities making 
surgical intervention high risk in many of these patients. Therefore a multidisciplinary 
team approach to managing these patients must be encouraged to allow careful and safe 
decision making.  
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Appendix 1 
Standard operating protocols for BAL and Sputum processing 
Sir William Leech Centre and Freeman Hospital Standard Operating Procedures 
 BAL processing SOP index S 01. Version 3 
 Sputum processing SOP index S 19. Version 2 
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Appendix 2 
Standard operating protocols for BAL and Sputum processing 
Sir William Leech Centre and Freeman Hospital Standard Operating Procedures 
 Geimsa 2 processing SOP index S 08. Version 3 
 Oil Red O processing SOP index T 15. Version 1 
 Perls Prussian Blue processing SOP index T 16. Version 1 
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Appendix 3 
Ethical Approval and NHS R&D approval 
 Approval letter from County Durham and Tess Valley 2 Research Ethics committee 
 IRAS application 
 NHS R&D Trust approval letter 
 R&D application form 
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Appendix 4 
Patient information sheet and consent forms 
 IPF patient information leaflet and consent form (version 2) 
 CF  patient information leaflet and consent form (version 2) 
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Appendix 5 
Successful Grant Application 
 Trustees grant application letter of approval 
 Trustees grant application 
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Appendix 6 
Reflux Questionnaires 
 Gastrointestinal Quality of Life Index (GIQLI) 
 DeMeester Questionnaire 
 Reflux Symptom Index Questionnaire (RSI)  
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The Gastrointestinal Quality of Life Index (GIQLI)  
1. How often during the past 2 weeks have you had pain in the abdomen? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
2. How often during the past 2 weeks have you had a feeling of fullness in the upper 
abdomen? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
3. How often during the past 2 weeks have you had bloating (sensation of too much gas in the 
abdomen)? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
4. How often during the past 2 weeks have you been troubled by excessive passage of gas 
through the anus? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
5. How often during the past 2 weeks have you been troubled by strong burping or belching? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
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6. How often during the past 2 weeks have you been troubled by gurgling noises from the 
abdomen? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
7. How often during the past 2 weeks have you been troubled by frequent bowel movements? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
8. How often during the past 2 weeks have you found eating to be a pleasure? 
never a little of the 
time 
some of the 
time 
most of the 
time 
all of the time 
     
9. Because of your illness, to what extent have you restricted the kinds of food you eat? 
very much much somewhat a little not at all 
     
10. During the past 2 weeks, how well have you been able to cope with everyday stresses? 
extremely 
poorly 
poorly moderately well extremely well 
     
11. How often during the past 2 weeks have you been sad about being ill? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
12. How often during the past 2 weeks have you been nervous or anxious about your illness? 
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all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
13. How often during the past 2 weeks have you been happy with life in general? 
never a little of the 
time 
some of the 
time 
most of the 
time 
all of the time 
     
14. How often during the past 2 weeks have you been frustrated about your illness? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
15. How often during the past 12 weeks have you been tired or fatigued? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
16. How often during the past 2 weeks have you felt unwell? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
17. Over the past week, have you woken up in the night? 
every night 5-6 nights 3-4 nights 1-2 nights never 
     
 
18. Since becoming ill, have you been troubled by changes in your appearance? 
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a great deal a moderate 
amount 
somewhat a little bit not at all 
     
19. Because of your illness, how much physical strength have you lost? 
a great deal a moderate 
amount 
some a little bit none 
     
20. Because of your illness, to what extent have you lost your endurance? 
a great deal a moderate 
amount 
somewhat a little bit not at all 
     
 
21. Because of your illness, to what extent do you feel unfit? 
extremely unfit moderately 
unfit 
somewhat unfit a little unfit fit 
     
22. During the past 2 weeks, how often have you been able to complete your normal daily 
activities (school, work, household)? 
never a little of the 
time 
some of the 
time 
most of the 
time 
all of the time 
     
 
 
 
23. During the past 2 weeks, how often have you been able to take part in your usual patterns 
of leisure or recreational activities? 
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never a little of the 
time 
some of the 
time 
most of the 
time 
all of the time 
     
24. During the past 2 weeks, how much have you been troubled by the medical treatment of 
your illness? 
very much much somewhat a little not at all 
     
25. To what extent have your personal relations with people close to you (family or friends) 
worsened because of your illness? 
very much much somewhat a little not at all 
     
26. To what extent has your sexual life been impaired (harmed) because of your illness? 
very much much somewhat a little not at all 
     
27. How often during the past 2 weeks, have you been troubled by fluid or food coming up 
into your mouth (regurgitation)? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
28. How often during the past 2 weeks have you felt uncomfortable because of your slow 
speed of eating? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
29. How often during the past 2 weeks have you had trouble swallowing your food? 
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all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
30. How often during the past 2 weeks have you been troubled by urgent bowel movements? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
31. How often during the past 2 weeks have you been troubled by diarrhoea? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
32. How often during the past 2 weeks have you been troubled by constipation? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
33. How often during the past 2 weeks have you been troubled by nausea? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
34. How often during the past 2 weeks have you been troubled by blood in the stool? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
 
35. How often during the past 2 weeks have you been troubled by heartburn? 
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all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
36. How often during the past 2 weeks have you been troubled by uncontrolled stools? 
all of the time most of the 
time 
some of the 
time 
a little of the 
time 
never 
     
Calculation of the score: 
most desirable option: 4 points 
least desirable option: 0 points 
GIQLI score: sum of the points 
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DeMeester Reflux Questionnaire  
1) In the last 2 weeks have you suffered from heartburn (i.e. a burning sensation in the 
chest)? 
grade 0, no 
symptoms 
grade 1, occasional 
episodes 
grade 2, reason for 
medical visit 
grade 3, 
interference with 
daily activities  
    
2) In the last 2 weeks have you suffered from regurgitation (acid or stomach contents coming 
up into your throat, mouth or lungs)? 
grade 0, no 
regurgitation 
grade 1, occasional 
episodes 
grade 2, predictable 
on position of 
straining 
grade 3, episodes 
of pulmonary 
aspiration, 
nocturnal cough or 
recurrent 
pneumonia 
    
3) In the last 2 weeks have you suffered from dysphagia (difficulty swallowing or food 
getting stuck)?  
grade 0, no 
dysphagia 
grade 1, occasional 
episodes 
grade 2, require 
liquid-to-clear diet 
grade 3, episodes 
of esophageal 
obstruction 
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Appendix 7 
Publication Related to thesis 
 Anti-reflux surgery in lung transplant recipients: Outcomes and effects on quality of life. 
Robertson AG, Krishnan A, Ward C, Pearson JP, Small T, Lordan J, Corris PA, Dark JH, 
Karat D, Shenfine J, Griffin SM. Eur Respir J. 2012 Mar;39(3):691-7 
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